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Abstract
The traditional approach to pharmacodynamic modelling relies on knowledge about the
pharmacokinetics. A prerequisite for obtaining kinetic information is reliable exposure data.
However, in several therapeutic areas, exposure data are unavailable—including when the
drug response precedes the systemic exposure (for example pulmonary drug administration)
and when the drug is locally administered (for example ophthalmics).
Dose-response-time (DRT) data analysis provides an alternative to exposure-driven phar-
macodynamic modelling when exposure data are sparse or lacking. In DRT modelling, the
response data are assumed to contain enough information about the drug kinetics, whereby
a biophase model can be developed and act as the driver of the pharmacological response.
The following work presents the fundamental principles of DRT modelling. This include the
entire procedure of identifying a DRT model, encompassing the assessment of the biophase
function and the pharmacodynamic model, extensions to cover population variations, identi-
fiability analysis, parameter estimation, and model validation. To demonstrate the utility of
the technique, two extensive pre-clinical DRT studies of the interaction between nicotinic
acid (NiAc) and free fatty acids (FFA) are presented. The first study covered the response
behaviour following intravenous and oral NiAc dosing in both normal (lean) and diseased
(obese) rats. The second study extended the models of the first study to incorporate insulin
as a driver of the FFA response. Moreover, data from chronic trials were analysed with the
aim to quantitatively understand the adaptive behaviours associated with long-term NiAc
treatments.
The aim of this work is to answer the questions of when and how to use DRT data
analysis, and what the limitations of the method are.
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The DRT models of the first study were successfully fitted to all response-time courses
in lean rats, with high precision in the parameter estimates (relative standard errors (RSE)
< 25%), visual predictive check (VPC) and individual plots that captured the population
and subject trends, and ε-shrinkages of less than 10%. The model for the obese rats were
less precise, with specific parameters being practically non-identifiable (with, for example,
RSE∼ 250%). The results for both lean and obese rats were generally consistent with those of
an exposure-driven reference model, albeit with less precision and accuracy in the parameter
estimates. Finally, the model was able to describe non-linear biophase kinetics, present at
high oral dosages of NiAc.
The DRT models of the second study were able to capture the response-time courses
for insulin and FFA on a population and individual level, and for both lean and obese rats.
However, many parameters were uncertain (with RSE of, for example, 30-50%) and some
were practically non-identifiable (with RSE of > 100%). The estimates were generally less
precise and more inaccurate than those obtained in an exposure-driven reference model.
Yet, most parameter estimates of the DRT models were within one standard deviation from
those of the exposure-driven model. The final model was used to predict steady-state FFA
exposures following repeated NiAc dosing for a range of different infusion protocols. The
optimal dosing regimens consisted of infusions and wash-out periods were the wash-outs
were 2h longer than the infusions. These predictions were consistent with those made by the
exposure-driven model. Albeit, the DRT model predicted a slightly lower optimal reduction
of FFA exposure.
It is important to recognise that DRT analyses introduce bias and variability in the parameter
estimates. To obtain reliable results, it is advisable to have rich pharmacodynamic data, cover-
ing drug administration at different routes, rates, and schedules. With these issues taken into
account, the technique still performed well in the two extensive studies presented in this work.
In conclusion, DRT data analysis is a modelling technique used in situations when ex-
posure data are unavailable. The method is versatile and can describe a range of different
pharmacological behaviours. Precision and accuracy is lost when comparing to an exposure-
driven pharmacodynamic modelling approach. Thus, DRT modelling is not to be considered
as a replacement of the gold-standard pharmacokinetic-pharmacodynamic framework, but
rather as a compliment when exposure data are unavailable.
Keywords: Dose-response-time modelling, Biophase functions, Pharmacodynamic
modelling, Nonlinear mixed-effects (NLME), Disease modelling, Tolerance, Adaptation,
Feedback
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Part I
Introduction
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Introduction
This thesis is divided into two parts, each with separate objectives; the first part serves to
describe what dose-response-time (DRT) data analysis and population modelling are and
how these techniques are applied. The second part focuses on why the studies of this PhD
project were conducted, and their respective contribution.
Aims and objectives
The aim of this thesis is primarily to answer the following questions:
• When and how do we use DRT data analysis?
• What are the limitations of DRT data analysis?
In order to achieve the aims, an exhaustive literature review and two major data analyses
were conducted. A key aspect of this project was to demonstrate how simple biophase
structures can be used as the underlying driving mechanism when describing complex
pharmacodynamic systems, where lack of pharmacokinetic data prohibits the standard
pharmacokinetic-pharmacodynamic modelling practice.
Quantitative pharmacology
Modelling and simulation are crucial in modern pharmaceutical research (Allerheiligen, 2014;
Breimer and Danhof, 1997; Burman and Wiklund, 2011; Lalonde et al., 2007; Leil and
Bertz, 2014; Manolis et al., 2013; Marshall et al., 2016; Staab et al., 2013). The methods at
hand provide quantitative ways to perform pharmacology; applicable when evaluating and
comparing drugs, and when designing future experimental protocols (Aarons et al., 2001;
Gabrielsson and Weiner, 2010; Rowland and Tozer, 2011). This allows for well-informed
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decisions throughout the drug development cycle, from initial in silico analyses to post-
marketing predictive studies on new populations (Bonate, 2011). In detail, modelling and
simulation enable a better understanding of the drug properties, or the pharmacokinetics
(PK) and pharmacodynamics (PD), which are the two main areas of pharmacology (Rowland
and Tozer, 2011). PK may in layman’s terms be described as what the body does to the drug,
which encompasses absorption, distribution, metabolism, and elimination of the drug (Benet
and Zia-Amirhosseini, 1995; Gibaldi and Perrier, 1982). The kinetic properties are assessed
by conducting in vivo studies wherein the drug is administered and the corresponding
exposure (typically in blood plasma) is measured over time. The experimental data provide
the basis for the PK model. A well-designed model may contribute quantitative knowledge
of the concentration-elimination relationship, the drug bioavailability, the unbound drug
concentration, the volume of distribution of the drug, and so forth.
In contrast to PK, PD represents what the drug does to the body. Generally, drugs are
designed to alter normal physiological or biochemical processes, inhibit pathological pro-
cesses, or disrupt parasites or microbes (Lees et al., 2004). Drugs typically function as
agonists, antagonists or inverse agonists on a specific receptor (Gabrielsson and Weiner,
2010). By binding to its receptor, and forming a receptor-ligand complex, the drug provokes
a stimulating, stabilising or inhibiting action. If the expression of the receptor-ligand complex
is measurable, or some downstream biomarker (Aronson, 2005) is measurable, then the PD
may be assessed. Measuring exposure and drug effect are done in parallel, whereby the drug
concentration-effect relation may be assessed. Traditionally, the PK is analysed first and
considered to drive the PD (Holford and Sheiner, 1982). Consequently, the fitted PK model
will act as the driving mechanism of the perturbed pharmacological response, and the final
PK-PD model will encompass both the kinetic and dynamic properties of the drug and how
these are related.
Dose-response-time data analysis
Dose-response-time data analysis is as an alternative to exposure-driven PK-PD modelling
when PK data are sparse or lacking, or when it is difficult to relate measured exposure
(typically in plasma) to exposure at the target (e.g., in the brain (Andersson et al., 2015;
Gabrielsson et al., 2000; Gabrielsson and Peletier, 2014; Jacqmin et al., 2007)). This
involves studies where, for example, it is undesirable to perform exposure sampling (e.g.,
in paediatrics (Tod, 2008)), the drug is locally administered (e.g. in ophthalmics (Audren
et al., 2004; Gabrielsson et al., 2000; Smolen, 1971b)), general clinical trials (Abou Hammoud
et al., 2009; Buil-Bruna et al., 2014; Ramon-Lopez et al., 2009; Wilbaux and He, 2014),
or the pharmacological response precedes the systemic exposure (e.g. pulmonary drug
administration (Musuamba et al., 2015; Nielsen et al., 2012; Wu et al., 2011)). In DRT
modelling, the pharmacological effect is assumed to be driven by the drug amount at the
active site, known as the biophase (Schoenwald and Smolen, 1971; Smolen, 1971b; Gabrielsson
et al., 2000). The biophase is a conceptual compartment that consists of any type of tissue or
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organ, or combinations of tissues and organs. The choice of structure of the biophase depends
on how the drug was administered, what characteristics are seen in the response-time data,
and the physiological knowledge of the system (Andersson et al., 2015; Gabrielsson and
Peletier, 2014).
Paper I - Dose-response-time
modelling
Paper II - Modelling of free fatty acid
dynamics
What? Develop a DRT model describing the
NiAc-FFA interactions
Develop a PK-PD model describing the
NiAc-Insulin-FFA interactions
Why? Demonstrate the utility of DRT models
in describing complex pharmacological
systems
Obtain a robust model able to describe
acute and chronic treatments
Design/data Pre-clinical meta-analysis Pre-clinical meta-analysis
Key findings Nonlinear biophase needed for
saturable absorption
Diseased animals develop full drug
resistance
Integral feedback control describes
adaptation
Diseased animals develop insulin
resistance
High parameter precision. Drug wash-outs necessary
Conclusions DRT is a versatile modelling approach Model captured both acute and chronic
treatments
The pharmacodynamic model can
describe acute treatments
Integral controller and dynamic efficacy
described different adaptations
Chronic treatment behaviours remain
to be assessed
The designed optimal protocols should
be experimentally verified
Table I: Summary of published articles that are presented in this thesis.
This work provides the principles of DRT data analysis in a population context; how
basic biophase and pharmacodynamic models are constructed, structural and practical
identifiability of these models, incorporation of variability, and assessment of the resulting
models. The technique is demonstrated by means of two pre-clinical meta-analyses. The data
sets for these analyses cover a range of routes, rates, and schedules of drug administration.
Both studies were conducted on the complex metabolic system of free fatty acid (FFA)
dynamics, under the provocation of the antilipolytic compound nicotinic acid (NiAc) (Carlson,
2005). In the first study, the drug dose-response relations are analysed in an acute setting,
using a single-biomarker data set of FFA response-time data. In this study, special emphasis
was placed on the selection process of the biophase functions. The modelled biophase amount
functioned as the driving-mechanism for a sigmoidal function that acted as an inhibiting
force on the turnover of FFA. In the second study, the model was extended to capture chronic
dose-response patterns. This was partly done by adding insulin as a second biomarker.
Two different types of adaptive behaviours were included in the model; one to describe
drug resistance and one to describe insulin resistance. For both studies, PK data were
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available, which allowed for a comparison between the DRT analysis and an exposure-driven
analysis (Andersson et al., 2017; Tapani et al., 2014). The first chapter of the thesis consists of
a thorough literature review of DRT data analysis. This is followed by a Methods and Models
chapter where it is demonstrated how a DRT model is constructed. Furthermore, population
modelling is introduced and, in particular, the nonlinear mixed-effects framework (Bonate,
2011; Davidian, Marie, 2003). This is followed by a section on parameter estimation and
model validation. The second part of the thesis starts with a chapter on the physiology
of NiAc-induced antilipolysis and a presentation of the analysed data. Chapters four and
five consist of the two major case studies where the potential of DRT data analysis is
demonstrated. The majority of the presented scientific contributions have been published
separately (Andersson et al., 2015, 2017) which are summarised in Table I.
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Chapter 1
Background and literature
review
Pharmacokinetic (PK) and pharmacodynamic (PD) modelling are cornerstones in model-
based drug development. The modelling techniques serve as a means to understanding and
quantifying patterns seen in pharmacological data. This enables the modeller to evaluate
the performance of pharmaceutical substances. Furthermore, suitable models can be applied
to simulate unobserved pharmacological events and thus predict optimal dosage strategies.
In this way, simulations provide valuable input in the design of future experimental trials.
The trials, in turn, contribute new data to be analysed. Hence, mathematical modelling and
simulation and experiments are used symbiotically to enhance the modeller’s knowledge of
the pharmacology and physiology. The iterative strategy of using modelling and simulation
and experiments advances the pharmacological development process until a drug has been
accepted or discontinued.
1.1 PK-PD modelling
The PK-PD modelling procedure is traditionally sequential1 in that the PK are initially
analysed and then considered to be known when assessing the PD. In detail, a PK model
1The sequential approach to PK-PD modelling has traditionally been favoured over the simultaneous one
as it tends to be less computationally involved and more prone to obtain parameter estimates. However, if
the PK model is misspecified, and the PD model is not, the simultaneous approach provide a better PD fit.
For more details and a further discussion on the methods and robustness, see Zhang et al. (2003a,b).
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is developed and fitted to the exposure-time data (typically drug plasma concentrations).
From the generated PK model, a time continuous exposure signal is generated to act as
an input to the PD model. Consequently, when assessing the PD, it is assumed that the
PK are known and that the simulated PK input corresponds to the true exposure. Given
this premise, the PK-PD modelling framework is constrained by the existence of reliable
exposure data. PKs is often modelled using compartmental models (Godfrey, 1983). These
models consist of ordinary differential equations, where the state variables represent drug
concentrations in different physiological compartments. In the simplest possible case, a
single-compartment model is used to represent the drug concentration in the plasma (model
illustrated in Fig. 1.1a). This concentration, denoted C(t), is given by
dC(t)
dt
= −k · C(t) = −Cl
V
· C(t) with C(0) = 0, (1.1)
where k is the elimination rate, Cl the clearance, and V the volume of distribution of the
drug (describing the fraction between the drug amount and the drug concentration2). Given
an intravenous bolus dose D, the initial condition in Eq. (1.1) becomes C(0) = D/V . For
extravascular drug administration, an intermediate absorption compartment is added to
Eq. (1.1) from where the drug is absorbed into the blood plasma compartment (model
illustrated in Fig. 1.1b). The drug kinetics are given by
dA(t)
dt
= −ka ·A(t) with A(0) = D, (1.2a)
dC(t)
dt
=
F · ka ·A(t)
V
− k · C(t) with C(0) = 0, (1.2b)
where A is the drug amount in the absorption compartment, ka the absorption rate, and
F the bioavailability. The bioavailability ranges from 0 to 1 and represents the fraction of
dose that reaches plasma intact. Generally, Eq. (1.2a) is solved for A(t) and the system is
reduced to, and considered as, a single-compartment model given by
dC(t)
dt
=
D · F · ka · e−kat
V
− k · C(t) with C(0) = 0. (1.3)
These elementary PK models may be expanded to include additional compartments, de-
scribing the drug kinetics in other tissues and organs. Such extensions may be required for
various reasons; if, for example there are two different phases in the drug plasma kinetics, the
drug distributes into different tissues, whereby a peripheral compartment is needed (model
illustrated in Fig. 1.1c). In this case, the plasma Cp(t) and tissue Ct(t) concentrations after
2The volume of distribution is an estimate of how well the drug distributes throughout the body. For
example, a high volume of distribution means that a large fraction of the drug distributes outside the plasma.
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a bolus dose could be given by
dCp(t)
dt
= k21 · Ct(t)− k12 · Cp(t)− k10 · Cp(t) with Cp(0) = D/V, (1.4a)
dCt(t)
dt
= k12 · Cp(t)− k21 · Ct(t) with Ct(0) = 0, (1.4b)
where k10 is the elimination rate from the plasma compartment, k12 the distribution rate
from the plasma to the tissue compartment, and k21 the distribution rate from the tissue to
the plasma compartment.
(a) (b) (c)
Figure 1.1: Examples of typical PK models: (a) represents a one-compartment model
with first-order drug elimination; (b) a two-compartment model with an absorption and
a central drug compartment. The drug is absorbed into, and eliminated from, the central
compartment via first-order processes; (c) a two-compartment model with a plasma and
a tissue compartment. The drug is distributed between plasma and tissue via first-order
processes and eliminated from the plasma via a first-order elimination.
The compartmental modelling framework can be expanded to include any number of
compartments in order to describe more complex kinetic scenarios. In particular, the
physiologically-based PK (PBPK) models consist of multiple compartments and aim at
explaining as much as possible of the drug disposition (Rowland et al., 2011). These sophis-
ticated multi-compartment models provide a more general picture of the drug kinetics, and
are convenient when, for example, translating results between species. However, the scope of
PBPK models often complicates parameter identification (see Section 2.2), and in order for
these models to be useful the modeller generally needs prior knowledge of the pharmacology
and physiology, and/or exposure assays generated at multiple sites (for a review on PBPK
models, see Rowland et al. 2011). As we will see, kinetic information is not always available,
whereby PBPK, and simpler PK models, fail.
1.2 Dose-response-time data analysis
Dose-response-time (DRT) data analysis is a modelling approach that is used for assessing
the PD response when PK data are lacking or uninformative. PK data may, for example, be
difficult to measure if
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(i) the turnover of the drug is quick (Uehlinger et al., 1992; Port et al., 1998)
(ii) the concentration of the drug is below the limit of quantification (Lalonde and Gau-
dreault, 1999)
(iii) the drug is locally administered (e.g., in ophthalmicss (Audren et al., 2004; Smolen,
1971b; Gabrielsson et al., 2000))
Furthermore, in certain clinical trials, it is undesirable to measure drug exposure due to
the invasiveness of the sampling methods. Invasiveness is generally an issue in paediatric
studies (Tod, 2008) and in situations where the patient is put under considerable dis-
tress (e.g., in oncology (Frances et al., 2011; Paule et al., 2012; Wilbaux and He, 2014)).
Moreover, if the drug effect precedes the systemic exposure (e.g., for pulmonary drug
administration (Musuamba et al., 2015; Nielsen et al., 2012; Wu et al., 2011)), the drug
concentration-time series may be uninformative about the unbound drug at the active site. In
addition, PK data may be uninformative when there are vast differences between the initial
and terminal phase of the drug treatment periods (Lange and Schmidli, 2014, 2015). The
traditional PK-PD modelling approach fails in situations where exposure data are lacking
or uninformative. In cases like these, DRT data analysis acts as a surrogate (a schematic
difference between DRT and PK-PD modelling is illustrated in Fig. 1.2).
DRT modelling is based on the premise that the pharmacological response data contain
information about the drug kinetics. This “hidden” information is assumed to be sufficient
to determine the drug amount in an intermediate biophase compartment. The biophase
represents any organ or tissue where the drug produces its pharmacological effect. From
a modelling perspective, the kinetics of the biophase and the pharmacodynamics need to
be assessed simultaneously, which is not the case in PK-PD modelling. This is achieved by
selecting a possible model that describes the hypothetical drug amount-time course in the
biophase. The biophase amount will subsequently act as the driver of a drug-mechanism
function—which acts on the pharmacological response.
A summary of published DRT data analyses is given in Table 1.1.
1.2.1 Instantaneous response models
Dose-response-time data analysis dates back to the 1960’s and 1970’s when Levy (Levy,
1964a,b, 1966; Gibaldi and Levy, 1972) and Smolen (Smolen, 1971b; Schoenwald and Smolen,
1971; Smolen and Schoenwald, 1971; Smolen, 1971a; Smolen and Weigand, 1973; Smolen
et al., 1975; Smolen, 1976b,a,c, 1978) introduced the concept. Levy described a relationship
between the amount of drug in the body and the corresponding pharmacological effect.
Smolen, on the other hand, analysed the dose-response relationship of a mydriatic3 drug
after oral and ophthalmic administration. In the qmydriatic studies, no exposure data were
available due to difficulties in assaying the drug in body fluids. Consequently, response
3Mydriatic drugs are ones that cause dilation of the pupil.
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PK-PD modelling approach
DRT modelling approach
Figure 1.2: Illustration of the conceptual difference between traditional PK-PD modelling
and DRT analysis. In traditional pharmacodynamic modelling, the response is assumed to
be driven by the pharmacokinetic model. In DRT modelling, the response is driven by the
drug amount in the biophase.
data were the sole source of information when quantifying the bioavailability and biokinetic
behaviours. Smolen’s studies were based on two major assumptions (Smolen, 1976c):
• “The dynamics of the drug’s disposition are linear.”
• “The intensity of pharmacological response is a single-valued function of the biophasic
drug levels.”
For example, with a biophase amount of Ab(t), and a pharmacological response of I(t)
(mydriatic response intensity, in this case), the functional relationship was assumed to be
given by
I(t) = f(Ab(t)), (1.5)
for some appropriate function f . Now, given the first assumption, a dose vs. effect relationship
was used to convert observed intensity-time courses into relative biophase amount-time
courses. Combining this with a compartmental model for the biophase dynamics, and
multiple relative biophase amount-time courses, the “true” biophase amount was estimated.
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Smolen analysed a range of two- and three-compartment biophase models to describe the
kinetics of the biophase (the are models illustrated in Fig. 1.3). The corresponding model
fits demonstrated the structural and practical identifiability4 issues associated with multi-
compartment biophase models (without making appropriate prior assessments). Nonetheless,
when applying an identifiable biophase function, the method was proven to be successful in
capturing the pharmacodynamic behaviours and the biophase kinetics. However, the second
of Smolen’s assumptions heavily constrains the application of the defined technique since
many pharmacological processes are non-direct (Dayneka et al., 1993).
Figure 1.3: Biophase models presented by Smolen (1971b). Smolen used two-compartment
models with a biophase Ab, and systemic fluid Ac compartment, and three-compartment
models with a biophase Ab, a systemic fluid Ac, and a tissue depot compartment Ad.
Moreover, a fourth compartment Aa, corresponding to the site of administration, was
included if the drug was not administered systemically.
Since those initial studies, DRT modelling was not applied until the early 1990’s when Verotta
and Sheiner (1991) further developed the existing techniques. In their study, semi-parametric
methods were applied to analyse pharmacodynamic data over a range of different data sets
(e.g., verapamil-induced changes in the PR interval of an electrocardiogram). Verotta and
Sheiner (1991) made the following model assumptions
• “Both the distribution of the drug and its effect vs. concentration relationship are
stationary processes.”
• “The distribution of the drug is linear with respect to the input of the drug.”
• “The pharmacodynamic response to the drug depends on the concentration of the drug
at a single site.”
• “The relationship between effect and drug concentration is memoryless.”
4The identifiability issues were discussed by Smolen. However, no formal identifiability analysis was
performed.
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The semi-parametric model consisted of an unobserved state X that was proportional to
the drug concentration at the active site Ce. The state X was given by the convolution of
the input function and a sum of exponentials. Furthermore, the pharmacological effect E
was related to X according to a cubic spline. As Verotta and Sheiner had access to PK
data in their study, the estimated exposure could be compared with the observed exposure.
Here, the uncertainty of the non-parametric technique was made clear, as the worst case
estimated exposure profile was far off the observed exposure. Furthermore, the assumption
of having stationary processes and a memoryless relationship between the effect and the
drug concentration limits the method substantially. However, the study by Verotta and
Sheiner inspired subsequent DRT studies. In particular, the response behaviour of the
muscle relaxant drug vecuronium was analysed in a range of studies (Bragg et al., 1994;
Fisher and Wright, 1997; Fisher et al., 1997; Warwick et al., 1998), where twitch depressions
of the muscles were used as the pharmacodynamic biomarker. In these studies, the drug
plasma concentration was measurable, but not the concentration at the neuromuscular
junction, which is the effective site. Regardless, the studies successfully characterised both
the respiratory and adductor pollicis muscle behaviours seen after vecuronium administration.
This was done by modelling the biophase concentration Ce (called effective concentration or
active concentration in the studies) with a first-order elimination model given by
Ce = keo ·D · A · (e
−λt − e−keot)
keo − λ , (1.6)
where keo is the elimination rate from the plasma compartment to the biophase compart-
ment, D is the dose, A the dose-normalised intercept, and λ the elimination rate from the
biophase compartment. This biophase concentration drives the response according to a Hill
equation (Gesztelyi et al., 2012)
Effect =
Ceγ
Ceγ + Cγ50
, (1.7)
where C50 is the steady-state concentration that produces 50% of the effect, and γ is the
Hill coefficient. This model was applied to both the respiratory and the adductor pollicis
twitch tension data. The models showed that the peak concentration of vecuronium occurred
earlier in the respiratory muscles than in the adductor pollicis. This implies a higher peak
concentration level and thus explains why the respiratory muscles more frequently experience
paralysis than the adductor pollicis after vecuronium exposure. Furthermore, Warwick et al.
(1998) showed the potential advantages associated with PK-free PD analysis. In particular,
the DRT approach allows for individual predictions of future dosing during anaesthesia. This
is not possible using the conventional PK/PD approach due to the time needed to assay the
drug. Further usage of DRT data analysis was successfully demonstrated in studies where
children were treated with erythropoietin (EPO) for renal anaemia (Uehlinger et al., 1992;
Port et al., 1998). Here, the drug-induced haemoglobin (Hb) production was assumed to be
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linearly dependent on the EPO dose
R = β ·D, (1.8)
where R is the drug-induced Hb production, D the dose, and β the production rate per dose
unit. A DRT approach was suitable in these studies since the EPO turnover is rapid in
comparison to the response turnover. Consequently, it is hard to relate the concentration-time
course of EPO to that of Hb.
1.2.2 Turnover models
Following the DRT studies of the 1990’s, the field saw a breakthrough when Gabrielsson
et al. (2000), introduced biophase-driven turnover models (Dayneka et al., 1993). In the
turnover model framework, the PD response R(t) is given by
dR(t)
dt
= kin − kout ·R(t) with R(0) = R0, (1.9)
where kin and kout are the turnover and fractional turnover rate of the response, respectively,
and R0 is the baseline response. For a biophase-driven response, the biophase amount Ab
will act on the production or elimination of response through a drug-mechanism function
H(Ab) according to
dR(t)
dt
= kin ·H(Ab)− kout ·R(t) (1.10)
or
dR(t)
dt
= kin − kout ·H(Ab) ·R(t). (1.11)
The drug-mechanism functions that were applied in the study by Gabrielsson et al. (2000)
included nonlinear Hill relations (similar to that of Eq. 1.7) that were either stimulatory
H(Ab) = 1 +
Emax ·Aγb
EDγ50 +A
γ
b
(1.12)
or inhibitory
H(Ab) = 1− Emax ·A
γ
b
EDγ50 +A
γ
b
. (1.13)
where Emax is the efficacy, ED50 the potency (based on dose), and γ the Hill coefficient.
Turnover models allow for a wide range of response-time behaviours, out of the scope of
previous DRT studies (due to their assumptions). The study by Gabrielsson et al. (2000),
contained four different cases of biophase-driven turnover models, describing response-time
data of miotic response, body temperature, antinociception, and cortisol/ACTH (one example
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is illustrated in Fig. 1.4). These case studies showed that DRT models are applicable when
the kinetics and/or dynamics behave non-linearly, when there are time-delays in the response
data, and when the system contains feedback mechanisms. This heavily expanded the
possible applications of DRT models. Beyond the study of Gabrielsson et al. (2000), the
Figure 1.4: Biohase-driven turnover model presented by Gabrielsson et al. (2000). The
input into the biophase is either direct (iv administration) or through absorption (oral
administration) F ·ka, where F is the biophase availability and ka is the first-order absorption
rate from an absorption compartment into the biophase. The parameter k is the first-order
(linear) elimination rate from the biophase. The biophase amount Ab was then driving
a drug-mechanism function H(Ab), which can, for example, inhibit the turnover kin or
fractional turnover kout of the response R.
biophase-driven turnover model was applied across a range of DRT studies in the late 1990’s
and early 2000’s (Lalonde and Gaudreault, 1999; Audren et al., 2004; Gruwez et al., 2005; Tod
et al., 2005). In particular, Lalonde and Gaudreault (1999), analysed parathyroid hormone
concentrations under treatment by the calcimimetic agent R-568. Since the concentration
of the specific agent was below the limits of quantification in more than half of the patient
samples, the exposure analysis was excluded and the PD model was assumed to be driven
by the drug amount in the biophase. Further, Gruwez et al. (2005) applied a dose-response
model to analyse categorical data when they explored the effect of paroxetine and pindolol.
Here, the response-time data consisted of total scores on the MADR scale (Montgomery and
A˚sberg, 1979).
1.2.3 Kinetic-Pharmacodynamic models
In addition to the original DRT-approach by Smolen (1971b), an alternative rate-driven
model (K-PD) was suggested by Jacqmin et al. (Gieschke et al., 2001; Goggin et al., 2001;
Jacqmin et al., 2001; Pillai et al., 2001). The concepts of the K-PD model are similar to
those of the traditional DRT model, except that the ‘virtual infusion rate’ (biophase turnover
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rate) is assumed to be the driver of the pharmacological response, rather than the biophase
amount. This is an unconventional approach in pharmacological modelling, where drug
exposure (or amounts) are generally assumed to drive the pharmacological effect.
To demonstrate the idea of the K-PD model, assume that the biophase amount Ab(t) has a
first-order elimination rate k given by
dAb(t)
dt
= −k ·Ab(t), (1.14)
with initial value Ab(0) = D. Furthermore, assume that the drug inhibits the turnover of
the pharmacodynamic response R(t) according to a nonlinear Hill relation. The response
behaviour would then, for the traditional DRT and the K-PD approach, be given by
dR(t)
dt
= kin ·
(
1− Emax ·A
γ
b(t)
EDγ50 +A
γ
b(t)
)
− kout ·R(t) DRT, (1.15)
and
dR(t)
dt
= kin ·
(
1− Emax · IR
γ(t)
EDKγ50 + IR
γ(t)
)
− kout ·R(t) K-PD, (1.16)
with
IR(t) = −dAb(t)
dt
= k ·Ab(t), (1.17)
where IR(t) is the virtual infusion rate and EDK50 (amount per time unit) the rate that
gives half-measured drug-reduced response. As is indicated by Eq. (1.17), the ‘drivers’ of the
DRT and K-PD models are proportional. Thus, the two frameworks only differ by a scaling
factor.
K-PD models have been applied in numerous studies (see for example Abou Hammoud et al.
(2009); Hamberg et al. (2013); Salem et al. (2016); Wu et al. (2011)) following its introduction
by Jacqmin et al. (2001, 2007). However, several studies have misunderstood the original
model definition and used the biophase amount as the driving force of the response (see
for example Gruwez et al. (2007); Jacobs et al. (2010); Mikaelian et al. (2013); Musuamba
et al. (2015); Nielsen et al. (2012)). These studies have in fact applied the traditional DRT
approach (Smolen, 1971b).
In a study of chemoradiotherapy-induced thrombocytopenia by Krzyzanski et al. (2015), no
biophase kinetics were addressed. Rather, the drug (carboplatin) was assumed to have an
on/off effect given by
Tx(t) =
Kmax if tj ≤ t ≤ tj + TTx,0 otherwise, (1.18)
15
that acted on the elimination of cells. Here, tj represents the starting time of the chemora-
diotherapy, TTx the duration of the toxic effect and Kmax is the maximal toxic effect. The
study by Krzyzanski et al. (2015) demonstrated that DRT modelling does not necessarily
need to include a compartmental biophase.
1.3 Summary and perspectives
DRT data analysis could be an option when the traditional PK-PD approach fails. This
occurs when exposure data are lacking or are uninformative, which may be due to:
• Exposure sampling is difficult—quick drug turnover, drug concentrations below limits
of quantification, local administration etc.
• Exposure sampling is undesirable—clinical studies, in particular within paediatrics.
• Exposure data are uninformative about the drug exposure—e.g., pulmonary adminis-
tered drugs or drugs that penetrate the blood-brain barrier.
• Large time differences between the initial and terminal phase—biologics (Morrow and
Felcone, 2004).
The technique has been applied for describing drug behaviour in several therapeutic areas
(see Table 1.1). In almost all of these studies, simple biophase models were used with
first-order elimination and first-order absorption (the latter being applied in cases where
drug is not directly administered into the biophase). During recent years, DRT modelling
has frequently been applied in clinical oncology (Buil-Bruna et al., 2014; Frances et al., 2011;
Parra-Guillen et al., 2013; Paule et al., 2012; Ramon-Lopez et al., 2009; Wilbaux and He,
2014)—a therapeutic area where invasiveness is undesirable. As for clinical oncology studies,
invasiveness is an issue in paediatric studies. Thus, DRT modelling is a promising technique
when other approaches fails (Tod, 2008).
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Chapter 2
Methods and models
This chapter serves to illustrate how to perform dose-response-time (DRT) data analysis.
In principle, the study constitutes five fundamental modelling techniques; model selection,
identifiability analysis, parameter fitting, sensitivity analysis, and modelevaluation. These
techniques will be examined in a logical order—albeit remembering that modelling is an
iterative exercise where the modeller goes back and forth until the final model meets some
quantitative or qualitative criteria. Since the methods ultimately are designed to be applied
in pharmacological studies, particular focus will be on the implementation of the ideas in
various examples.
The first section of this chapter covers model selection in a standard DRT data analysis—
wherein mean population behaviours are described. Central to these studies is the choice
of the biophase function. The biophase generally has a basic structure with, for example,
zero- or first-order drug absorption and first-order drug elimination from the biophase. The
modelled drug amount in the biophase is subsequently assumed to act as the driver of
the pharmacological response via a drug-mechanism function. To successfully choose the
PD model with a suitable drug-mechanism function, the response-time data need to be
qualitatively analysed and the characteristic response behaviours recognised. The second
section of the chapter is devoted to population modelling, where it is demonstrated how a
biophase-driven PD model may be extended to incorporate random effects. These allow for
a quantitative way to assess differences in a population, such as between-subject, inter-study,
and inter-occasional variabilities (Bonate, 2011; Davidian, Marie, 2003). To determine
such variabilities is of paramount importance in pharmacology since drug behaviours tend
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to vary in populations (Mould and Upton, 2012). The section will mainly focus on the
nonlinear mixed-effects frameworksince this has been the standard population modelling
approach in pharmacology for more than 30 years (Sheiner and Beal, 1980, 1981, 1983). In
the subsequent section, the developed models will be subject to an identifiability analysis
to verify that the parameter estimation problems are well-posed (Raue et al., 2014). The
discussion will encompass both a priori and data-based identifiability techniques. The
identifiability analysis is followed by a section on different methods for parameter estimation,
particularly for nonlinear mixed-effects models. The fourth section will cover sensitivity
analysis; a framework that studies how the system output is affected by uncertainties, or
perturbations, of the input. Sensitivity analysis techniques will be proven to be useful in both
model selection and validation. Finally, tools for validation and diagnostics are examined as
ways for quantitative and qualitative evaluation of the analysis.
2.1 Model selection
One of the biggest challenges of developing a DRT model is that the biophase dynamics and
the PD need to be assessed simultaneously. Consequently, it may be difficult to distinguish
the kinetic and dynamic properties of the drug from each other. More specifically, time-delays
in the dose-response data could, for example, be a consequence of rate-limiting absorption or
slow onset of the biomarker. To discriminate between the kinetic and dynamic properties, it
is important to have a rich1 data set. The data should preferably include multiple dosages
and administration routes, as well as careful selection of the dosages (Gabrielsson et al.,
2000).
2.1.1 Biophase function
The biophase model is generally simple due to the difficulties associated with identifying
a complex kinetic model without exposure data (for identifiability analysis, see Sec. 2.2).
More sophisticated biophase models may be used by making prior assessments and fixing
some parameter values. The simplicity of the single–compartment biophase model makes
it a suitable candidate for describing the biophase dynamics. This model will be slightly
modified depending on the drug administration route. If the drug enters directly into the
biophase, the input function is that of an intravenous (IV) administration. With a first-order
elimination rate from the biophase, denoted by k, the dynamics of the biophase following a
direct bolus input or an infusion input are given by
dAb(t)
dt
= −k ·Ab(t) with Ab(0) = D bolus, (2.1)
1Obtained from experiments where the system has been properly ‘provoked,’ thereby revealing the full
range of the drug-induced effects.
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or
dAb(t)
dt
= Inf(t)− k ·Ab(t) with Ab(0) = 0 infusion, (2.2)
where Ab(t) is the biophase drug amount, Inf(t) a function dependent on the infusion protocol,
D the drug dose (the models are illustrated in Fig. 2.1a and Fig. 2.1c, respectively). If
(a) (b) (c)
(d) (e) (f)
(g) (h) (i)
Figure 2.1: Examples drawn from the biophase model library: (a) represents a bolus input
and first-order elimination; (b) a bolus input and biphasic first-order elimination; (c) a
zero-order input and first-order elimination; (d) a zero-order input and Michaelis-Menten
elimination; (e) a first-order input and elimination; (f) a first-order input, scaled by the
biophase availability, and first-order elimination; (g) Michaelis-Menten input and first-
order elimination; (h) Michaelis-Menten input and elimination; (i) two-compartment model
with first-order distribution between the central compartment and the biophase and first-
order elimination from the biophase. The parameters Ab, Inf, k, ka, F and MM represent,
respectively, the biophase amount, the constant rate infusion input, the first-order elimination
rate constant, the first-order absorption rate constant, the biophase availability and the
Michaelis-Menten absorption/elimination process, respectively. All models presented in the
library have been applied in published DRT studies (see Table 1.1)
the drug is administered to a peripheral compartment, and subsequently absorbed into the
biophase via a first-order process, then the biophase dynamics are given by
dAa(t)
dt
= −ka ·Aa(t) with Aa(0) = D, (2.3a)
dAb(t)
dt
= F · ka ·Aa(t)− k ·Ab(t) with Ab(0) = 0, (2.3b)
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where Aa(t) is the drug amount in the absorption compartment, ka the first-order absorption
rate into the biophase, and F the availability, or the biophase availability (Smolen (1971b),
model illustrated in Fig. 2.1e). By solving for Aa(t) in Eq. (2.3a), the system can be re-written
as
dAb(t)
dt
= D · F · ka · e−kat − k ·Ab(t) with Ab(0) = 0. (2.4)
The aforementioned models are the simplest biophase functions and these have been frequently
applied in DRT studies (see Table 1.1). Apart from these models, Andersson et al. (2015)
introduced nonlinear absorption/elimination models to describe the biophase dynamics.
In their study, an extravascular dose D was absorbed into the biophase via a nonlinear
Michaelis-Menten model, which gives the following biophase dynamics
dAa(t)
dt
= −Vmax ·Aa(t)
Km +Aa(t)
with Aa(0) = D, (2.5a)
dAb(t)
dt
=
Vmax ·Aa(t)
Km +Aa(t)
− k ·Ab(t) with Ab(0) = 0, (2.5b)
where Vmax is the maximal absorption rate from the absorption compartment and Km the
drug amount at which 50% absorption is attained. The biophase elimination could, of course,
also be modelled using the nonlinear Michaelis-Menten model. A typical scenario is that the
drug amount (or concentration) is measurable in a central compartment (e.g., plasma) but
not in the biophase. In cases like these, multi-compartmental biophases could be applied.
Such a model could, for example, be characterised in the following way:
dAb(t)
dt
= k12 ·Ac(t)− k21 ·Ab(t)− k ·Ab(t) with Ab(0) = D, (2.6a)
dAc(t)
dt
= k21 ·Ab(t)− k12 ·Ac(t) with Ac(0) = 0, (2.6b)
where Ac(t) is the drug amount in a central compartment, k12 and k21 are the absorption/e-
limination rates between the biophase and central compartment, k the elimination rate from
the biophase out of the system, and D the drug amount (model illustrated in Fig. 2.1i).
Models like the aforementioned have been used by Fisher et al. (1997) among others (Smolen,
1971b; Warwick et al., 1998).
2.1.2 Pharmacodynamic model
The pharmacology literature encompasses a plethora of PD models—aimed at describing
different pharmacological phenomena. This section will cover the ones most commonly
applied in DRT studies. This includes, for instance, direct and indirect models with linear
and nonlinear dose-response relations. For a more thorough discussion on PD modelling, see
for example Gabrielsson and Weiner (2010).
The PDs in the DRT framework are assumed to be driven by the biophase amount Ab(t). If
there is a rapid equilibrium between the biophase amount and the pharmacological effect
then the system can be modelled using a direct response model (Gabrielsson and Weiner,
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2010). The simplest possible direct response model assumes a linear effect-amount relation
given by
E(t) = E0 ± β ·Ab(t), (2.7)
where E(t) is the effect, E0 the baseline, and β the slope parameter. However, the linear
dose-response relationship is unbounded and therefore violates basic physiological principles
(e.g., a limited receptor pool). The Emax model, on the other hand, has a saturable dose-
response relationship as well as physiologically interpretable parameters (Gabrielsson and
Weiner, 2010). The standard (γ = 1) and sigmoidal form of this model are given by
E(t) = E0 ± Emax ·A
γ
b(t)
EDγ50 +A
γ
b(t)
, (2.8)
where Emax is the maximal drug effect (efficacy), ED50 the biophase drug amount at 50%
maximal effect (potency), and γ the Hill exponent. The linear and saturable direct response
models in Eqs. (2.7) and (2.8) have been applied in several DRT studies (Uehlinger et al., 1992;
Port et al., 1998; Bragg et al., 1994; Fisher et al., 1997; Fisher and Wright, 1997; Warwick
et al., 1998). To illustrate the connection between the Emax-model and ligand-receptor
binding, consider the law of mass action, which states
[L] + [R]
kon

koff
[LR], (2.9)
where [L] is the free concentration of a specific ligand, [R] the free concentration of the
corresponding receptor, [LR] the free concentration of the receptor-ligand complex, kon
the rate constant for association, and koff the rate constant for the dissociation. For the
receptor-ligand binding, assume that
• The interaction is reversible.
• The interaction is rapid.
• The receptor has one binding site for the ligand.
• The receptor, ligand, and receptor-ligand complex are in equilibrium.
Under equilibrium, Eq. (2.9) implies that
kon[R][L] = koff [LR], (2.10)
or
[R][L]
[LR]
=
koff
kon
= Kd, (2.11)
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where Kd is known as the the dissociation constant. Now, assume that a drug-induced effect
is proportional to the free concentration of the receptor-ligand complex as
E = α · [LR]. (2.12)
This implies that the maximal drug-induced effect is given by
Emax = α · ([LR] + [R]). (2.13)
By taking the fraction of the drug-induced effect and the maximal effect, we get
E
Emax
=
[LR]
[LR] + [R]
(2.14)
=
1
1 + [R][LR]
. (2.15)
Using the identity in Eq. (2.11) gives
E
Emax
=
[L]
[L] +Kd
(2.16)
or
E =
Emax · [L]
[L] +Kd
, (2.17)
and we are done. To conclude, under some assumptions, the Emax-model may be derived
from the law mass action of receptor-ligand binding.
The previous discussion has focused on direct response models. Generally though, the
relationship between the biophase drug amount and the pharmacological effect is indirect,
whereby turnover models are frequently applied (Dayneka et al., 1993). In a turnover model,
the response R(t) is given by
dR(t)
dt
= kin − kout ·R(t) with R(0) = R0, (2.18)
where kin and kout are the turnover rate and the fractional turnover rate of the response,
respectively, and R0 the baseline response. Depending on the nature of the drug, its induced
effect is typically given by a drug-mechanism function H(Ab(t)) that is either stimulatory
H(Ab(t)) = S(Ab(t)) = 1 +
Smax ·Aγb(t)
SDγ50 +Ab(t)
γ
, (2.19)
or inhibitory
H(Ab(t)) = I(Ab(t)) = 1− Imax ·A
γ
b(t)
IDγ50 +A
γ
b(t)
. (2.20)
26
Here, Smax and Imax represent the maximum stimulatory and inhibitory effect (efficacies),
respectively, SD50 and ID50 are the biophase drug amounts were 50% of the effect is attained
(potencies), and γ is the Hill exponent. The stimulatory (displayed in Eq. (2.19)) or inhibitory
(displayed in Eq. (2.20)) drug effect acts on the production or loss (or both) of response
in Eq. (2.18). For example, a stimulatory effect on the turnover would yield the following
relation:
dR(t)
dt
= kin · S(Ab(t))− kout ·R(t), (2.21)
and an inhibitory effect on the fractional turnover would be given by
dR(t)
dt
= kin − kout · I(Ab(t)) ·R(t). (2.22)
Turnover equations with nonlinear inhibition or stimulation have frequently been applied in
DRT studies (see for example Abou Hammoud et al. (2009); Audren et al. (2004); Lalonde
and Gaudreault (1999); Gabrielsson et al. (2000); Mikaelian et al. (2013); Wilbaux and He
(2014)).
Example 2.1.2.1 Turnover model (Gabrielsson et al., 2000)
In order to illustrate how the characteristic behaviours of a generic response-time
data set are extracted, consider the following example where an antinociceptive drug has been
given both as an IV bolus (in two different doses of 40 and 80 µg kg−1) and subcutaneously
(in three different doses of 50, 100, and 200 µg kg−1) to Sprague-Dawley rats (the data are
adapted from Gabrielsson et al. (2000)). Post drug administration, radiant heat is focused
on the tail of the rat and the time, in seconds, is measured until the rat removes its tail. The
response-time behaviour was observed during 180 min (the data are illustrated in Fig. 2.2).
Since the drug was administered via two different routes, we need two separate biophase
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Figure 2.2: Example of response-time data (dots) collected from from five different individuals
following IV bolus doses of 40 and 80 µg kg−1 and subcutaneous doses of 50, 100, and
200 µg kg−1, respectively, and model simulations of the response (solid lines).
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functions. The following functions are selected:
dAb(t)
dt
= −k ·Ab(t) with Ab(0) = DIV bolus, (2.23)
and
dAb(t)
dt
= DSC · ka · e−kat − k ·Ab(t) with Ab(0) = 0 subcut., (2.24)
where k and ka are the first-order elimination and absorption rates of the biophase, respec-
tively, whilst DSC and DIV represent the subcutaneous and bolus (intravenous) drug dose,
respectively. Now, by inspection of the response-time data, there appears to be a constant
baseline response. Moreover, the onset of response is not instantaneous, and, thus a turnover
model is needed. Furthermore, there is a peak-shift between the two IV doses2, indicating a
nonlinear stimulatory drug-mechanism function. Gabrielsson et al. (2000) concluded that
the following PD model is a suitable choice
dR(t)
dt
= kin ·
(
1 +
Smax ·Aγb(t)
SDγ50 +A
γ
b(t)
)
− kout ·R(t) with R(0) = R0, (2.25)
where kin and kout are the turnover and fractional turnover rates of the response, respectively,
R0 is the baseline response, Smax the efficacy, SD50 the potency, and γ the Hill exponent.
In cases where the turnover rate, or fractional turnover rate, is saturable, the standard
turnover model of Eq. (2.18) can be expanded to incorporate nonlinear elimination and/or
production. In particular, Gabrielsson and Peletier (2014), applied a saturable elimination
model to the describe locomotor activity, following treatment with dexamphetamine. In
their study, the response was given by
dR(t)
dt
= S(Ab(t))− kout,max R(t)
Km +R(t)
with R(0) = 0, (2.26)
where S(Ab(t)) is a stimulative drug-mechanism function, kout,max the maximal fractional
turnover of R(t), and Km the response at 50% maximal turnover rate.
Some drugs experience time-delays in their onset. In cases like these, a transduction pathway
with additional compartments can be added to the turnover model in Eq. (2.18) to capture
the time-delay:
dR1(t)
dt
= kin ·H(Ab(t))− kout ·R1(t) with R1(0) = R0,
...
...
dRi(t)
dt
= kout · (Ri−1(t)−Ri(t)) with Ri(0) = R0, i = 2, . . . , n.
(2.27)
2That is, the peak of the lower IV dose appear to occur after ∼20 min while the peak of the higher dose
appear to occur after ∼30 min.
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Here, n is the number of steps in the transduction pathway and Rn(t) is the measured
response. The transduction compartment model has been used by, for example, Krzyzanski
et al. (2015) among others (Gabrielsson and Peletier, 2014; Hamberg et al., 2013; Perez-Ruixo
et al., 2012; Ramon-Lopez et al., 2009).
For physiological systems that exhibit feedback behaviours, displayed as rebound and/or
overshoot in the response dynamics, a moderator model has been suggested by Gabrielsson
et al. (2000) among others (Andersson et al., 2015; Luu et al., 2009; Isaksson et al., 2009;
Gabrielsson and Peletier, 2014)). In the moderator model, the response affects the moderator
via a first-order process
dM1(t)
dt
= ktol · (R(t)−M1(t)) with M1(0) = M0,
...
...
dMi(t)
dt
= ktol · (Mi−1(t)−Mi(t)) with Mi(0) = M0, i = 2, . . . , n,
(2.28)
where ktol is the turnover rate of the moderator, M0 the moderator baseline (typically
M0 = R0), and n the number of moderator compartments (n depends on the magnitude
of the feedback mechanisms). The feedback impacts the turnover or fractional turnover
(or both) of response in equation (2.18). For example, a feedback mechanism that directly
triggers a decrease in the turnover, and slowly triggers an increase in the fractional turnover,
of response would be given by
dR(t)
dt
= kin · M0
M1
− kout · Mn
M0
·R(t) with R(0) = R0. (2.29)
The models presented here and, in the first section, are applicable when the modeller wants
to describe a single one-to-one relation between dose and response. This is sufficient if
each dose-group comprises a single individual, or when the primary aim is to describe
population mean behaviour. However, there are situations in which individual variations in
the dose-response relationship need to be quantified (this is specifically relevant in clinical
studies). In order to do this, a population modelling framework needs to be applied. The
models that have been presented up to know will from here on be referred to as the base
structure in a population model. The additional components that are introduced in the next
section constitute the statistical model.
2.1.3 Mixed-effects modelling
Kinetic and dynamic drug properties are prone to vary between individuals with in a
population (Mould and Upton, 2012). The distinctive traits of an individual, such as sex,
weight, age, etc., affect the physiology and thereby the pharmacology (Bonate, 2011). The
extent to which these variations influence the pharmacology needs to be quantified to ensure
drug safety and efficacy throughout the population. The na¨ıve approach in establishing
between-subject variability is performed in two stages; first, the pharmacological model
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is fitted on an individual level, through which parameter estimates are obtained for each
subject. In the second stage, some form of regression analysis is performed on the resulting
parameter distributions. From this analysis, the modeller may draw statistical inference
about the system. This approach is known as the standard two-stage (STS) (Bonate, 2011)
method. The disadvantage of using the STS method is that information is lost, and variability
added, in the intermediate step. Moreover, the method is constrained by the assumption
that individual data are rich enough whereby parameter estimations can be performed in a
practically identifiable manner (see Sections 2.2 and 2.3 for parameter identifiability and
estimation, respectively). Due to these limitations of the STS method, another framework is
often required for quantifying population characteristics.
The nonlinear mixed-effects (NLME) method performs the two stages of the STS method
simultaneously, thereby alleviating the problems associated with the STS approach (Bonate,
2011). The title mixed effects refers to the fact that the model has both fixed effects
and random effects. The fixed effects refer to parameters that are shared throughout
the population, while the random effects introduce between-subject variations. A NLME
state-space model is defined in the following way:
x˙i(t) = f(xi(t),ui(t),φi) with xi(0) = x0(φi), (2.30a)
yij = h(xi(tj),ui(tj),φi) + eij for i = 1, . . . , N, (2.30b)
where xi(t) ∈ Rn represents the state variables for the ith individual (e.g., biophase amounts,
PD responses), yij ∈ Rm the observations of the system at times tj (i.e., the data), ui(t) ∈ Rq
the input functions (e.g., IV or PO doses), φi ∈ Rr the parameters, x0 the initial conditions,
eij ∼ N (0,R(xi(tj),ui(tj),φi)) the residual variabilities (e.g., measurement noise, model
misspecification), and N the number of individuals in the population. The vector-valued
function f(xi(t),ui(t),φi) describes the dynamics of the system and h(xi(t),ui(t),φi)
characterises the system observations—both functions are assumed to be smooth. The
parameters of the ith individual φi have a functional relation to the fixed effects θ ∈ Rp via
φi = g(θ,Zi,ηi), (2.31)
where the Zi are the individual covariates (e.g., sex, age, weight) and ηi the random
effects, which are usually assumed to be multivariate Gaussian ηi ∼ N (0,Ω) (Grimmett
and Stirzaker, 2002) with covariance matrix Ω ∈ Rs×s (s represents the number of random
effects). The vector-valued function g is assumed to be smooth with respect to its arguments.
As an example, consider a drug with PK properties that vary between subjects. Assume
that the clearance of the ith individual is given by
Cli = α · weightβi , (2.32)
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and the volume of distribution given by
Vi = Vµ · eηVi . (2.33)
In this example, Cli, Vi ∈ φi are individual parameters, α, β, Vµ ∈ θ fixed effects, ηVi ∈ ηi a
random effect, and weighti ∈ Zi a covariate. Since ηVi is normally distributed, Eq. (2.33)
implies that the volume of distribution is log-normally distributed in the population. This is
a common assumption for PK parameters, particularly due to the positive support of the
log-normal distribution (Bonate, 2011). Apart from between-subject variability, the NLME
framework allows for inter-study and/or inter-occasion variabilities. These variabilities are
typically considered in drug trials that are conducted over extended periods of time, and in
meta-analyses, wherein data are collected from several studies (Bonate, 2011). Inter-study
and inter-occasion variabilities may manifest themselves on either of the fixed or random
effects, or both. As an example, assume that data have been collected from S different
studies. If a model parameter is log-normally distributed, with standard deviations that vary
between the studies (i.e., differences in the random effects), then the parameter of the ith
individual φi is given by
φi = θµ · exp(ηi + η1 · Study1 + . . .+ ηS · StudyS) (2.34)
where θµ is the fixed effect, ηi and η1, . . . , ηS are random effects and
Studyk =
1 if individual i is in study group k0 otherwise. (2.35)
Similarly, if the fixed effects differ, but the random effects stay fixed, the parameter for the
ith individual is given by
φi = (θµ + θ1 · Study1 + . . .+ θS · StudyS) · exp(ηi), (2.36)
where θµ and θ1, . . . , θS are fixed effects and ηi is a random effect. Inter-occasional variability
is modelled in the exact same way as inter-study variability.
The remaining, unexplained discrepancy between the observed and predicted system be-
haviour is referred to as the residual variability. The occurrence of this variability is generally
a consequence of model misspecification and measurement noise. Residual variability is
modelled in a couple of different ways—often dependent upon the types of observation. With
an observed response Ri(t) and predicted response R̂i(t), the residual variability is typically
additive
Ri(t) = R̂i(t) + ei(t) (2.37)
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or proportional
Ri(t) = R̂i(t)(1 + ei(t)) (2.38)
or a combination of them
Ri(t) = R̂i(t)(1 + ei1(t)) + ei2(t). (2.39)
As a rule of thumb, the proportional model is applied when the observations vary substantially
in magnitude (for example, drug exposure is often measured on a log-scale with 10-fold
differences between the maximal and minimal exposure), whilst the additive model is applied
when the observations vary little around a constant baseline. The variabilities are assumed to
be Gaussian ei ∼ N (0,R(xi(t),ui(t),φi)), often uncorrelated and time-independent. This
implies that eik ∼ N (0, σ2), for the kth variability and where σ is the standard deviation.
Generally, one assumes that the posed model accurately describes the pharmacology and
that any deviations are solely due to noisy data (Leander et al., 2014, 2015). This is a very
strong assumption, yet is frequently made (typically for convenience). An alternative way is
to try to quantify the model misspecification by applying stochastic differential equations
(SDE’s) (rather than ordinary differential equations). In the SDE framework, the dynamical
model uncertainties are estimated—besides the aforementioned sources of variability (for an
introduction to SDE’s see Klebaner (2005) and for examples in pharmacology see Leander
et al. (2014, 2015)).
2.1.3.1 Modelling random effects
The na¨ıve way of modelling random effects in an NLME model is to assume that all parameters
vary between individuals. However, as the number of additional parameters—introduced by
including random effects—grow as n2 (n being the number of random effects) this exhaustive
strategy is often infeasible. In fact, the number of random effects is constrained by the
quantity and quality of the data and the choice of estimation algorithm (for details on the
performance of different estimation algorithms, see Plan et al. (2012)). As data are often
limited, a subset of the model parameters needs to be selected for estimation on an individual
level. This is a non-trivial task that will be addressed in the following discussion:
In the ideal situation (i.e., in the case of sufficiently rich data and utilising an optimal
estimation algorithm), random effects may be included in all of the parameters. The parameter
estimation will then reveal if any of the random effects are superfluous. Redundancy is
inferred by inspecting the covariance matrix where entries and eigenvalues that are close to
zero indicate that the model is (probably) over-parametrised (Pinheiro et al., 1995). With
an over-parametrised model, reductions are made by removing the random effects that have
corresponding eigenvalues close to zero.
If the data are not sufficiently rich, whereby a full covariance matrix cannot be estimated,
a simple diagonal matrix may be applied. The parameters are then estimated and the
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correlation between the empirical Bayes estimates (EBE) (i.e., the individual parameters
φi) is investigated to determine if any of the random effects are correlated. If correlations
are apparent, the corresponding entries in the covariance matrix may be added whereby the
matrix, and the other parameters, are re-estimated.
However, the extent of the data often prohibits random effects to be added to all system
parameters (even in the case of a simple covariance matrix). In this case, insightful knowledge
of the physiology and pharmacology may prove useful. When applying a semi-mechanistic
model, it might be biologically justified to keep some parameters fixed in a population and
vice versa for varying parameters. However, if the modeller lacks a deeper understanding of
the system, an a priori sensitivity analysis (see Sec. 2.4)—wherein the impact the respective
parameters have on the system output is quantified—often provides a valuable tool. If
the model output is sensitive to changes in a specific parameter, this may indicate that
this parameter should include a random effect to enhance the model’s ability to pick up
different variabilities and to make the system more flexible. However, the system sensitivity
is analysed at a specific point in the parameter space, which in turn is chosen by graphically
analysing the data, from prior physiological knowledge, and/or from model simulations.
Consequently, the approach is crude and only holds locally.
Example 2.1.3.2 Mixed-effects turnover model
This example demonstrates how the NLME framework is implemented given a standard
response-time data set—generated by simulation. The example is inspired by the study
by Urquhart and Li (1969b) on adrenocortisol secretion following administration of the
hormone adrenocorticotropin (ACTH). The ACTH affects the secretion rate of cortisol, and
has been given for 6 h as constant-rate IV infusion to eight separate individuals. These
individuals demonstrate different responses to the drug (the data are illustrated in Fig. 2.3).
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Figure 2.3: Example of cortisol secretion rate response-time data collected from from eight
different individuals following IV infusions of ACTH 6 h. The data were simulated (inspired
by the study by Urquhart and Li (1969b)).
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It is assumed that the drug enters directly into the biophase and that it follows a first-order
elimination process. The biophase dynamics are then given by
dAb(t)
dt
= Inf(t)− k ·Ab(t) with Ab(0) = 0, (2.40)
where k is the first-order elimination rate from the biophase and Inf(t) the drug infusion func-
tion. Inf(t) is implemented as a step-function with magnitude corresponding to the infusion
rate. By inspecting the response-time data it is apparent that the drug effect is stimulative.
Furthermore, the initial time-delay suggests an indirect dose-response relationship whilst the
post-infusion data indicate that there is a constant baseline. Due to the indirect response,
we choose to describe the response dynamics using a turnover model. Now, by inspecting the
initial onset and the post-infusion drop in response, there is an apparent tendency for the
response to overshoot and rebound. These typical feedback characteristics are implemented
using a moderator compartment that will act on the fractional turnover of the response.
Thus, the resulting PD model is given by
dR(t)
dt
= kin ·
(
1 +
Smax ·Ab(t)
SD50 +Ab(t)
)
− kout · M(t)
R0
·R(t) with R(0) = R0, (2.41)
and
dM(t)
dt
= ktol · (R(t)−M(t)) with M(0) = R0, (2.42)
where kin and kout are the turnover and fractional turnover rate, respectively, R0 the baseline
response, SD50 the potency, Smax the efficacy, and ktol the moderator turnover rate. The
model described by Eqs. (2.40), (2.41), and (2.42) constitutes the base structure of the
NLME model. Assuming that R(t) and M(t) initially are at steady-state with R(t) = R0
and M(t) = R0, the turnover rate kin may be eliminated as dR/dt = 0 implies that
0 = kin ·
(
1 +
Smax ·Ab(t)
SD50 +Ab(t)
)
− kout · M(t)
R0
·R(t), (2.43)
and so at t = 0
0 = kin − kout ·R0, (2.44)
whereby
kin = kout ·R0. (2.45)
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Consequently, the remaining fixed effects θ are given by the vector
θ =

k
kout
R0
SD50
Smax
ktol

. (2.46)
The statistical part of the NLME model will comprise a number of random effects. Now,
efficacy is a drug-specific property that is assumed to be fixed in the population. The
remaining parameters are assumed to be log-normally distributed3. The individual parameters
for the ith individual (i = 1 . . . 8) are given by
ki = k · eηki (2.47a)
kouti = kout · eηkouti (2.47b)
R0i = R0 · eηR0i (2.47c)
SD50i = SD50 · eηSD50i (2.47d)
ktoli = ktol · eηktoli (2.47e)
where k, kout, R0, SD50, and ktol are the fixed effects. Let ηi be the random effects for the
ith individual, given by
ηi =

ηki
ηkouti
ηR0i
ηSD50i
ηktoli

. (2.48)
Then, ηi ∼ N (0,Ω) with
Ω =

ω2k ωkkout ωkR0 ωkSD50 ωkktol
ωkoutk ω
2
kout
ωkoutR0 ωkoutSD50 ωkoutktol
ωR0k ωR0kout ω
2
R0
ωR0SD50 ωR0ktol
ωSD50k ωSD50kout ωSD50R0 ω
2
SD50
ωSD50ktol
ωktolk ωktolkout ωktolR0 ωktolSD50 ω
2
ktol

. (2.49)
As covariance matrices are symmetric, the off-diagonal entries (i.e., the correlations) will
satisfy ωkoutR0 = ωR0kout , ωkoutSD50 = ωSD50kout , and so forth.
3This parameter distribution is chosen due to its positive support, which is generally expected for the
parameters of a turnover model.
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Finally, since the response-time relationship experiences relatively small deviations around a
constant baseline, an additive residual error model is chosen. Consequently, the observations
are assumed to relate to the model response R(t) as
yij = R(tj) + eij where i = 1, . . . , 8, j = 1, . . . , ni, (2.50)
and eij ∼ N (0, σ2).
The chosen NLME model comprises several parameters. In particular, the covariance matrix
alone has 10 unique ones. It remains to examine if all of these can be estimated given the
quality and quantity of the data available. However, before that, it must be ensured that
the parameters are identifiable.
2.2 Parameter identifiability
In order for a parameter estimation problem to be well-posed, the parameters need to be
uniquely defined by the input-output relation4 of the model. A model for which this holds is
known to be structural identifiable. For a formal definition, consider a state-space model
given by
x˙(t) = f(x(t),u(t),θ) with x(0) = x0 = g(θ), (2.51a)
y(t) = h(x(t),u(t),θ), (2.51b)
where x(t) ∈ Rn represents the state variables (e.g., biophase amounts, PD responses),
y(t) ∈ Rm the observations of the system (i.e. the data), u(t) ∈ Rq the input functions (e.g.,
IV or PO doses), θ ∈ Θ ⊂ Rp the system parameters (e.g., potencies, efficacies, turnover
rates—here, Θ is the feasible parameter space), and where the vector-valued functions f , g
and h are smooth with respect to their respective arguments. Assuming ideal, noise free
observations, the system defined by Eqs. (2.51a) and (2.51b) is said to be structurally globally
identifiable at θ ∈ Θ if θ¯ ∈ Θ and y(t,θ) = y(t, θ¯) (for all t) imply that θ = θ¯. If this
property holds in a neighbourhood of θ then the model is said to be locally identifiable
at θ (Anguelova et al., 2012; Raue et al., 2014; Yates et al., 2009). Moreover, the model
itself is said to be structurally globally/locally identifiable if the previous statements hold
for any generic θ ∈ Θ. If this is not the case, the model is structurally non-identifiable (or
unidentifiable).
Example 2.2.0.1 Non-identifiable PK model
A well-known example of an unidentifiable PK model is the one-compartment absorption
model following oral administration. Given a dose D, the concentration of the central
4Provided that the input and output functions satisfy some conditions of ‘persistence of excitation’ (see
Bellman and A˚stro¨m, 1970 (Bellman and A˚stro¨m, 1970)).
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compartment C(t) is given by
V · dC(t)
dt
= D · F · ka · e−kat − Cl · C(t) with C(0) = 0, (2.52)
where F is the bioavailability, ka the absorption rate, Cl the clearance, and V the volume of
distribution. This equation can be solved analytically as
C(t) =
D · F · ka
V · (ka − ke) (e
−ket − e−kat), (2.53)
where ke = Cl/V . Given the relation between D and C(t) in Eq. (2.53), it is trivial
to see that the degrees of freedom of the system can be reduced, without any loss of
generality, by replacing the fraction F/V with a parameter α. Hence, the individual
parameters F and V (but not their fraction) are non-identifiable, as is the model (by
definition). Yet, the parameters ka and ke are locally identifiable, and the model as a whole is
structurally identifiable if re-parameterised with α or by fixating any of the parameters F or
V . Given a non-identifiable model, multiple sets of parameters will yield the same response
behaviour, rendering any interpretations of the estimates futile. Even if the estimation
procedure converges and an optimal solution is found—with high accuracy and precision in
the parameter estimates—the model might still be non-identifiable (Janze´n, 2016). Thus,
convergence is not a guarantee for identifiability and an a priori analysis is advised. Model
non-identifiability may be resolved by, for example, fixing some of the parameters or by
performing additional measurements or experiments (Janze´n, 2016). In the case of the
one-compartment absorption model given by Eq. (2.53), identifiability may be attained by,
for example, fixing the bioavailability to one. Alternatively, additional experiments with IV
drug administration may be conducted.
Although structural identifiability is a necessary condition for parameter identification, it is
not sufficient to guarantee a successful estimation. In fact, the model might still be practically
non-identifiable (Raue et al., 2009; Janze´n, 2016), i.e., the parameter estimates cannot be
determined—with acceptable precision and accuracy—given the available data. Practical
non-identifiability can occur when, for example, the quality of the data is low and/or when
the system has not been sufficiently ‘excited’ 5 (Raue et al., 2014).
2.2.1 Identifiability methods
Identifiability analysis can be performed using various methods and software (Raue et al.,
2014). The following discussion will cover the fundamental concepts of two different a priori
identifiability analysis approaches, with corresponding references to software where these are
implemented. An additional data-driven identifiability method will be discussed in Sec. 2.3.
5The system could have been challenged with poorly chosen dosages (for example, exposures way below
or way above the drug potency).
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2.2.1.1 Input-output relation
Assume a general state-space model, as presented in Eqs. (2.51a) and (2.51b), with functional
dependencies f , g, and h that are rational or polynomial in their respective arguments.
By repeatedly differentiating the output function, the state variables of this model can be
eliminated to obtain an input-output representation of the system, depending only on u(t)
and y(t) and their derivatives. This representation can be expressed as a polynomial, with
monomials that are algebraically dependent and arise from a differential ring (Bellu et al.,
2007) generated by the output functions y(t). This polynomial is in turn parametrised by
rational expressions in θ. By introducing an auxiliary parameter θ¯ in the input-output
relation, the coefficients of the monomials can be pair-wise compared to establish if they are
linearly independent and that θ = θ¯, which will imply global identifiability of the model.
Example 2.2.1.2 Identifiable turnover model
As an example, we derive the input-output relation of the following DRT model
dAb(t)
dt
= −k ·Ab with Ab(0) = D, (2.54)
and
dR(t)
dt
= kin − (1 + α ·Ab(t)) · kout ·R(t) with R(0) = R0, (2.55)
where Ab(t) is the biophase amount, R(t) the PD response, k the biophase turnover rate,
kin and kout the turnover and fractional turnover rate of the response, respectively, α the
slope parameter, R0 the baseline response, and D the bolus drug dose. In this case, D is the
known input and y(t) = R(t) is the measured output. It is trivial to see that the parameter
R0 is identifiable as y(0) = R0. We will therefore exclude R0 in the following input-output
analyis. Now, by replacing R(t) with y(t) in Eq. (2.55) and differentiating we get
y¨(t) = −α · A˙b(t) · kout · y(t)− (1 + α ·Ab(t)) · kout · y˙(t). (2.56)
Eqs. (2.54) and (2.55) allow us to re-write Ab(t) and A˙b(t) in terms of R(t), and thereby in
terms of y(t), as
Ab(t) =
kin − y˙(t)− kout · y(t)
kout · α · y(t) , (2.57)
and
A˙b(t) = −k · kin − y˙(t)− kout · y(t)
kout · α · y(t) . (2.58)
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Substitution of Eqs. (2.57) and (2.58) in Eq. (2.56) gives
y¨(t) · y(t) + (kin − y˙(t)) · y˙(t) + k · y˙(t) · y(t) + k · kout · y(t)2 − k · kin · y(t) = 0, (2.59)
which represents a reduced output relation6, independent of the remaining state variables.
Assume that there exists another set of parameters θ¯ given by
θ¯ = {k¯, k¯in, k¯out, α¯}, (2.60)
that satisfies Eq. (2.59). By comparing the coefficients of the corresponding monomials we
obtain
k = k¯, (2.61a)
kin = k¯in, (2.61b)
k · kout = k¯ · k¯out, (2.61c)
...
From the Eqs. (2.61a) to (2.61c) it follows that k, kin, and kout are uniquely identifiable.
Knowing this, Eq. (2.55) yields that α also is uniquely identifiable. Thus, the model is
globally structurally identifiable.
The advantages of the input-output method are that it can be applied to determine global,
local, or non-identifiability. Furthermore, the method performs a priori identifiability, where
no data are needed (Janze´n, 2016). However, the method is very computationally expensive
for high dimensional nonlinear systems, in terms of calculation time (Raue et al., 2014).
An implemented Maple version have been presented by Forsman (1991) and Evans et al.
(2013). Moreover, the approach has been implemented in similar way in the software DAISY
(Differential Algebra for Identifiability of SYstems) (Bellu et al., 2007).
2.2.1.3 Exact arithmetic rank approach
Before presenting the exact arithmetic rank (EAR) method, we will consider an alternative
way of defining local identifiability (based on system observability (Sedoglavic, 2002)). Recall
that the system output y(t) can be written as a vector-valued function of the states x(t),
the input functions u(t), and the parameters θ as
y(t) = h(x(t),u(t),θ). (2.62)
6Reduced in the sense that this expression only includes the output function and its derivatives (note
that the input function is only present in the initial condition for Ab(t)).
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Define the extended Lie derivative differential operator Lf as
Lf :=
m∑
i=1
fi
∂
∂xi
+
∑
j∈N
q∑
i=1
u
(j+1)
i
∂
∂u
(j)
i
, (2.63)
and let L(k)f denote the k:th repeated Lie derivative, i.e., L(k)f =
k times︷ ︸︸ ︷
Lf ◦ · · · ◦ Lf . Now, assume
that y(t) is analytic on an open interval around an arbitrary initial time-point t0. This
allows us to evaluate repeated differentiations of y(t) at t0. From the functional relationship
given in Eq. (2.62) and the definition of the Lie derivative in Eq. (2.63), it follows that
y(k)(t) = L(k)f h(x(t),u(t),θ). (2.64)
It can be shown that the n+ p− 1 first repeated time-derivatives of y(t) (where n and p
are the dimensions of the state space and parameter space, respectively) are algebraically
independent. Any further differentiations of y(n+p−1)(t) will yield terms that are algebraically
dependent on the previous ones (for details, see Sedoglavic (2002)). The n + p − 1 first
repeated time-derivatives of y(t) will generate a system of algebraic equations given by
y(t0) = h(x(t0),u(t0),θ), (2.65a)
y˙(t0) = L(1)f h(x(t0),u(t0),θ), (2.65b)
...
y(n+p−1)(t0) = L(n+p−1)f h(x(t0),u(t0),θ). (2.65c)
By definition, the system in Eqs. (2.51a) and (2.51b) is said to be locally identifiable if the
system of algebraic equations given by Eqs. (2.65a) to (2.65c) has solutions x(t0) and θ that
are locally unique almost everywhere7.
Now, the left-hand side of the system in Eqs. (2.65a) to (2.65c) constitutes time-derivatives
y(k)(t0)—which are known for any k = 0, 1, . . . , n+ p− 1. The right-hand side represents
expressions in x(t0), θ, and u(t0) (with the latter being known). Using vector notation, the
right-hand side may be expressed as Y(x(t0),u(t0),θ). It follows from the inverse function
theorem that Eqs. (2.51a) and (2.51b) have a locally unique solution x(t0) and θ if and only
if the Jacobian defined by
J(x(t0),u(t0), θ) =
∂Y(x(t),u(t),θ)
∂(x,θ)
∣∣∣∣∣
t=t0
, (2.66)
has full rank.
The EAR method is based on performing a rank test on the Jacobian in Eq. (2.66) (Pohjanpalo,
1978; Sedoglavic, 2002; Karlsson et al., 2012). Since identifiability is a generic property that
7Almost everywhere means that the condition holds with potential exception on a set of measure 0 (for
more on measure theory, see Folland (Folland, 1999)).
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holds almost everywhere8 in Θ, the rank of the Jacobian may be evaluated numerically
by selecting a random integer representation of the parameters and the initial conditions.
Moreover, the symbolic complexity of calculating the entries of the Jacobian may be avoided
by performing power series expansions in x0 and θ of the partial derivatives. The complexity
is further enhanced by performing all calculations modulo a large prime, preventing the
switch to slow arithmetics for large integers.
Example 2.2.1.4 Identifiable feedback turnover model
The following example demonstrates how the model of Example 2.1.3.2 can be proven to be
(at least) structurally locally identifiable, using the EAR method. The method is implemented
in the Mathematica application IdentifiabilityAnalysis (Karlsson et al., 2012). The
following Mathematica code was used:
In[1]:= Get["IdentifiabilityAnalysis‘"];
In[2]:= system = {Ab’[t] == input[t] - kb*Ab[t],
R’[t] == kout*R0*(1 + Smax*Ab[t] /(SD50 + Ab[t])) -
(M[t]/R0)*kout*R[t],
M’[t] == ktol (R[t] - M[t]),
Ab[0] == 0, R[0] == R0, M[0] == R0};
In[3]:= output = {R[t]};
In[4]:= parameters = {kb, Smax, SD50, kout, R0, ktol};
In[5]:= states = {Ab, R, M};
In[6]:= iad = IdentifiabilityAnalysis[{system, output}, states,
parameters, t, input]
Out[6]= "IdentifiabilityAnalysisData[True, <>]"
The calculations in the analysis were performed in a matter of seconds, and it can be concluded
from "IdentifiabilityAnalysisData[True, <>]" that the model is structurally locally
identifiable.
2.3 Parameter estimation
Estimating the parameters of a dose-response-time (DRT) model amounts to minimise, using
some metric, the difference between the model predicted and the observed behaviour (Bonate,
2011). In theory, this is achievable given continuous, noise-free observations of the system,
and a structurally identifiable model (Raue et al., 2009; Janze´n, 2016). Practically, the
8I.e., except possibly on a set of measure zero.
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success of a parameter estimation tends to depend on several determinants such as quantity
and quality of data, choice of estimator, desired accuracy and precision, selecting suitable
initial estimates and so forth (Rice, 1988; Nocedal and Wright, 2006; Bonate, 2011). The
following section will address different aspects of parameter estimation, provided models of
varying complexity; including simple linear models, nonlinear (fixed-effects) models, and
nonlinear mixed-effects models.
The estimation theory that is presented in this section has been adapted from Mathematical
Statistics and Data Analysis by Rice (1988) and Pharmacokinetic-Pharmacodynamic Modeling
and Simulation by Bonate (2011). The optimisation theory has been adapted from Numerical
Optimization by Nocedal and Wright (2006). The reader is referred to those texts for further
theory around estimation and optimisation.
2.3.1 Linear models
In the case of simple linear regression, the method of (ordinary) least squares is the benchmark
technique for parameter estimation. To demonstrate the method, consider a linear model of
the following form
y = Xβ + ε, (2.67)
where y represents an n× 1 vector9 of dependent variables (i.e, the observations), X is an
n× (p+ 1) design matrix of independent variables given by
X =

1 x11 · · · x1p
1 x21 · · · x2p
...
...
. . .
...
1 xn1 · · · xnp
 , (2.68)
β is the (p+ 1)× 1 vector of model parameters
β =

β0
β1
...
βp
 , (2.69)
and ε is an n× 1 vector of independent, normally distributed residuals with εi ∼ N (0, σ2)
for i = 1, . . . , n. The term Xβ is often referred to as the expectation function since
E[y] = E[Xβ + ε] = E[Xβ] + E[ε] = Xβ, (2.70)
9In this definition, we consider a single observation. The framework may readily be extended to include
an arbitrary number of observations.
42
where we have used the linearity of the expected value, the fact that E[ε] = 0, and that
X and β are deterministic. The method of least squares finds an estimate βˆ of the true
parameter β by minimising the squared difference between the expectation function and the
observations. We define the sum of squares as
Sn(β) =
n∑
i=1
(yi − yˆi)2, (2.71)
where yˆi is the predicted response at the ith time-point, given by
yˆi =
p∑
j=0
Xij βˆj , (2.72)
and n is the number of observations. Thus, the estimation problem may be stated as
arg min
β
Sn(β). (2.73)
It turns out that there is a closed-form solution to Eq. (2.91) in the linear case. To obtain
the solution, note that the partial derivatives of Sn(β) evaluated at βˆ need to satisfy
∂Sn(β)
∂βj
∣∣∣∣∣
β=βˆ
= 0 for j = 0, . . . , p. (2.74)
Thus, we have
2
n∑
i=1
yi − p∑
j=0
Xij βˆj
 (−Xik) = 0 for k = 0, . . . , p, (2.75)
or
n∑
i=1
p∑
j=0
XikXij βˆj =
n∑
i=1
Xikyi for k = 0, . . . , p, (2.76)
which in matrix notation is
XTXβˆ = XTy, (2.77)
known as the normal equations. Hence, the solution is given by
βˆ = (XTX)−1XTy. (2.78)
2.3.1.1 Accuracy and precision of the estimates
The estimate of β conveys little information about the true value unless the accuracy and
precision of the estimate are quantified. In statistical analysis, accuracy and precision are
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commonly referred to as bias and variability. Bias is a measure of how the expected value of
an estimate differs from the true value. Variability, on the other hand, quantifies the spread
of the empirical distribution of the estimate. In other words, how much separate realizations
of the true parameter differ (Taylor, 1996). By definition, a parameter estimate is unbiased
if its expected value is the true value. This is indeed the case for the estimate derived by the
least squares method (given by Eq. (2.78)) since
E[βˆ] = E[(XTX)−1XTy] = (XTX)−1XT E[y] = (XTX)−1XTXβ = β. (2.79)
Here, we have used the linearity of the expected value and the assumption that the residuals
are independent and normally distributed with E[ε] = 0.
The variability of an estimate is often expressed in its coefficient of variation (CV), also
known as the relative standard error (RSE) or relative standard deviation (RSD) (Bonate,
2011). The CV is defined as
CV =
σ
µ
× 100%, (2.80)
where σ represents the standard deviation and µ the mean of the estimate. For an estimate
βˆ, the CV is given by
CVβˆj =
√
Var (βˆj)
|βˆj |
× 100% for j = 0, . . . , p. (2.81)
The estimated variance Var (βˆj) of the jth parameter is obtianed from the covariance matrix
Cov(βˆ) = σ2(XTX)−1, (2.82)
where σ2 is the true variance of the residuals, which of course is an unknown quantity.
However, an unbiased estimate of σ2, denoted s2, is obtained as
s2 =
eTe
n− p− 1 , (2.83)
where e represents the observed residuals
e = y − yˆ. (2.84)
Example 2.3.1.2 Parameter estimation of linear model (Lefe`vre et al., 1997)
The following example is based on the work by Lefe`vre et al. (1997), who investigated how
renal impairment affects the pharmacokinetics and pharmacodynamics of the anticoagulant
desirudin. Here, desirudin clearance is the measured effect, as a function of creatinine
clearance (lowered creatinine clearance is a sign of mild renal failure). The data are obtained
from the Lefe`vre et al. (1997) study, and are illustrated in Fig. 2.4.
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Figure 2.4: Plasma clearance of desirudin in relation to creatinine clearance in patients of
various level of renal failure. The dots represent the data and the line the linear fit. The
data are obtained from the study by Lefe`vre et al. (1997).
When plotting the data, there appears to be a linear relation between the clearance of
desirudin and that of creatinine. Consequently, we choose to model the relationship as
Clde = β0 + β1 · Clcr, (2.85)
where Clde and Clcr are the clerance of desirudin and creatinine, respectively, β0 is the
intercept and β1 the slope parameter. Applying the least squares method, closed-form
estimates of β0 and β1 are obtained as
βˆ =
βˆ0
βˆ1
 = (XTX)−1XTy, (2.86)
where
X =

1 8.22
1 9.79
1 25.07
1 24.28
1 25.07
1 27.42
1 36.19
1 44.41
1 44.26
1 58.75
1 63.45
1 76.37
1 82.25
1 82.64
1 93.21
1 96.34
1 107.70
1 105.74
1 106.14
1 111.23
1 125.72

and y =

13.61
17.33
16.09
19.8
23.51
27.23
29.21
47.03
56.93
70.54
133.66
105.2
134.9
141.09
102.72
170.79
148.51
170.79
199.26
195.54
170.79

. (2.87)
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Thus, by solving Eq. (2.86) we obtain
βˆ =
−15.1
1.71
 , (2.88)
with the corresponding covariance matrix given by
Cov(βˆ) =
 92.3 −1.09
−1.09 0.0168
 . (2.89)
Hence, the variability of the parameter estimates, expressed in CV%’s, are found to be
Parameter CV%
βˆ0
√
92.3
15.2 × 100 = 63.6
βˆ1
√
0.0168
1.71 × 100 = 7.59
Table 2.1: Uncertainty in the parameter estimates, expressed in CV%’s.
The relative standard error for βˆ0 is high, while βˆ1 is relatively small. Thus, there is high
uncertainty in the estimate for the intercept.
2.3.2 Nonlinear models
Consider a nonlinear regression model given by
y = h(x;θ) + ε, (2.90)
where y represents the observations, h is the expectation function (which is assumed to be
differentiable with respect to its arguments), θ the model parameters, x the state variables,
and ε independent, normally distributed residuals. As for linear regression, the objective is
to find an estimate θˆ of the true parameters θ such that the model optimally (by means of
some measure) fits the data. This estimation problem can be approached in a similar way to
the linear case, i.e, by finding
arg min
θ
Sn(θ), (2.91)
where Sn(θ) is the sum of squares given by
Sn(θ) =
n∑
i=1
(yi − h(xi|θ))2. (2.92)
This estimation method is the nonlinear least squares estimator. An alternative approach
is to use maximum likelihood (ML) estimation; wherein the aim is to find the “most likely”
parameter estimates, given the observed data. In terms of probability, this is equivalent
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to maximising the conditional probability of the data, given the parameters. Let L(θ;y)
represent the likelihood function, defined as
L(θ;y) = f(y|θ). (2.93)
where f is the joint conditional probability density function. Assuming that the observations
are independent, the joint probability density may be written as a product of the probability
densities of the separate observations. Moreover, since the residuals of the nonlinear model
are assumed to be normally distributed, the probability density functions are Gaussian.
Thus, we have
f(y|θ) =
n∏
i=1
f(yi|θ) =
n∏
i=1
1√
2piσ
exp
(
− (yi − h(xi;θ))
2
2σ2
)
, (2.94)
where σ is the standard deviation of the residuals10. It is often convenient to consider the
logarithm of the likelihood function, rather than the function itself11. Since the logarithm
is monotonically increasing, a log-transformation will preserve the stationary points of the
likelihood function. Consequently, the likelihood function and the log-likelihood function
have the same maxima. Let l(θ;y) denote the log-likelihood function, given by
l(θ;y) = logL(θ;y) =
n∑
i=1
log f(yi|θ) = −n
2
log 2piσ2 − 1
2σ2
n∑
i=1
(
yi − h(xi;θ)
)2
. (2.95)
The ML estimation now amounts to determining
arg max
θ
l(θ;y), (2.96)
which in fact is equivalent to
arg min
θ
n∑
i=1
(yi − f(xi|θ))2 = arg min
θ
Sn(θ). (2.97)
Consequently, under the assumption that the residuals are normally distributed, ML estima-
tion and nonlinear least squares estimation are equivalent12.
The optimisation problems in Eqs. (2.96) and (2.97) do not typically have closed-form
solutions in the nonlinear case. Rather, approximate solutions are found numerically by
iteratively refining the estimates until convergence occurs. There are several optimisation
methods designed for this task, where one of the most well-known is Newton’s method.
10Note that f represents two different probability densities in this identity; the former being a multivariate
normal distribution and the latter being univariate one. Yet, for convenience, we use the same notation for
the two densities (and will do so in similar cases later in this section).
11The logarithm will, for example, transform the product of the likelihood function into a sum.
12We introduce ML estimation since it is a benchmark method within estimation theory. Moreover, the
Hessian of the objective function (used in the gradient methods of the optimisation) of the ML method is
related to the Fisher information (see Sec. 2.3.2.6), which will prove to be of importance when quantifying
the estimation errors.
47
2.3.2.1 Newton’s method
In Newton’s method, the objective function is locally approximated by its quadratic Taylor-
expansion. For the log-likelihood function13, this approximation around the iterative θk is
given by
l(θk + pk) ≈ l(θk) +∇l(θk)Tpk + 1
2
pTkH[l(θk)]pk =: mk(pk), (2.98)
where pk is the search direction, H[l(θk)] the Hessian of l evaluated at θk, and mk(pk) the
kth model function evaluated at pk (defined as the second-order expansion of l). The idea
behind Newton’s method is to choose pk such that mk(pk) is a stationary point, satisfying
∇mk(pk) = ∇l(θk) +H[l(θk)]pk = 0, (2.99)
or
pNk = −H[l(θk)]−1∇l(θk), (2.100)
which specifices the Newton step pNk . Alternatively, the step length is scaled by γk ∈ (0, 1)
such that
pNk = −γkH[l(θk)]−1∇l(θk), (2.101)
where an appropriate step length is found by imposing some form of conditions. A typical
choice are the Wolfe conditions (Wolfe, 1969, 1971), defined as
l(θk + γkp
N
k ) ≤ l(θk) + c1γk∇l(θk)TpNk (2.102a)
∇l(θk + γkpNk )TpNk ≥ c2∇l(θk)TpNk , (2.102b)
where 0 < c1 < c2 < 1. Here, c1 is typically chosen to be very small (≈ 10−4) and c2 is near
1 (Nocedal and Wright, 2006).
2.3.2.2 The Gauss-Newton method
A major drawback of Newton’s method is that the inversion of the Hessian in Eq. (2.100)
tends to be complicated, error prone, and costly. However, this inversion is avoided in many
gradient methods by employing some form of approximation of the Hessian.
13For the sake of convenience, the dependence on y in the log-likelihood function is disregarded, i.e,
l(θ) = l(θ|y).
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Consider the gradient and Hessian of the sum of squares Sn(θ), which are given by
∇Sn(θ) =
n∑
i=1
ri∇ri (2.103)
H[Sn(θ)] =
n∑
i=1
∇rTi ∇ri + ri∇2ri, (2.104)
where ri represents the residual
ri = yi − h(xi|θ) for i = 1, . . . , n. (2.105)
The Gauss-Newton method finds parameter estimates in nonlinear least squares problems,
using Newton’s method with an approximated Hessian. In this approximation, the second-
order terms in Eq. (2.104) are excluded such that
Bk =
n∑
i=1
∇rTi ∇ri = JTk Jk, (2.106)
where Bk is the approximated Hessian of the kth iteration in the Gauss-Newton method,
and Jk is the Jacobian of Sn, evaluated at θk. Thus, the Gauss-Newton step p
GN
k becomes
pGNk = −(JTk Jk)−1JTk rk, (2.107)
where
rk = y − h(x|θk). (2.108)
As for Newton’s method, this step may be scaled by a factor γk such that, for example, the
Wolfe conditions are satisfied.
It is straightforward to show that the Gauss-Newton step is taken in a descent direction
(provided that the Jacobian has full rank and the gradient is non-zero) since
pGNk ∇Sn(θk) = pGNk JTk rk = −pGNk JTk JkpGNk = −||JkpGNk ||2 ≤ 0, (2.109)
where we have used the definition of the gradient (∇Sn(θk) = Jkrk) and the Gauss-Newton
step in Eq. (2.107). Thus, provided that the step length is sufficiently small, the value of
the objective function will decrease in the kth iteration. Another advantage of the Gauss-
Newton method is that the Jacobian is often known from the calculation of the gradient.
Hence, no additional computations need to be performed when approximating the Hessian.
Moreover, in many situations, the first-order term of the Hessian dominates the second-order
term—rendering the latter insignificant. This typically occurs when the problem is “almost
linear” or if the residuals are “small”. In cases like these, the Gauss-Newton method is
expected to be efficient. Finally, the identity in Eq. (2.107) is equivalent to that of the linear
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least squares solution in Eq. (2.78). Thus, the Gauss-Newton step could be regarded as the
solution to the linear problem
min
pGNk
∥∥∥JkpGNk + rk∥∥∥2 . (2.110)
The advantage of viewing the Gauss-Newton approach as a linear problem, defined by
Eq. (2.110), is that the computation of the approximated Hessian JTk Jk is not required to
solve this problem. Rather, the problem in Eq. (2.110) may be solved by using, for example,
Cholesky or SVD decomposition, or QR factorisation. (Heath, 2002).
2.3.2.3 Levenberg-Marquardt method
The Gauss-Newton method may have convergence issues if the Jacobian is (or nearly is)
locally rank-deficient. Problems like these may be alleviated by damping the approximated
Hessian. Given that the step size of the kth iteration is insufficient, the step in Eq. (2.107)
may be damped according to
pk =(J
T
k Jk + λk1)
−1JTk rk, (2.111)
for some λk > 0. If λk is large, the relation in Eq. (2.111) approaches that of the steepest
descent. Conversely, λk ≈ 0 results in the Gauss-Newton step. By adjusting λk in each
iteration, it is ensured that the objective is reduced. This method is known as the Levenberg-
Marquardt approach (Levenberg, 1944; Marquardt, 1963). Like the Gauss-Newton method,
the problem in Eq. (2.111) may be regarded as a linear problem, given by
min
pLNk
∥∥∥∥∥∥∥
 Jk√
λ1
pLNk +
rk
0

∥∥∥∥∥∥∥
2
, (2.112)
where pLNk is the Levenberg-Marquardt step. Typically, λk is initially large and subsequently
reducued in each iteration if the step size is sufficiently small (thereby approaching Gauss-
Newton in convergence). If the step is insufficient, λk is generally increased in the following
iteration. For details and suitable choices of λk, see Marquardt (1963).
2.3.2.4 Quasi-Newton methods
The aforementioned Gauss-Newton and Levenberg-Marquardt methods are designed to find
optima in nonlinear least squares problems. The following section will introduce more
general techniques, known as quasi-Newton methods, which can be applied to optimise any
real-valued function. The quasi-Newton methods rely on approximations of the full Hessian,
and therefore tend to be better suited (than Gauss-Newton or Levenberg-Marquardt) for
nonlinear least squares problems (or equivalently, maximum likelihood problems) that are
non-smooth or highly nonlinear.
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In order to derive the quasi-Newton methods, consider a general optimisation problem given
by
minimize
x
g(x)
subject to x ∈X.
(2.113)
As in Newton’s method, f is locally approximated by its second-order Taylor expansion,
given by
g(xk + pk) ≈ mk(pk) = g(xk) +∇g(xk)Tpk + 1
2
pTkBkpk, (2.114)
where xk is the iterate, pk the search direction, mk the approximated quadratic model
function, and Bk the approximated Hessian. The iterations are intitiated with an initial
point x0 and a positive definite, symmetric Hessian approximation B0 (typically chosen
to be the identity matrix). Given x0 and B0, a search direction p0 can be found through
Newton’s equation
B0p0 = ∇g(x0). (2.115)
The subsequent Hessian approximation will then be chosen such that the gradient of the
model function is the same in the two last iterates. For a general iteration k+ 1, this implies
that
∇mk+1(0) = ∇g(xk+1) =
∇mk+1(−αk+1pk+1) = ∇g(xk)− αk+1Bk+1pk+1,
(2.116)
or
∇g(xk+1) = ∇g(xk)− αk+1Bk+1pk+1 (2.117)
if and only if
∇g(xk)−∇g(xk+1) = Bk+1(xk+1 − xk). (2.118)
where αk+1 is the step length (which again may be imposed by, e.g., the Wolfe conditions).
By introducing the notation
sk = xk+1 − xk, (2.119)
and
yk = ∇g(xk+1)−∇g(xk), (2.120)
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we can express the relation in Eq. (2.118) as
Bk+1sk = yk, (2.121)
which is known as the secant equation. Furthermore, we assume that Bk+1 is as close as
possible to Bk, and that Bk+1 is symmetric. Thus, finding the next iteration of the Hessian
amounts to finding
min
B
‖B −Bk‖
subject to B = BT and Bsk = yk.
(2.122)
The solution of the system in Eq. (2.122) gives rise to the Davidon-Fletcher-Powell (DFP)
algorithm. However, it turns out that a better choice for the updated Hessian is obtained by
letting the inverse Hessian Hk+1 = B
−1
k+1 satisfy the system in Eqs. (2.122). This will give
rise to the Broyden-Fletcher-Goldfarb-Shanno (BFGS) algorithm, which is one of the most
prominent quasi-Newton methods. By solving the system in Eq. (2.122) for the inverse of
the Hessian, we get
Bk+1 = Bk +
yky
T
k
yTk pk
− Bkpk(Bkpk)
T
pTkBkpk
. (2.123)
The updated Hessian is then employed to find the next search direction pk+1, thus re-initiates
the iterative procedure.
2.3.2.5 Convergence analysis
The optimisation methods presented in this chapter are only ensured to converge globally
under certain circumstances. In detail, given a twice continuously differentiable function
f , an initial point x0, and a symmetric positive definite initial Hessian H, the level set Ω,
defined as
Ω = {x ∈ Rn : g(x) ≤ g(x0)}, (2.124)
needs to be convex 14 and there must exist positive constants M and m such that
m ‖z‖ ≤ zTH(x)z ≤M ‖z‖ (2.125)
for all z ∈ Rn and all x ∈ Ω (‖·‖ represents the Eucledian norm (Folland, 1999)). The
stated conditions imply that g is convex on Ω and that the optimum x∗ ∈ Ω is unique.
Clearly, these conditions are strong and tend not to be satisfied. Under slightly weaker
conditions, the methods ensure local convergence. If g(x) is a quadratic function, then
the optimum is reached in a single iteration in Newton’s method. Otherwise, the method
converges quadratically under the following conditions:
14A set Ω ⊂ Rn is said to be convex if ∑ni=1 λixi ∈ Ω for any list of vectors x1, . . . ,xn ∈ Ω and
λ1, . . . , λn ∈ [0, 1] such that
∑n
i=1 λi = 1 (i.e., the set is closed under convex summation).
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(i) g(x) is twice continuously differentiable.
(ii) The Hessian is Lipschitz continuous in a neighbourhood of the optimum x∗.
(iii) x0 is sufficiently close to x
∗ (for details, see Nocedal and Wright (2006)).
Under the same conditions, the BFGS converges superlinearly (Nocedal and Wright, 2006).
Thus, Newton’s method has a higher rate of convergence than the BFGS. However, depending
on the complexity of the problem, the BFGS may be faster and more stable. For the Gauss-
Newton method, local convergence is guaranteed if
(i) The resiudal functions ri(x), i = 1, . . . , n, are Lipschitz continuously differentiable in a
neighbourhood U of the level set Ω.
(ii) The Jacobian J(x) satisfies the uniform full-rank condition15.
Similar conditions apply for the Levenberg-Marquardt method (for details, see Nocedal and
Wright (2006)). The rate of convergence of both the Gauss-Newton and Levenberg-Marquardt
methods depends on the significance of the second-order derivatives in the true Hessian or,
in other words, how good the approximation is. In the best case scenario, the convergence of
these methods is approached quadratically (indeed, the convergence is quadratic in limit).
As a final note, the convergence criteria demonstrate the importance of selecting sound initial
estimates. This is to decrease the risk of converging to a saddle point or suffering from bad
numerics.
2.3.2.6 Bias and variability of the estimates
The ML method has asymptotic properties that generally provide valid error estimates for
large sample sizes (Rice, 1988). Specifically, an estimate θˆML satisfies
θˆML
d∼ N (θ0, [I(θˆML)]−1) (2.126)
i.e, it converges in distribution to the normal distribution, centred at the true value θ0 (Rice,
1988). Here, I(θˆML) represents the observed Fisher information matrix, evaluated at
θˆML (Rice, 1988). For a formal definition of the Fisher information matrix, let X ∈ Rn be
an observable random variable and f(X|θ) the corresponding probability density function,
conditioned on the distribution parameters θ. Then, the Fisher information matrix is the
p× p (p being the number of parameters) matrix defined as
I(θ) = E
[(
∂
∂θ
log f(X|θ)
)2]
=
∫ (
∂
∂θ
log f(x|θ)
)2
f(x|θ) dx. (2.127)
It turns out that the Fisher information matrix is related to the curvature of the log-likelihood
function, which is described by the Hessian of the log-likelihood function. In fact, the expected
15I.e., there exist ξ > 0 such that
∥∥J(x)z∥∥ > ξ ‖z‖ for all z ∈ Rn and all x ∈ U .
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Hessian of the log-likelihood is given by
E
[
Hij(f(y|θ))
]
= E
[
Dij log f(y|θ)
]
(2.128)
= E
Di(Djf(y|θ)
f(y|θ)
) (2.129)
= E
[
Dijf(y|θ)
f(y|θ) −
Dif(y|θ)
f(y|θ)
Djf(y|θ)
f(y|θ)
]
(2.130)
= E
[
(Di log f(y|θ))(Dj log f(y|θ))
]
(2.131)
= −Iij(θ) (2.132)
where we have used the identity Di log f(y|θ) = Dif(y|θ)/f(y|θ) and the fact that
E
[
Dijf(y|θ)
f(y|θ)
]
=
∫
Dijf(y|θ)y = Dij1 = 0. (2.133)
Here, we have interchanged the order of the derivative and the integral. This is valid if the
integrand is Lebesgue integrable, bounded, and that its derivative exists almost everywhere;
conditions that are generally satisfied for probability density functions (Folland, 1999; Rice,
1988). The relation between the Hessian and the Fisher information matrices implies that
I(θˆML) = −H[f(y|θML)], (2.134)
which is utilised in combination with Eq. (2.126) to estimate the covariance of the estimates
and approximate confidence intervals for the point estimates. In conclusion, by applying,
for example, a quasi-Newton method in combination with the maximum likelihood measure,
the model parameters may be determined. Moreover, the approximated Hessian in the
quasi-Newton method can be utilised to quantify the variability and bias of the estimates.
An alternative approach to estimating the bias of the estimates is to use some form of
bootstrapping technique (Davison and Hinkley, 1997).
Naturally, the question arises as to how to interpret the quantified bias and variability?
There is no clear answer to this issue since what is ‘acceptable’, regarding bias and variability,
depends on the application of the model. Bonate (2011) suggests that, as a rule of thumb, a
pharmacodynamic estimate is considered to be precise if its CV is below 25%.
Example 2.3.2.7 Parameter estimation of nonlinear model (Schulte et al., 1991)
The following example is based on a study by Schulte et al. (1991) on the pharmacokinetic
and pharmacodynamic properties of the drug AF-DX 116. The drug has a positive effect on
the heart rate. The increase in heart rate was measured for various plasma concentrations of
AF-DX 116. The results are illustrated on a log-linear scale in Fig. 2.5a.
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Figure 2.5: Response-concentration course of heart rate increase as a function of AF-DX 116
plasma concentration in (a). The dots represent the data and the line the fitted Emax-model.
The data are adapted from Schulte et al. (1991). (b) illustrates the path taken by Newton’s
method in the parameter estimation, starting at n = 1 and IC50 = 0.25.
By analysing the data, it appears that there is a nonlinear, saturable relationship between
concentration and response. We therefore propose the following pharmacodynamic model
E(t) =
Emax · C(t)n
ICn50 + C(t)
n
with E(0) = 0. (2.135)
To simplify the problem, we set Emax = 30. We now want to estimate the unknown
parameters n and IC50. Let the objective function be the MSE given by
g(n, IC50) =
1
m
m∑
i=1
(
yi − Emax · C(t)
n
ICn50 + C(t)
n
)2
, (2.136)
where yi represents the measured response in the ith time-point. The optimisation problem
is given by
arg min
n,IC50
g(n, IC50). (2.137)
This problem can be solved by using Newton’s method and a suitable initial estimate. A
visual inspection of the data suggests that n ≈ 1 and IC50 ≈ 0.25; these are used as our
initial estimates. In 10 steps, the method finds the optimum at n = 1.16 and IC50 = 0.271.
The parameter estimation was performed in Mathematica using the Levenberg-Marquardt
method. Finally, by inverting the Hessian of the objective function, standard errors of the
estimates were approximated with the following result:
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Parameter CV%
n
√
0.000532
0.271 × 100 = 8.50
IC50
√
0.0121
1.16 × 100 = 9.50
Table 2.2: Uncertainty in the parameter estimates, expressed in CV%’s.
Hence, with the guidelines suggested by Bonate (2011), the estimates are precise.
2.3.3 Nonlinear mixed-effects models
The following section will address parameter estimation for nonlinear mixed-effects models.
As for nonlinear regression, the parameter estimation is performed using the maximum
likelihood (ML) method. To apply the ML method, we need to derive an expression for the
population likelihood function L(θ,Ω,R;y), which is defined as
L(θ,Ω,R;y) = f(y|θ,Ω,R). (2.138)
For simplicity, the individuals are considered to be independent. Consequently, the population
likelihood can be expressed as a product of the individual likelihoods according to
f(y|θ,Ω,R) =
N∏
i=1
f(yi|θ,Ω,R). (2.139)
The underlying model is dependent on the unobserved random effects ηi. By marginalising
on ηi, the individual likelihoods can be expressed as
f(yi|θ,Ω,R) =
∫
f(yi,ηi|θ,Ω,R) dηi. (2.140)
Furthermore, the definition of conditional probability, P (A,B) = P (A|B)P (B), is used to
rewrite the joint probability density as
f(yi,ηi|θ,Ω,R) dηi = f(yi|ηi,θ,R)f(ηi|Ω) dηi, (2.141)
where f(yi|ηi,θ,R) is the conditional density function of yi, given ηi, and f(ηi|Ω) is the
marginal distribution of ηi. Both of these density functions are Gaussian with
f(yi|ηi,θ,R) = exp
−1
2
ni∑
j=1
(
εTijR
−1
ij εij + log |2piRij |
) , (2.142)
and
f(ηi|Ω) = exp
[
−1
2
(
ηTi Ω
−1ηi + log |2piRij |
)]
. (2.143)
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Here, εij represents the jth residual of the ith individual and Rij the covariance of the
corresponding residual. Let li denote the individual joint log-likelihoods such that
L(θ,Ω,R;y) =
N∏
i=1
∫
exp(li(ηi)) dηi (2.144)
The integral over ηi seldom has a closed-form solution for nonlinear systems. Moreover,
solving this integral numerically is commonly computationally heavy. To overcome this issue,
we will use the Laplacian approximation of the log-likelihoods around the point ηi0. This
approximation will render a closed-form solution of the integral. We have
l(ηi) ≈ l(ηi0) +∇l(ηi0)(ηi − ηi0) + 1
2
(ηi − ηi0)T∆l(ηi0)−1(ηi − ηi0). (2.145)
In order to eliminate the first-order term of the Laplacian approximation, we choose ηi0
to be the mode of the log-likelihoods, denoted η∗i , since it satisfies ∇l(η∗i ) = 0. Now, the
zero-order term in the approximation is independent of ηi, which allows us to place it outside
the integral and obtain
L(θ,Ω,R;y) =
N∏
i=1
exp(li(η
∗
i ))
∫
exp
[
1
2
(ηi − η∗i )T∆l(η∗i )−1(ηi − η∗i )
]
dηi. (2.146)
The remaining integral is known as a Gaussian (or Euler-Poisson) (Persson and Bo¨iers,
2005) integral, and has the following closed-form solution
∫
exp
[
1
2
(ηi − η∗i )T∆l(η∗i )−1(ηi − η∗i )
]
dηi =
∣∣∣∣∣−∆l(η∗i )(2pi)p
∣∣∣∣∣
−1/2
, (2.147)
where p is the dimension of ηi. Thus, we arrive at the following expression for the population
likelihood
L(θ,Ω,R;y) =
N∏
i=1
exp(li(η
∗
i ))
∣∣∣∣∣−∆l(η∗i )(2pi)p
∣∣∣∣∣
−1/2
. (2.148)
For convenience, we consider the logarithm of the likelihood (this is motivated in Section 2.3.2),
which is given by
l(θ,Ω,R;y) = logL(θ,Ω,R;y) =
N∑
i=1
li(η
∗
i )−
1
2
log
∣∣∣∣∣−∆l(η∗i )(2pi)p
∣∣∣∣∣ . (2.149)
The Hessian ∆l(η∗i ) in Eq. (2.149) contains second-order partial derivatives of the log-
likelihoods with respect to ηik (k = 1, . . . , p). These second-order derivatives are often
neglected for computational reasons and because they are generally insignificant in comparison
to the first-order terms. Consequently, we arrive at the following first-order approximation
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of the Hessian:
Hikl = −1
2
ni∑
j=1
2(dεTij
dηik
− εTijR−1ij
dRij
dηik
)
R−1ij
(
dεTij
dηil
− εTijR−1ij
dRij
dηil
)T
+tr
[
−R−1ij
dRij
dηik
R−1ij
dRij
dηil
]−Ω−1kl for k, l = 1, . . . , p. (2.150)
This version of the Laplacian approximation is known as the first-order conditional estimation
with interactions (FOCEI). A common assumption is that the residual matrix Rij is inde-
pendent of ηi. This is known as the first-order conditional estimation without interactions
(FOCE).
As described in Section 2.3.2, gradient methods like Newton’s method or the quasi-Newton
method are applied to find the optimum of the individual likelihoods.
2.3.3.1 Expectation-Maximisation
Returning to the population log-likelihood function, given by
l(ψ;y) = log f(y|ψ), (2.151)
where ψ = (θ,Ω,R). Maximum likelihood (ML) estimation of l(ψ;y) tends to be involved
here since the underlying model is dependent on the unobserved random effects η. Con-
sequently, the likelihood function needs to be marginalised with respect to η according
to
log f(y|ψ) =
∫
log f(y,η|ψ) dη, (2.152)
where the integral over η is computed for every evaluation of l(ψ;y). This computation can
be simplified by utilising a Laplacian approximation of the log-likelihoods (as is down in
the previously mentioned FOCE and FOCEI methods). As a consequence of applying the
Laplacian approximation, the integral becomes Gaussian, and thus has an analytic solution.
Nonetheless, the Hessian of the log-likelihoods still needs to be computed, which may be
costly, error prone and complicated.
The aforementioned estimation is a form of incomplete data problem, as y is observed but
not η. A probabilistic approach to problems constituting incomplete data is to compute the
expected value of the unobserved data, conditioned on the posterior distribution—which
is assumed to be known. These values will subsequently be used to find ML estimates,
from which the expected value of the unobserved data can be re-computed. This iterative
scheme is known as the Expectation-Maximisation (EM) method (Dempster et al., 1977). To
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demonstrate the algorithm, define the Q-function as
Q(ψ|ψk) = Ef(·|y,ψk)[log f(X|ψ)] =
∫
log f(x|ψ)f(x|y,ψk) dx, (2.153)
where x = (y, z) is the complete data (y being the incomplete, observed data, and z(= η)
the unobserved data) and p(x|y,ψk) the posterior distribution (conditioned on the observed
data and current iterate ψk). Computing the Q-function is the expectation step in the EM
algorithm. In the subsequent maximisation step, the Q-function is maximised with respect
to ψ as
ψk+1 = arg max
ψ
Q(ψ|ψk). (2.154)
To show that the EM algorithm improves the likelihood, note that
l(ψk+1;y)− l(ψk;y) = log f(y|ψk+1)− log f(y|ψk), (2.155)
which by taking the expected value, conditioned on y and ψk, yields
l(ψk+1;y)− l(ψk;y) = Ef(·|y,ψk)[log f(y|ψk+1)]
− Ef(·|y,ψk)[log f(y|ψk)], (2.156)
since the left hand side is a constant. Moreover, as P (A|C) = P (A,B|C)/P (B|A,C), it
follows that
l(ψk+1;y)− l(ψk;y) = Ef(·|y,ψk)
log( f(X|ψk+1)
f(Z|y,ψk+1)
)
− Ef(·|y,ψk)
log( f(X|ψk)
f(Z|y,ψk)
) , (2.157)
rearranging the terms gives
l(ψk+1;y)− l(ψk;y) = Q(ψk+1|ψk)−Q(ψk|ψk)
+ Ef(·|y,ψk)
− log( (Z|y,ψk+1)
f(Z|y,ψk)
) . (2.158)
Moreover, since the negative logarithm is convex, Jensen’s inequality gives
Ef(·|y,ψk)
− log(f(Z|y,ψk+1)
f(Z|y,ψk)
) ≥ − log Ef(·|y,ψk)
[
f(Z|y,ψk+1)
f(Z|y,ψk)
]
= 0. (2.159)
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Thus, by choosing ψk+1 such that
Q(ψk+1|ψk) ≥ Q(ψk|ψk), (2.160)
we get
l(ψk+1;y)− l(ψk;y) ≥ Q(ψk+1|ψk)−Q(ψk|ψk) ≥ 0 (2.161)
which imply
l(ψk+1;y) ≥ l(ψk;y). (2.162)
Thus, the likelihood has been improved in the iterate ψk+1, relative ψk, which shows that
the EM algorithm improves the likelihood.
2.3.3.2 Monte Carlo and Stochastic Approximation of the Expectation-Maximisation
The integral computed in the expectation step of Eq. (2.153) does not necessarily have a
closed-form solution. If this is the case, Monte Carlo integration may be used to find an
approximation of the Q-function. The expectation step is then replaced by a simulation step
where nk realisations of the posterior distribution are generated at the kth iteration, and
the Q-function is approximated according to
Q̂(ψ|ψk) = 1
nk
nk∑
i=1
log f(Xi|ψ), (2.163)
where Xi ∼ f(·|y,ψk) for i = 1, . . . , nk. This modification of the EM approach is known as
the Monte Carlo EM (MCEM). In situations where it is difficult to generate random samples
from the posterior distribution, an alternative distribution may be used according to the
importance sampling method. Importance sampling relies on the premise that
Ef(·|y,ψk)[log f(X|ψ)] =
∫
log f(x|ψ)f(x|y,ψk) dx (2.164)
=
∫
log f(x|ψ)f(x|y,ψk)
g(x|y,ψk) g(x|y,ψk) dx (2.165)
= Eg(·|y,ψk)
[
log f(X|ψ) f(X|y|ψk)
g(X|y,ψk)
]
. (2.166)
Thus, nk samples can be drawn from g(·|y,ψk)16, rather than from f(·|y,ψk), and the
Q-function approximated as
Q̂(ψ|ψk) = 1
nk
nk∑
i=1
log f(Xi|ψ) f(Xi|y|ψk)
g(Xi|y,ψk) . (2.167)
16The probability distribution g does not necessarily have to be dependent on y or ψk.
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The distribution g(·|y,ψk) is preferably chosen to mimic the posterior distribution f(x|y,ψk).
In this way, the frequencies of the samples correspond to their weights log f(X|ψ) f(X|y|ψk)g(X|y,ψk) —
thus, favouring the “important” samples. By the inverse sampling method, it is possible to
generate samples as long as the proposed density has an injective cumulative distribution.
Moreover, the performance of the method may be improved17 by applying a quasi-random
method, such as Sobol sequences, to generate the random sample—known as the Quasi-
Random Parametric Expectation-Maximisation (QRPEM) method.
Finally, another popular modification of the EM algorithm is Stochastic Approximation
(SAEM). Here, a simulation step, where nk samples are drawn from the posterior distribution,
replaces the expectation step. However, the approximation of the Q-function is
Q˜(ψ|ψk) = Q˜(ψ|ψk−1) + γk
 1
nk
nk∑
i=1
log p(Xi|ψ)− Q˜(ψ|ψk−1)
 , (2.168)
where {γk}k≥1 is a decreasing sequence of positive numbers. For details on the convergence
of the EM methods, see lDelyon et al. (1999).
2.3.4 Profile likelihood
Profile likelihood is a tool for structural and practical identifiability analysis. The premise of
the method is that parameter non-identifiability manifests itself as flat hypersurfaces of the
likelihood function (Raue et al., 2009). The profile of these surfaces can be analysed before
the parameter estimation, without any real data, by studying the likelihood obtained from a
randomly generated realisation of the system. Since identifiability is a generic property of a
model structure (i.e., independent of the parameter values), the identifiability holds even if
the generated parameters are infeasible.
Consider a maximum likelihood estimation problem with the log-likelihood function l(θ,y)
and a random sample θˆ, drawn from the parameter space Θ. By fixing all but one parameter
θˆi, (i = 1, . . . , p), the profile likelihood is readily visualised as a function of a single parameter
according to
PL(θˆi) = max
θˆj 6=i
l(θˆ;y). (2.169)
Thus, for each value θi, the profile likelihood is found by optimising the likelihood. Potential
local parameter non-identifiability manifests itself by a flat profile likelihood curve. By
analysing one parameter at a time, the profile likelihood can be used to find specific
parameters, or parameter combinations (by examining a multidimensional profile likelihood),
that are non-identifiable.
In the posterior profile likelihood analysis, non-identifiability characterises itself as high
uncertainty in the parameter estimates. Unlike the prior analysis, this analysis also ensures
17Improved performance in the sense of decreased sample size and increased accuracy.
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practical local (non-)identifiability.
2.3.5 Software
The NLME modelling and simulations, and the identifiability analysis in this thesis, were
performed using Wolfram Mathematica (Wolfram Research, Inc., Mathematica, Version
11.1, Champaign, IL (2017)). Mathematica is a powerful mathematical programming
language which supports multiple programming paradigms and is powerful for symbolic
computations and visualisations. The estimation was computed by maximising the FOCE
approximation of the population likelihood. This was done using a method developed
at the Fraunhofer-Chalmers Research Centre for Industrial Mathematics (Gothenburg,
Sweden) (Almquist et al., 2015), which combines exact gradients of the FOCE likelihood
based on the so-called sensitivity equations with the Boyden-Fletcher-Goldfarb-Shanno
optimisation algorithm (Nocedal and Wright, 2006). Parameter standard errors were derived
using the Hessian of the approximate population likelihood with respect to the parameters,
evaluated at the point estimate. The Hessian was computed using finite differences of the
exact gradients.
When performing numerical calculations with plenty of data, MATLAB (The MathWorks
Inc., Natick, MA) is an alternative to Mathematica. MATLAB is a user-friendly software,
which compromises a plethora of toolboxes—designed for a range of different mathematical
problems. The language is highly efficient when handling linear algebraic problems.
2.3.5.1 Nonlinear mixed-effects estimation
There exists a variety of software for parameter estimation in nonlinear mixed-effects models.
Sheiner and Beal (Sheiner et al., 1977; Sheiner and Beal, 1980, 1981, 1983) developed the
most frequently used NONMEM (ICON Development Solutions, Ellicott City, MD, USA)
software in the 80’s. Some other commonly used software in practise today are the Monolix
(Lixoft, Orsay, France) and Phoenix NLME (Pharsight Corporation, St Louis, MO, USA)
tools, based on the SAEM and QRPEM algorithm, respectively.
2.4 Sensitivity analysis
Sensitivity analysis (SA) constitutes a modelling and simulation framework in which the
aim is to quantify the sensitivity and robustness of a modelled system output concerning
variations in the input. SA strives to answer the following important questions:
• Redundancy—are there parts of the model which are unnecessary?
• Prioritisation—are there specific components of the system that need to more thoroughly
analysed to ensure robustness?
• Hidden relationships—in particular, do they make sense from a biological or pharma-
cological point-of-view?
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• If changes occur in the system—how will this affect the output?
• Critical values—e.g., what are the maximum possible responses?
• Design and communication—is the system particularly sensitive at some instance?
Knowledge like this is informative when designing future experiments (to, for example,
decide when to sample during the experiments).
2.4.1 Methods
There are several ways to approach an SA. One method is one-at-a-time, where all but one of
the input signals or parameters are held fixed while the particular signal is moved throughout
feasible values. An alternative method is local sensitivity analysis. For an expected response
h(x,u,φ) and a local point in the parameter space φ0 (e.g., the optimal solution), we analyse
∂h(x,u,φ)
∂φi
∣∣∣∣∣
φ0
, (2.170)
or
∂h(x,u,φ)
∂ui
∣∣∣∣∣
φ0
, (2.171)
for one parameter φi, or input signal ui, at-a-time.
For more SA techniques and details, see Clemson et al. (1995) or Greenland (1996).
2.5 Model evaluation
The derived and estimated regression models (whether they are linear, nonlinear, or nonlinear
mixed-effects) rely on some fundamental assumptions. It is crucial to recognise these
assumptions, question their validity, and understand their implications. It is assumed that:
• The proposed model captures all vital components of the system without incorporating
any redundancy.
• Individuals are independent.
• The residuals are independent, identically normally distributed with mean zero and
time-invariant standard deviation.
In many ways, the first assumption represents the core objective of model identification;
to find an accurate mathematical representation of, in our case, a pharmacological system.
The question of what constitutes vital components of the system depends on the purpose
of the model, rightly stated before the modelling procedure. The assumption that the
individuals are independent is strong, and generally, does not hold. Still, it may prove to be
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a valid representation of reality since the dependencies tend to be negligible. Assuming that
individuals are independent often simplifies computations without introducing too much
bias. The last assumption is central when deriving the maximum likelihood estimator.
The following discussion will aim to verify the validity of the stated assumptions. Moreover,
we will discuss how to assess the performance of the model, as well as introduce methods
for comparisons of separate models. A central theme will be the concepts of bias and
variability. With a finite data set, model bias is inversely proportional to the variability.
Thus, there is a trade-off between having an accurate model and a precise model, which
is a well-known phenomenon in mathematical and statistical modelling (Myers, 2000). An
estimation with high accuracy, but low precision, is known to be overfitted, and one with
low accuracy and high precision is underfitted. What characterises overfitted models is that
they describe the available data well, but lack the generality needed to, for example, predict
future experimental trials. Underfitted models, on the other hand, lack the ability to capture
all of the important aspects of the system.
A standard approach in model identification, if data are abundant, is to divide the data into
training and test sets. The training set serves to derive and estimate the model, while the
test set acts to assess the performance of the model. As a rule of thumb, 80% of the data are
assigned as training data and 20% test data—either by randomization or by a deterministic
division of the data (Bonate, 2011). However, this modelling approach requires a sufficient
amount of data to uphold practical identifiability. The data in pharmacological studies are
often sparse, specifically in pre-clinical studies. Thus, the method is not always applicable.
The following discussion on model validation presents a range of quantitative and qualitative
tools. Quantitative validations provide a direct measure of the performance of the model,
while qualitative validations rely on graphical representations of the results, which are
interpreted by the modeller.
2.5.1 Quantitative analysis
The most obvious quantitative measure of how well a model fits a set of data is the uncertainty
of the parameter estimates. As discussed previously, there is a trade-off between bias and
variability of the parameter estimates. As a rule of thumb, we consider parameter estimates to
be precise if the corresponding CV% is less than 25% (Bonate, 2011). Besides the precision of
the parameter estimates, we will introduce the concept of shrinkage as a quantitative measure
of the variability of the residuals and the Empirical Bayes Estimates (EBE). Shrinkage serves
as a valuable tool for validating the graphical results. Finally, we discuss information criteria
as measures of the model fit, and thereby its quality in comparison to other possible candidate
models.
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2.5.1.1 Shrinkage analysis
Assume a nonlinear mixed-effects model. The individual predictions (sometimes referred to
as the IPRED) for individual i at time-point tj is given by
yˆij = h(xi(tj),ui,φi), (2.172)
where h are the expectation functions, which characterise the system behaviour, xi are the
state variables, ui the input functions, and φi the system parameters. Define the individual
weighted residual as
IWRESij =
yij − yˆij
σ
, (2.173)
where yij are the observed data for individual i at time-point j, and σ is the standard
deviation of the residuals. The ε-shrinkage is then defined as
εshrinkage := 1− SD(IWRESij) (2.174)
As the individual predictions tend toward the dependent variable, the distribution of the
IWRES shrinks towards 0, and the εshrinkage tends to 1. A shrinking distribution of IWRES
indicates that the model is overfitted. On the other hand, a high εshrinkage expresses an
underfitted model.
In contrast to ε-shrinkage, η-shrinkage describes the variability of the Empirical Bayes
Estimates (EBE). Given that a random effect has the estimated standard error ω, its
corresponding η-shrinkage is given by
ηshrinkage := 1− SD(ηEBE)√
ω2
. (2.175)
The η-shrinkage describes the information in the data on an individual level. If data are
uninformative on an individual level, the standard deviation of the EBEs will shrink towards
0, giving an η-shrinkage near 1.
In the presence of shrinkage the diagnostics, involving EBEs and residuals, may lose their
validity and distort the true relationships. For example, high levels of ε-shrinkage may result
in the residual distribution deviating from a Gaussian distribution, even if the underlying
model is correct (or vice versa). Similarly, high levels of η-shrinkage may result in misleading
correlations between the EBEs and the covariates (or may fail to show existing correla-
tions). It has been shown that at shrinkage levels of 20-30%, the results may start to be
misleading (Savic and Karlsson, 2009).
2.5.1.2 Information criterion
Consider a scenario with two, or more, candidate models that describe an observed system.
The natural question that arises is what model produces the ‘best fit’? In general, the more
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complex the model, the higher the accuracy. On the other hand, a complex model will
introduce variability. The Akaike information criterion (AIC) is a measure of the fit of a
model—based on the premise that the criterion rewards accuracy but penalise complexity.
This criterion serve as tools for model comparison, as it do not require the models to have
the same parameters, the same state variables, or even the same response relation.
In order to derive the AIC, assume a sample of observations y = y1, . . . , yn from the true
underlying density function g(y). Consider a set of potential models denoted byM. A model,
Mi ∈M, will be known as a candidate model. Each candidate model has a corresponding
class of probability density functions defined as
Fk = {f(y|θk) : θk ∈ Θk}, (2.176)
where k is the dimension of the parameter vector θk and Θk is the set of potential parameter
vectors of dimension k.
2.5.1.3 Akaike information criterion
Consider the Kullback-Leibler information IKL(θ)
18 defined as
IKL(θ) = E
log( g(y)
f(y|θ)
) , (2.177)
where the expected value is taken over the density g(·). The Kullback-Leibler information is a
measure of how much f(y|θ) diverges from g(y), and it will be positive unless f(y|θ) = g(y)
almost everywhere. Consider the re-written relation
2IKL(θ) = DKL(θ)− E[−2 log g(y)], (2.178)
where
DKL(θ) = E[−2 log(f(y|θ))], (2.179)
is known as the Kullback divergence. Note that the term E[−2 log g(y)] is independent of
the candidate model. Hence, minimising the Kullback-Leibler information is equivalent to
maximising the Kullback divergence. We will consider the Kullback divergence, evaluated at
the MLE estimate θˆ, for model comparisons. This would seem to be an appropriate measure
of the fit of a model. Yet, DKL(θˆ) cannot be directly computed as the underlying density
g(y) is unknown. However, we will see that the following term
AIC := −2l(θˆ|y) + 2k, (2.180)
18The index k of θk will be dropped for the sake of convenience.
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is an unbiased estimator of DKL(θˆ) (here, k is the dimension of θ). To show this, assume
that the true distribution belongs to model Mi
19. In that case, g(y) = f(y|θ0) for some
θ0 ∈ Θk. The expected Kullback divergence can be expressed as
E[DKL(θˆ)] = E[−2 log f(y|θˆ)] (2.181)
+ (E[−2 log f(y|θ0]− E[−2 log f(y|θˆ)]) (2.182)
+ (E[DKL(θˆ)]− E[−2 log f(y|θ0]). (2.183)
By applying the second-order expansion of log f(y|θ0) about θˆ, we get
E[−2 log f(y|θ0)] = E[−2 log f(y|θˆ)]− E[(θˆ − θ0)TH[f(y|θˆ)]−1(θˆ − θ0)] +O(1), (2.184)
or
E[−2 log f(y|θ0)] = E[−2 log f(y|θˆ)] + E[(θˆ − θ0)TI(y|θˆ)−1(θˆ − θ0)] +O(1), (2.185)
where I(y|θˆ) is the expected Fisher Information matrix and where the first-order term
disappears since the likelihood is maximised over θˆ. Note the expected Fisher information is
related to the Hessian as H[f(y|θˆ)] = −I(y|θˆ). Furthermore, by applying a second-order
expansion of d(θˆ) about θ0, we obtain
E[d(θˆ)] = E[−2 log f(y|θ0)] + E[(θˆ − θ0)TI(y|θ0)−1(θˆ − θ0)] +O(1), (2.186)
where I(y|θ0) is the observed Fisher Information matrix and where the first-order term
again disappears since d(θ) is maximised over θ0. Thus, we have
E[d(θˆ)] = E[−2 log f(y|θˆ)] (2.187)
+ E[(θˆ − θ0)TI(y|θˆ)−1(θˆ − θ0)] (2.188)
+ E[(θˆ − θ0)TI(y|θ0)−1(θˆ − θ0)] +O(1). (2.189)
However, as θ0 ∈ Θk, we have
(θˆ − θ0)TI(y|θˆ)−1(θˆ − θ0) d→ χ2(k), (2.190)
i.e., the second-order term converges in distribution to a χ2 distributed variable with k
degrees of freedom. As E[χ2(k)] = k we obtain
E[d(θˆ)] = E[−2 log f(y|θˆ)] + 2k +O(1) = (2.191)
= −2l(θˆ|y) + 2k +O(1), (2.192)
19This is obviously a strong assumption. For details on how this assumption affects the conclusion, see
Cavanaugh et al. (Cavanaugh and Neath, 2011).
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and we are done.
2.5.2 Qualitative analysis
The following discussion will introduce graphical tools for assessing the fit of a model in
a population, as well as at an individual, level. Moreover, we will discuss techniques for
verifying the prior assumptions of, for example, normally distributed residuals and EBE’s.
2.5.2.1 Visual predictive check plots
The visual predictive check (VPC) plots capture many of the important features of a model.
A VPC typically includes the observed data, the estimated population mean or median, a
simulation-based confidence interval for the mean or median, observed quantiles, a model
predicted quantile-quantile span that, for example, covers 90% of the predicted behaviour
(i.e., a band is plotted between the 5% and 95% quantiles), simulation-based confidence
interval for the quantiles (for details, see Bergstrand et al. (2011)). An example, generated
from the model and data from Example 2.1.3.2, is illustrated in Fig 2.6.
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Figure 2.6: Visual predictive check plot generated from Example 2.1.3.2. The dots represent
the data, with colours indicating separate individuals, the black line the estimated median
individual, and the grey area the 90% population prediction interval.
2.5.2.2 Individual fits
Individual plots serve to demonstrate the ability of the model to capture the between-subject
variability seen in the population. The plots involve the observed data of an individual along
with the IPRED. Two examples, generated from the model and data of Example 2.1.3.2, are
illustrated in Fig 2.7. The individual plots suggest that the model captures between-subject
variability well.
2.5.2.3 Scatter and probability plots
Scatter plots illustrate pair-wise comparisons between two quantities, typically the observed
and predicted behaviours. Fig. 2.8b shows an example of a scatter plot with the observed and
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Figure 2.7: Individual predicted response behaviour of two individuals taken from Exam-
ple 2.1.3.2. The blue dots represent the data and the the black line the model predicted
behaviour.
the predicted response from Example 2.1.3.2. The example illustrates a linear relationship
between the two quantities along the line y = x, which shows that the model captures
the observed behaviour well. Probability plots refer to quantile-quantile (Q-Q) plots or
probability-probability (percent-percent) (P-P) plots, which are particular instances of scatter
plots. In Q-Q plots, two cumulative distribution functions (CDF) are outlined against each
other. Typically, one of the CDF’s is a theoretical (predicted) distribution and the other an
empirical (data) distribution. The quantiles of the theoretical distribution can be selected
in various ways. Given a set of n data points, one common approach is to chose the k/n
quantiles, where k = 1, . . . , n, in which the n/n is the 100% quantile. Alternatively, the
(k − 0.5)/n quantiles are chosen, where k = 1, . . . , n. In contrast to Q-Q plots, P-P plots
represent the CDF’s themselves, rather than their quantiles. The P-P plot is a slightly
less common probability plot due its features; whereas a Q-Q plot is weighted to provide
additional information about the outliers (which often are of most interest when assessing
the difference between, for example, an empirical and theoretical CDF), the P-P plots are
weighted to be denser near the medians. The Q-Q plot of the empirical and theoretical
distributions from Example 2.1.3.2 are illustrated in Fig. 2.8c and the corresponding P-P plot
is illustrated in Fig. 2.8d. The P-P plot indicates a nearly perfect fit between the observed
and theoretical probabilities while the Q-Q plot suggests a somewhat higher kurtosis (heavier
tails) of the observed distribution.
2.5.2.4 Histograms
A histogram represents an estimation of the underlying probability density function (PDF)
of, for example, the data. Histograms are constructed by dividing the range of the PDF
into equally sized bins20, and then plot a bar for each bin, whose size corresponds to the
number of observations in the given interval of the bin. There are many different approaches
20Using equally sized bins are the standard approach when constructing histograms. The bins may vary
in size (Freedman et al., 2007).
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Figure 2.8: Plot of results in Example 2.1.3.2. Fig. (a) illustrates the distribution of the
standardised residuals in the form of a histogram, (b) a scatter plot of the observations vs.
the predicted values, (c) a Q-Q plot of the observed vs. the predicted residuals, and (d) a
P-P plot of the observed vs. the predicted residuals.
to choose the number of bins. For a tutorial, see Freedman et al. (2007). An example of a
histogram is illustrated in Fig. 2.8a. The histogram suggests that a normal distribution is
possible for the standardised residuals.
2.6 Summary
This chapter has served to illustrate the dose-response-time model identification procedure.
Starting by investigating the data, a suitable pharmacodynamic model, as well as driving
biophase function, are selected. The biophase function is typically simple in its structure,
consisting of few parameters, and the choice of biophase depends on the route of administra-
tion. For the pharmacodynamic model, this chapter has demonstrated a range of different
structures, able to describe the direct and indirect response, nonlinear drug-response be-
haviour, feedback mechanisms, adaptation and so forth. Dependent on the type of data and
the aim of the model, the structure may be extended to capture between-subject variability.
This is done by applying a nonlinear mixed-effects modelling framework. Here, it was demon-
strated how to choose fixed and random effects as well as the covariance structure of the
random effects. For the selected model to make sense, and for the parameters to be uniquely
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determined by the data, the model needs to be structurally identifiable. Three different a
priori identifiability methods and one a posteriori method were presented for determining
structural and practical identifiability, respectively. Given that the model is structurally
identifiable, the parameter estimation may be initiated. Here, different approaches were
demonstrated depending on the type of model. In the linear case, the parameters may be
found analytically by solving the linear system for the parameters and then evaluating the
solution at the observed data points. In the case of a nonlinear model, the parameters are
estimated numerically. The estimation is typically done by applying some form of Newton’s
method. Here, the quasi-Newton methods, in particular, the Broyden-Fletcher-Goldfarb-
Shanno algorithm, and the Levenberg-Marquardt method were discussed. This includes
convergence analysis for the different methods. Further, parameter estimation for nonlinear
mixed-effects models was examined. Here, the population likelihood function was derived
and a range of software, designed for parameter estimation of nonlinear mixed-effects models,
was presented. Following the discussion on parameter estimation, sensitivity analysis was
introduced, both from an a priori and an a posteriori perspective. Finally, model validation,
from both a quantitative and qualitative perspective, were considered to verify the results
obtained from the parameter estimation.
Although the different methods were presented logically, where each method represented a
natural continuation of the modelling procedure, it is important to recognise that model
identification is not typically a linear process. The different steps are often iterated and, for
example, practical non-identifiability may require the model structure to be modified, which
in turn leads to an updated structural identifiability analysis (unless the modified model is a
simplified version of the original), after that the parameters may be re-estimated.
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Part II
Analysis and results
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Chapter 3
Background
The dose-response-time (DRT) modelling framework will be demonstrated by two extensive
meta-analyses of the nicotinic acid (NiAc) interaction with free fatty acids (FFA). Since the
pharmacokinetic properties of NiAc have been thoroughly characterised by Ahlstro¨m et al.
(2011b), the results of the two meta-analyses can be compared to those of exposure-driven
analyses.
This chapter serves to provide a brief description of the drug; comprising the underlying
physiology of antilipolysis, the pharmacokinetics of NiAc, and the data analysed in the two
studies.
3.1 Nicotinic acid-induced antilipolysis
Nicotinic acid (NiAc; or niacin; or vitamin B3) is an organic compound with a long clini-
cal history in the treatment of dyslipidemia (Altschul and Hoffer, 1960; Carlson and Oro¨,
1962). When administered in large doses (1-3 g/day), NiAc improves the plasma lipid
profile by reducing total cholesterol, triglycerides, low-density lipoprotein cholesterol, and
very-low-density lipoprotein cholesterol, while increasing levels of high-density lipoprotein
cholesterol (Kendall et al., 2002). Furthermore, by binding to the G-protein coupled re-
ceptor GPR109A, NiAc potently inhibits lipolysis in adipose tissue, resulting in decreased
plasma free fatty acid (FFA) concentrations (Offermanns, 2006; Tunaru et al., 2003). The
mechanisms of NiAc-induced antilipolysis have been thoroughly analysed by Heemskerk
et al. (2014) among others (Chen et al., 2015; Li et al., 2011; Oh et al., 2011). Chronically
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Figure 3.1: Mechanisms of nicotinic acid (NiAc) and insulin induced antilipolysis in adipose
tissue. NiAc binds and activates the inhibitory G-protein (Gi) coupled receptor GPR109A,
abundantly expressed in adipose tissue. Following activation, GPR109A inhibits adenylate
cyclase (AC), a membrane-bound enzyme that hydrolyses adenosine triphosphate (ATP)
into cyclic adenosine monophosphate (cAMP), resulting in reduced intracellular cAMP
concentrations. Consequently, the activity of the cAMP-dependent protein kinase A (PKA)
is reduced. The rate limiting step in free fatty acid (FFA) and glycerol mobilization from
intracellular triglyceride (TG) stores involves TG hydrolysis by adipocyte lipases; primarily
hormone sensitive lipase (HSL) and adipocyte triglyceride lipase (ATGL). The activity of
these lipases is governed by PKA. Thus, failed PKA-mediated lipase phosphorylation results
in attenuated lipolysis and subsequently reduced release of FFA into the circulation. Insulin
is a potent inhibitor of adipocyte lipolysis. Activation of the insulin receptor results in a
series of enzyme phosphorylations, ultimately activating phosphodiesterase 3B (PDE3B), an
enzyme that breaks down cAMP into AMP. Thus, insulin disrupts cAMP-mediated signalling
pathways and hence lipolysis. PKA may also activate PDE3B, thus regulating its own
activity. NiAc has also been suggested as an inhibitor of glucose-stimulated insulin secretion
via binding of the GPR109A receptor in pancreatic β-cells. Long-term NiAc exposure may
also be involved in down-regulation of PDE3B gene expression.
elevated plasma FFA concentrations are associated with several metabolic diseases, including
insulin resistance (Eckel et al., 2005; Krauss, 2004; Morita et al., 2012). The hypothesis is
that NiAc-induced FFA lowering could ameliorate these conditions. However, the clinically
applied dosing regimens are designed for treating dyslipidemia, and not for reducing FFA
levels (Carlson, 2005).
Although acute administration of NiAc results in rapid reduction in FFA concentrations (Ahlstro¨m
74
et al., 2013a; Carlson and Oro¨, 1962), sustained treatments are associated with tolerance
development (drug resistance) and plasma FFA concentrations returning to pre-treatment
levels (complete adaptation) (Kroon et al., 2015). Moreover, abrupt cessation of the NiAc
infusions produces an FFA rebound that overshoots the pre-infusion levels (Kroon et al.,
2015; Oh et al., 2011). Numerous studies have sought to quantitatively determine the acute
concentration-response relationship between NiAc and FFA (Ahlstro¨m, 2011; Ahlstro¨m et al.,
2013a, 2011a, 2013b, 2011b; Andersson et al., 2015; Isaksson et al., 2009; Leander et al., 2015;
Tapani et al., 2014). Although the current pharmacokinetic/pharmacodynamic (PK/PD)
models are successful in characterising the acute NiAc-induced FFA response, the associated
chronic behaviour has not been successfully captured. Thus, an improved model is required
to predict optimal treatment regimens, aimed to achieve durable NiAc-induced FFA lowering.
3.2 Pharmacokinetics of NiAc
The pharmacokinetic properties of NiAc have been thoroughly characterised in previous
studies (Ahlstro¨m, 2011; Ahlstro¨m et al., 2013a, 2011a, 2013b, 2011b; Isaksson et al., 2009;
Iwaki et al., 1996; Leander et al., 2015; Tapani et al., 2014). Ahlstro¨m (2011) introduced a two-
compartment disposition model with parallel nonlinear (Michaelis-Menten) elimination for
lean Sprague-Dawley rats, and a one-compartment model with a single nonlinear elimination
for obese Zucker rats (the model structures are illustrated in Fig. 3.2).
(a) Lean (b) Obese
Figure 3.2: NiAc disposition models for lean Sprague-Dawley (a) and obese Zucker rats (b).
NiAc is either infused directly into the central compartment (intravenous administration) or
absorbed via a subcutaneous compartment (subcutaneous administration via an implanted
mini-pump) or absorbed from the gut (oral administration).
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3.2.0.1 Lean rats
A model for the NiAc disposition in lean Sprague-Dawley rats is given by
Vp · dCp(t)
dt
= Input(t) + Synt− Vmax1 · Cp(t)
Km1 + Cp(t)
− Vmax2 · Cp(t)
Km2 + Cp(t)
− Cld · Cp(t)
+ Cld · Ct(t), (3.1)
Vt · dCt(t)
dt
= Cld · Cp(t)− Cld · Ct(t), (3.2)
where Cp(t) is the observed NiAc concentration in the central plasma compartment and
Ct(t) is the concentration in the peripheral tissue compartment (both measured in µM),
and Vp and Vt (both measured in l) are the volumes of distribution of the plasma and
tissue compartments, respectively. The parameters Vmax1 (µmol min
−1 kg−1) and Km1
(µM) are the maximal elimination rate and the Michaelis constant of the first pathway,
and Vmax2 (µmol min
−1 kg−1) and Km2 (µM) are the maximal elimination rate and the
Michaelis constant of the second pathway (low and high affinity pathway, respectively).
Furthermore, Cld (l min
−1 kg−1) represents the inter-compartmental distribution and Synt
(µmol min−1 kg−1) the endogenous NiAc synthesis. To derive the initial conditions of the
plasma and tissue compartments, we propose that the system given in Eqs.(3.1) and (3.2) is
at steady-state at t = 0, and after 10 min of constant rate infusion (Ahlstro¨m et al., 2011b),
with
dCp(t)
dt = 0. Consequently, we can solve for the steady-state concentration Cpss(= Ctss)
as
Vc · dCpss
dt
= input + Synt︸ ︷︷ ︸
=α
−Vmax1 · Cpss
Km1 + Cpss
− Vmax1 · Cpss
Km1 + Cpss
+ Cld · Ctss − Cld · Cpss︸ ︷︷ ︸
=0
= 0. (3.3)
This gives rise to a quadratic equation with positive real root
Cpss =
−b+√b2 − 4ac
2a
, (3.4)
where
a = α− Vmax1 − Vmax2 (3.5)
b = α · (Km1 +Km2)− Vmax1 ·Km2 − Vmax2 ·Km1, (3.6)
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and
c = α ·Km1 ·Km2. (3.7)
Consequently, the initial steady-state concentration is given by Eqn, 3.4 with Const. = Synt
and the steady-state attained after 10 min of infusion is given by Eqn. 3.4 with Const. =
input + Synt. The term Input(t) in (3.1) is a time-dependent function determined by the
route of administration according to
Input(t) =

Inf. rate Intravenous infusion
kasc ·Asc(t) Subcutaneous infusion
kag ·Ag(t) + Vmaxg·Ag(t)Kmg+Ag(t) Oral dose,
(3.8)
where Inf. rate (µmol min−1 kg−1) is the infusion rate, Asc(t) (µmol kg−1) the amount of drug
in the subcutaneous compartment, kasc (min
−1) the absorption rate from the subcutaneous
compartment to plasma, Ag(t) (µmol kg
−1) the amount of drug in the gut, kag (min−1)
the absorption rate from the gut to plasma of the linear translocation pathway, Vmaxg
(µmol min−1 kg−1) the maximal absorption rate from the gut to plasma of the nonlinear
translocation pathway, and Kmg the amount in the gut corresponding to 50% absorption
from the gut to plasma of the nonlinear translocation pathway. The rate of change of Asc(t)
is given by
dAsc(t)
dt
= Pump rate− kasc ·Asc(t), (3.9)
with initial condition Asc(0) = 0. Here, Pump rate represents the infusion rate from a
subcutaneous mini-pump. Surgical implantation of the mini-pump occurred seven days
before the final acute experiment. During this period, when the pump was not infusing,
interstitial tissue fluid could diffuse into the tip of the catheter, diluting the NiAc dosing
solution. Therefore a concentration gradient may have formed, resulting in an apparently
lower initial infusion rate compared to the pre-programmed setting. To capture this, the
pump infusion rate is modelled as
Pump rate = Inf. rate · erf
(
t · δ√
t0
)
, (3.10)
where Inf. rate is the programmed infusion rate of the pump, δ (min−1/2) is a lumped
diffusion parameter, and t0 is the pump inactivation time (in this case 7 days). Here erf is
the error function (Andrews, 1997), defined as
erf(t) =
2√
pi
∫ t
0
e−τ
2
dτ. (3.11)
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The concentration gradient, described by Eq. (3.10), is derived by viewing the catheter as
a one-dimensional diffusion problem and applying Fick’s law. The one-dimensional fluid
equation has the solution
c(x, t) = c0 · erfc
(
x
2
√
δˆt
)
, (3.12)
where c0 is the concentration at the boundary (of where the fluid diffuses from), x the
diffusion direction, t the time, δ the diffusion parameter, and erfc the complementary error
function (Andrews, 1997). Given that the intestinal fluids take the form given in Eq. (3.12),
the NiAc concentration in the catheter will, due to symmetry, be scaled by the factor
erf
(
x
2
√
δˆt
)
, (3.13)
where erf is the error function (Andrews, 1997). Now, we assume that the diffusion is negligible
after the infusion has started. Consequently, only the time between the implantation and
the initiation of the pump, given by t0, affects the concentration gradient. Then the infusion
rate will be scaled by the factor in Eq. (3.12), with t = t0. The direction can be expressed
as x = v · t, where v is the infusion velocity and t the time after the infusion has started.
The velocity is fixed in the experiment and can be lumped with the factor 1
2
√
δˆ
as
δ =
v
2
√
δˆ
, (3.14)
and the rate is scaled by
erf
(
t · δ√
t0
)
(3.15)
where the parameter δ is estimated from the data.
For simplicity, the bioavailability from the subcutaneous compartment was assumed to be
equal to unity. The rate of change of Ag(t) is given by
dAg(t)
dt
= −kag ·Ag(t)− Vmaxg ·Ag(t)
Kmg +Ag(t)
, (3.16)
with initial condition Ag(0) = D.
3.2.0.2 Obese rats
For obese Zucker rats, the NiAc disposition is given by
Vp · dCp(t)
dt
= Input(t) + Synt− Vmax1 · Cp(t)
Km1 + Cp(t)
, (3.17)
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where Cp(t) is the NiAc concentration in the central plasma compartment, Vc the volume of
distribution, Vmax1 the maximal elimination rate, Km1 the Michaelis constant, and Synt the
endogenous synthesis. The term Input(t) is the same as for the lean rats (the relations given
in Eqs. 3.8, 3.9 and 3.10).
3.3 Data
The data sets used in the two meta-analyses of this thesis consist of FFA (and insulin for study
DRT II) response-time series obtained from experiments on lean (normal) Sprague-Dawley
rats and obese (diseased) Zucker rats under provocation of NiAc. The NiAc was administered
at different rates, routes, and modes. A detailed outline of the experiments of DRT study I
can be found in the thesis by Ahlstro¨m (2011). The data of this study are given in Table 3.1.
Number of rats
Admin. route Dose (µmol kg−1) Acute exp. (min) Inf. rate (µmol kg−1 min−1) Lean rats Obese rats
Infusion 0 30 0 10 2
1 0.033 4 -
5 0.170 8 -
20 0.660 9 7
0 300 0 8 2
5 0.017 9 -
10 0.033 8 -
51 0.170 7 8
0 210a 0-0.170 1 -
20 0 5 -
0 240b 0-0.170 1 -
25 0 5 -
Oral 0 - - 6 -
24.4 - - 6 -
81.2 - - 6 -
812 - - 6 -
Table 3.1: Study I data characteristics—including route of administration, dose, duration of
experiment, infusion rate, and the number of lean (a total of 95) and obese (a total of 19)
rats within each experiment.
aConstant rate infusion at 0.17µmol kg−1 min−1 for 30 min, followed by a step-wise decrease every 10 min
for 180 min to an infusion rate of 0µmol kg−1 min−1.
bConstant rate infusion at 0.17µmol kg−1 min−1 for 30 min, followed by a step-wise decrease every 10 min
for 180 min to an infusion rate of 0 µmol kg−1 min−1, followed by another 30 min constant rate infusion at
0.17µmol kg−1 min−1.
The data of DRT study II are given in Table 3.2.
3.3.1 Outline of experimental procedures
The following section will present a detailed outline of how the data of DRT study II were
obtained.
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Number of rats
Admin. route Pre-treat.(h) Acute exp.(h) Protocol Lean rats Obese rats
Conscious Subcutaneous 0 5 NiAc Na¨ıve 7(2) 7(5)
animals inf. 120 5 Cont. NiAc 6(2) 8(2)
120 5 Inter. NiAc 6(2) 8(3)
Anaesthetised Intravenous 0 1 NiAc Off 1 h 4(3) 5(3)
animals inf. 0 1 NiAc Stp-Dwn 1 h 5(2) 5(2)
Subcutaneous 0 12 NiAc Off 12 h 5(2) 4(2)
inf. 0 12 NiAc Stp-Dwn 12 h 5(3) 4(3)
Table 3.2: Study II data characteristics—including conscious or anaesthetised state, route
of administration, duration of experiment, protocol name, and the number of lean (a total
of 54) and obese (a total of 61) rats within each experiment (the numbers of saline infused
controls given in parenthesis).
3.3.1.1 Animals
Male Sprague Dawley (lean) and Zucker rats (fa/fa, obese) were purchased from (conscious
groups) Harlan Laboratories B.V. (The Netherlands) or (anesthetized groups) Charles
River Laboratories (USA). Experimental procedures were approved by the local Ethics
Committee for Animal Experimentation (Gothenburg region, Sweden). Rats were housed
in an Association for Assessment and Accreditation of Laboratory Animal Care accredited
facility with environmental control: 20-22◦ C, relative humidity 40-60%, and 12 h light-dark
cycle. During acclimatization (≥5 days), animals were housed in groups of 5 with free access
to both water and standard rodent chow (R70, Laktamin AB, Stockholm, Sweden).
3.3.1.2 Surgical preparations
To prevent potential infections in conjunction with surgery, oral antibiotics were given
1 day before pump/catheter surgery and then once daily for 3 days (sulfamethoxazole
and trimethoprim 40 mg mL−1 + 8 mg mL−1; Bactrim R©, 0.2 mL/animal, Roche Ltd, Basel,
Switzerland). Surgery was performed under isoflurane (Forene R©, Abbott Scandinavia AB,
Solna, Sweden) anesthesia, with body temperature maintained at 37◦C. For NiAc/saline
administration, a programmable mini pump (iPrecio R© SMP200 Micro Infusion Pump,
Primetech Corporation, Tokyo, Japan) was implanted subcutaneously, via a dorsal skin
incision. To allow blood sampling during the terminal experiment (conscious animals only),
a polyurethane catheter (Instech Laboratories Inc, Plymouth Meeting, PA USA) was placed
in the right jugular vein via an incision in the neck. In order to maintain its patency
up to the acute experiment, the jugular catheter was filled with sterile 45.5% (wt/wt)
PVP (polyvinylpyrrolidone, K30, MW ∼40 000 Fluka, Sigma-Aldrich, Sweden) dissolved
in a sodium-citrate solution (20.6 mmol), sealed and exteriorized at the nape of the neck.
Each animal received a post-operative, subcutaneous analgesic injection (buprenorphine,
Temgesic R©, 1.85 µg kg−1, RB Pharmaceuticals Ltd, Berkshire, GB). Animals were then
housed individually and allowed three days of recovery before the start of the pre-programmed
pump infusion. Throughout the study, body weight and general health status were monitored
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and recorded daily.
3.3.1.3 Nicotinic acid exposure selection and formulation
A key aspect of the study design was to achieve plateau plasma nicotinic acid (NiAc)
concentrations corresponding to therapeutically relevant levels in the rat (∼1 µM), based
on the relationship between plasma NiAc levels and FFA lowering (Ahlstro¨m, 2011). For
intravenous infusions (i.v.), NiAc (pyridine-3-carboxylic acid, Sigma-Aldrich, St. Louis, MO,
USA) was dissolved in sterile saline. For subcutaneous (s.c.) infusions, NiAc was dissolved
in sterile water and adjusted to physiological pH using sodium hydroxide. Vehicle, for
control animals, consisted of sodium chloride solutions at equimolar concentrations. Freshly
prepared formulations were loaded into the infusion pump (see below) via a 0.2 µm sterile
filter (Acrodisc R©, Pall Corporation, Ann Arbor, MI, USA) just before pump implantation.
3.3.1.4 Experimental protocols
Conscious animals (NiAc na¨ıve, Cont. NiAc and Inter. NiAc groups)
Both lean and obese animals were divided into 3 dose groups and NiAc was given either
acutely (NiAc na¨ıve) or following 5 days of either continuous (Cont. NiAc) or intermittent
(Inter. NiAc) administration. Each dose group was matched with corresponding saline
infused controls. NiAc infusions were given subcutaneously at 170 nmol min−1 kg−1. The
intermittent infusion protocol was programmed as a 12 h on-off cycle (infusion on at 13:00).
Following overnight fast, in the morning of the acute experimental day, the jugular catheter
was connected to a swivel system to enable blood sampling in unrestrained animals. Jugular
catheter patency was maintained by continuous infusion (5 µmol min−1) of sodium-citrate
solution (20.6 mM). After a 3-4 h adaptation period, at ∼12:00, the basal phase of the acute
experiment commenced with 2-3 blood samples drawn between -60 and -5 min, relative to
start of NiAc/saline infusion (note that, in the Cont. NiAc groups, infusion pumps were on
throughout this sampling period). Blood samples (16-17/animal) were drawn under an 8 h
experimental period. Samples, 30-150 µl (with total loss less than 5% of blood volume), were
collected in potassium-EDTA tubes, centrifuged and plasma stored at 80◦C pending analysis
for NiAc, FFA and insulin.
Anaesthetised animals (NiAc Off and NiAc Stp-Dwn 12 h infusion groups)
Before the infusions began, lean and obese rats were fasted for 8 h. On the day of the acute
study, at 01:00 (corresponding to time=0 h), the implanted pre-programmed pump began
infusing NiAc at a constant rate of 170 nmol min−1 kg−1 for 12 h. At 8.5 h animals were
anaesthetised (Na-thiobutabarbitol, Inactin R©, 180 mg kg−1, i.p., RBI, Natick, MA, USA),
underwent a tracheotomy with PE 240 tubing, and breathed spontaneously. One catheter
(PE 50 tubing) was placed in the left carotid artery for blood sampling and for recording
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arterial blood pressure and heart rate. One catheter (PE 10 tubing) was placed in the right
external jugular vein to infuse top-up doses of anaesthetic. The arterial catheter patency
was maintained by continuous infusion of sodium-citrate (20.6 mM in saline, 5 µl min−1)
from shortly after carotid catheterising until the experiment ended. Body temperature was
monitored using a rectal thermocouple and maintained at 37.5◦C by means of servo controlled
external heating. After surgery, animals were allowed a stabilization period of at least 1.5 h
and blood sampling began at 11.0 h. At 12.0 h, NiAc infusion was either programmed to
switch off (NiAc Off) or to decrease in a step-wise manner, with final switch-off at 15.5 h
(NiAc Stp-Dwn). The step-down NiAc infusion rates were 88.9, 58.3, 43.7, 34.0, 24.3, 17.0,
and 9.7 nmol min−1 kg−1. All NiAc protocols were matched with saline-infused controls.
Blood samples (18/animal) were drawn during a 6 h experimental period. Samples, 30-150 µl
(with total loss less than 5% of blood volume), were collected in potassium-EDTA tubes,
centrifuged, and plasma was stored at 80◦C pending analysis for NiAc, FFA and insulin.
Anaesthetised animals (NiAc Off and NiAc Stp-Dwn 1 h infusion groups)
After an overnight fast, lean and obese rats were anaesthetize and surgically prepared,
as described above. They were allowed a stabilization period after surgery of at least 1.5 h.
Two basal blood samples were obtained, after which an i.v. NiAc infusion was given at a
constant rate (170 nmol min−1 kg−1) for 1.0 h (the start of infusion was taken as time=0 h).
The NiAc infusion was then either switched off (NiAc-Off 1 h) or decreased in a step-wise
manner, with final switch-off at 4.5 h (NiAc Stp-Dwn 1 h). The step-down NiAc infusion rates
were: 31.1, 20.4, 15.3, 11.9, 8.50, 5.95 and 3.40 nmol min−1 kg−1. All NiAc protocols were
matched with saline infused controls. Blood samples (13-18/animal) were drawn during a 6 h
experimental period. Samples, 30-150 µl (with total loss less than 5% of blood volume), were
collected in potassium-EDTA tubes, centrifuged, and plasma was stored at 80◦C pending
analysis for NiAc, FFA, and insulin.
3.3.1.5 Analytical methods
Plasma FFA was analysed using an enzymatic colorimetric method (Wako Chemicals GmbH,
Neuss, Germany). Plasma insulin from obese rats was analysed with a radioimmunoassay
kit (rat insulin RIA kit, Millipore Corporation, St. Charles, Missouri, USA). Plasma insulin
concentrations from lean rats were determined using a colorimetric ELISA kit (Ultra Sensitive
Rat Insulin ELISA Kit, Crystal Chem INC, Downers Grove, IL, USA). The ELISA was used
for lean rats to minimize blood sample volume (only 5 µl plasma required vs. ∼50 µl plasma
for RIA). The RIA was used for the obese rats because their high lipid levels in plasma
interfere with the ELISA but not the RIA measurement. Due to the hyperinsulinemia in the
obese rats only 5 µl of plasma was required. For lean-rat plasma (with low lipid levels) the
absolute insulin measurements are equivalent for the RIA and ELISA assays, according to an
in-house comparison. Plasma NiAc concentrations were analysed using LC-MS/MS with a
hydrophilic interaction liquid chromatography (HILIC) approach, separated on a 50×2.1 mm
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Biobasic AX column, with 5 µm particles (Thermo Hypersil-Keystone, Runcorn, Cheshire,
UK) as previously described by Ahlstro¨m (2011).
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Chapter 4
DRT I - Free fatty acid
dynamics
The first study presents a dose-response-time (DRT) analysis based on an extensive preclinical
biomarker data set on the nicotinic acid-induced (NiAc) reduction of free fatty acids (FFA).
The data constitute FFA-time courses, collected from studies that examined different rates,
routes, and modes of NiAc provocations on lean (normal) and obese (diseased) rats. All
information regarding the exposure to NiAc was excluded to demonstrate the utility of a
DRT model. The study emphasised the selection process of the biophase function. An
inhibitory Imax-model, driven by the biophase amount, acted on the turnover rate of FFA. A
second generation NiAc-FFA model, which encompasses integral (slow build-up of tolerance)
and moderator (rapid and oscillatory) feedback control, was simultaneously fitted to all time
courses. The results of the study were compared to an exposure-driven analysis to assess the
performance of the DRT analysis.
4.1 Model development
In contrast to the traditional pharmacokinetic-pharmacodynamic modelling approach—where
the kinetic and dynamic properties of the drug can be assessed sequentially1—the biophase
1Although PK-PD modelling traditionally have been performed sequentially, simultaneous fitting of the
models is preferable in many cases (Zhang et al., 2003a,b), and has indeed been done in several studies (see,
for example, Standing et al. (2010)).
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and pharmacodynamics need to be determined simultaneously in dose-response-time (DRT)
modelling. Thus, the evolution of the biophase, described in the following section, acted in
parallel with the development of the pharmacodynamic model.
A fundamental assumption for this study was that systems for the lean and obese rats could
be described with the same DRT model. As the data generated from experiments on lean
rats were more extensive than those for the obese rats, those data were analysed when
developing the model. When a satisfactory DRT model was selected and fitted to the data
for the lean rats, the model was fitted to the data for the obese rats.
4.2 The biophase function
Dose-response-time (DRT) data analysis relies on the assumption that the pharmacological
response contains enough information about the kinetics to develop a biophase, which in
turn acts as a ‘driving’ function for the pharmacological response. Depending on the route of
administration, the input is either approximated to be directly into the biophase (intravenous
dosing) or absorbed into the biophase (oral dosing).
(a) (b) (c)
(d) (e) (f)
Figure 4.1: Examples drawn from the biophase model library: (a) bolus input and first-
order elimination; (b) zero-order input and first-order elimination; (c) zero-order input and
Michaelis-Menten elimination; (d) first-order input and elimination; (e) Michaelis-Menten
input and first-order elimination; (f) Michaelis-Menten input and elimination. The parameters
Ab, Inf., k, ka, and MM represent, respectively, the biophase amount, the constant rate
infusion input, the first-order elimination rate constant, the first-order absorption rate
constant, and the Michaelis-Menten absorption/elimination process.
4.2.1 Selection process of biophase models
Developing the biophase model was done sequentially, starting with the simplest data
(intravenous administration). In a pair-wise accept-reject procedure, two candidate models
were qualitatively and quantitatively analysed and compared, and the best fit was selected
and further challenged with more complex data (see Table 4.1). In detail, the goodness-of-fit
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was assessed by the Akaike information criterion (AIC) and by graphical inspection of the
visual predictive check (VPC), and individual, plots.
Step I The first biophase model evaluated consists of a zero-order input into, and first-
order elimination from, the biophase (Fig. 4.1b). The analysed data consist of response-time
courses, derived from constant-rate intravenous infusion experiments.
Step Model Description Data
I

Zero-order input
First-order elimination
Intravenous
II

Zero-order input
Michaelis-Menten elimination
Intravenous
Pair-wise accept-reject procedure between the models in Step I and Step II.
The model in Step I was considered the better model.
III

Zero-order input (IVa)
First-order input (POb)
First-order elimination
Intravenous
and oral
IV

Zero-order input (IVa)
Michaelis-Menten input (POb)
First-order elimination
Intravenous
and oral
Pair-wise accept-reject procedure between the models in Step III and Step IV.
The model in Step IV was considered the better model.
aIntravenous
bOral
Table 4.1: Evolution of the biophase model structure. The table depicts Steps I-IV, a
description of the biophase function, the data used for the regression analysis, and the
pair-wise accept/reject procedures applied when addressing the biophase disposition and
absorption.
Step II The next biophase model evaluated consists of a zero-order input into, and
Michaelis-Menten elimination from, the biophase (Fig. 4.1c). The analysed data were the
same as in step I.
86
The model that best describes (regarding goodness-of-fit) the dynamics of the dose-response-
time data was kept for the later stages of the biophase evolution. In this case, the models
in steps I and II had close to similar likelihood and were indistinguishable by graphical
inspection of the VPC’s. Nonetheless, by the AIC, the simpler model was consider to be the
best fit.
Step III Given a model for the biophase elimination, response-time data derived from
experiments for oral administration were analysed to address the biophase absorption. The
first biophase absorption model evaluated consists of first-order input into, and first-order
elimination from, the biophase (Fig. 4.1d).
Step IV The final absorption model evaluated consists of Michaelis-Menten input into,
and first-order elimination from, the biophase (Fig 4.1e). The analysed data are the same as
in step III.
The model in step IV was selected in accordance with the AIC.
4.2.2 The final biophase model
The biophase model is given by
dAb(t)
dt
= Input(t)− k ·Ab(t) with Ab(0) = 0, (4.1)
where Ab(t) (µmol kg
−1) represents the biophase drug amount, k (min−1) the biophase
elimination rate, and Input(t) a time-dependent function determined by the route of admin-
istration according to
Input(t) =
Inf. rate Intravenous administrationVmaxg·Ag(t)
Kmg+Ag(t)
Oral administration,
(4.2)
where Inf. rate (µmol kg−1 min−1) is the infusion rate to the biophase, Ag(t) (µmol kg−1)
the drug amount in the gut, Vmax (µmol kg
−1 min−1) the maximal absorption rate from the
gut to the biophase, and Kmg (µmol kg
−1) the amount in the gut corresponding to 50%
absorption rate from the gut to the biophase. The infusion rate is modelled as a either a
constant, or a stepwise decreasing, Heaviside function to mimic the infusion regimens used
in the experiments. The rate of change of Ag(t) is given by
dAg(t)
dt
= −Vmax,g ·Ag(t)
Km,g +Ag(t)
with Ag(0) = D, (4.3)
where D (µmol kg−1) is the oral drug dose.
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4.3 The pharmacodynamic model
The free fatty acid (FFA) dynamics are characterised by a turnover equation according to
dF (t)
dt
= k˜in(t)− k˜out(t) · F (t) with F (0) = F0, (4.4)
where F (t) denotes the observed FFA level, F0 the baseline FFA level, both expressed in mM,
and k˜in(t) and k˜out are functions describing the lumped effects of NiAc, insulin, and other
hormones, on the turnover and fractional turnover of FFA, respectively. The NiAc-induced
action on FFA is described by means of an inhibitory drug-mechanism function given by
I(Ab(t)) = 1− Imax ·Ab(t)
γ
IDγ50 +Ab(t)
γ
, (4.5)
where Imax (unitless
2) denotes the efficacy, ID50 (µmol kg
−1) the potency, and γ the Hill
exponent. Furthermore, the FFA level is affected by a chain of moderator compartments
M1, . . . ,M8. These moderator compartments represent a conglomerate of insulin, and other
hormonal, regulators of the FFA disposition. Insulin, for example, acts as a dual regulator
on the FFA level via rapid inhibition of the lipolysis and slow re-esterification of FFA to
triglycerides (Frayn et al., 1994; Sadur and Eckel, 1982; Str˚alfors et al., 1984). The rapid
inhibition is captured by the dynamics of the first moderator M1 and the re-esterification by
the last moderator M8. The moderators dynamics are given by
dM1(t)
dt
= ktol · (F (t)−M1(t))
dM2(t)
dt
= ktol · (M1(t)−M2(t)) (4.6)
...
dM8(t)
dt
= ktol · (M7(t)−M8(t)),
where ktol (min
−1) is the fractional turnover rate of the moderators. Consequently, all
moderator compartments have the same transit time of 1/ktol (min). The moderators are
initially assumed to be in equilibrium with the response with
M1(0) = . . . = M8(0) = F0. (4.7)
The number of moderator compartments selected has previously been discussed by Ahlstro¨m
et al. (2011b). Long-term exposure to NiAc has proven to induce insulin resistance in
adipocytes (Fabbrini et al., 2010; Poynten et al., 2003). The resistance is believed to be a
consequence of down-regulated gene expressions of the insulin and β-adrenergic pathways in
2Notation will from hereon be omitted for unitless parameters.
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Figure 4.2: Example of FFA-time course data under intravenous and oral NiAc dosing.
(a) represents 30 min NiAc infusion and (b) 300 min NiAc infusion, both for lean rats. (c)
represents oral NiAc dosing for lean rats. (d) represents 300 min NiAc infusion for obese rats.
The blue lines represent the NiAc treated animals, the red lines the vehicle control group,
and the black lines the infusion periods.
adipose tissue (Heemskerk et al., 2014). Insulin resistance ultimately leads to full systemic
adaptation with an FFA level that returns to its baseline within a few days (Oh et al., 2011).
This slow and complete adaptation is captured by an integral feedback controller, with
output u(t), that slowly forces deviating FFA levels back towards their baseline F0, despite
persistent perturbations such as a constant rate infusion of NiAc (the adaptation can partly
be seen in Fig. 4.2b and Fig. 4.2d). The integral controller is given by
u(t) = Ki
t∫
0
(
1− F (τ)
F0
)
dτ, (4.8)
where Ki represents the integral gain parameter (hereafter referred to as the adaptation
rate).
The integral controller may also be expressed as a rate equation
du
dt
= Ki ·
(
1− F (t)
F0
)
, (4.9)
with initial condition
u(0) = 0. (4.10)
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Figure 4.3: Schematic structure of the pharmacodynamics of the DRT feedback model. The
pharmacodynamic model structure consists of a turnover equation coupled with a chain of
moderator compartments, with slow and rapid feedback, as well as a slow integral control
feedback. Here kin denotes the turnover rate of FFA, kout the fractional turnover rate
of FFA, ktol the turnover rate of the moderators, p the amplification factor, I(Ab) the
drug-mechanism function, and M1 and M8 the first and last moderator, respectively. Solid
lines represent fluxes whilst the dashed lines represent flow of information (i.e., how the
different entities affect one another)
With all model components introduced, the expanded turnover equation of FFA under NiAc
provocation is modelled by
dF (t)
dt
= kin ·
(
1 + u(t)
) · 1(
M1(t)
F0
)p · I(Ab(t))
− kout ·
(
M8(t)
F0
)
· F (t), (4.11)
with initial condition
F (0) = F0, (4.12)
where F (t) denotes the FFA level, kin (mM min
−1) the basal turnover rate, kout (min−1)
the basal fractional turnover rate, F0 the FFA baseline, u(t) the integral controller, p the
amplification factor, and M1(t) and M8(t) the first and last moderator, respectively (all
moderators have unit mM). The moderators are normalised in the turnover Eq. (4.11) with
the baseline FFA value F0. The levels of the moderators follow the concentration of the
FFA according to Eq. (4.6). In turn, the first moderator M1(t) modifies the turnover rate
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kin, amplified with the exponent p, whilst the last moderator M8(t) modifies the fractional
turnover rate kout. These feedback mechanisms represent the fast inhibition of lipolysis and
the slower re-esterification of FFA to triglycerides, triggered by insulin and other hormones,
that strive to dampen fluctuations in the FFA level (these physiological processes manifest
themselves as, for example, rebound in the FFA dynamics post drug infusion—a feature seen
in all data (see Fig. 4.2)). Furthermore, when the FFA level drops below the baseline level,
the integral controller, given by Eq. (4.8), will accumulate and provide a positive contribution
to the turnover rate kin of FFA (this adaptation can be seen in, for example, Fig. 4.2b and
Fig. 4.2d). Similarly, when the FFA level increases and rises above the baseline level, the
integral controller will accumulate and provide a negative contribution to the turnover rate.
The pharmacodynamic model structure is illustrated in Fig. 4.3.
4.3.1 Structural identifiability
The model structure, summarised in Table 4.2 (including the biophase function, the pharmaco-
dynamic model, the parameters, and the input-output), was proven to be structurally locally
identifiable. Identifiability was tested using the Exact Arithmetic Rank (EAR) approach
(presented in Sec. 2.2.1.3, see Anguelova et al. (2012); Karlsson et al. (2012); Raue et al.
(2014) for details). EAR requires that the functions of the system of differential equations
are rational polynomial expressions in their variables and parameters. In this study, the
inhibitory drug-mechanism function and the feedback function of the first moderator compart-
ment in Eq. (4.5) and Eq. (4.11), respectively, do not fulfil this requirement since the state
variables are raised to the powers of γ and p, respectively (which are real-valued). However,
by introducing auxiliary variables, the system may be re-written in rational form (Lindskog,
1996). As an example, let
B(t) = Aγb(t), (4.13)
with
B(0) = B0 (= A
γ
b(0)). (4.14)
Then we have that
dB
dt
= γ
B(t)
Ab(t)
· dAb
dt
, (4.15)
and by introducing the parameter I˜D50(=ID
γ
50) the non-rational functions in the inhibitory
drug-mechanism function can be written as
1− Imax ·B(t)
I˜D50 +B(t)
, (4.16)
which is a rational expression of the parameters and the variables. The Mathematica code
used for the identifiability analysis can be found in the Appendix A.
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4.3.2 Modelling between-subject variability
The data were analysed in a nonlinear mixed-effects framework in order to quantify between-
subject variability. Individual model fitting and an a priori sensitivity analysis (see Sec. 2.4)
were applied to identify parameters with a significant spread in the population or high
sensitivity. These parameters were selected to vary in the population. The remaining
parameters were considered to be fixed effects. The fixed effects were Vmaxg, Kmg, Imax,
ID50, γ, and p. The parameters with a population distribution were k, Ki, F0, kout, and ktol.
These parameters were assumed to be uncorrelated (to simplify the model) and log-normally
distributed (to keep the parameters positive). Thus, for example, the individual biophase
elimination rate ki of subject i is given by
ki = k · exp ηi, (4.17)
where k is the population median of the biophase elimination rate and ηi the associated
random effect of subject i. If ηi is the vector of all random effects of subject i, we have
ηi ∼ N (0,Ω), where
Ω =

ω11 0 0 0 0
0 ω22 0 0 0
0 0 ω33 0 0
0 0 0 ω44 0
0 0 0 0 ω55

. (4.18)
Here, ω11, ω22, ω33, ω44, and ω55 are the standard devations of the population parameters.
The individual parameter estimates, or the Empirical Bayes Estimates (EBEs), provide model
diagnostics. The validity of the diagnostics is quantified by the corresponding η-shrinkage of
the EBEs (Savic and Karlsson, 2009; Bonate, 2011).
4.4 Parameter estimation
The parameter estimation of the DRT model in this study was performed using a mixed effects
modelling framework implemented in Mathematica, developed at the Fraunhofer-Chalmers
Research Centre for Industrial Mathematics (Gothenburg, Sweden Almquist et al. (2015)).
A summary of the model structure, the model parameters, the input, and output is given in
Table 4.2.
The Mathematica code used for the parameter estimation can be found in the Appendix B.
4.4.1 Initial parameter estimates
At time zero, before administration of NiAc, the system is in steady-state with the moderators
set at F0. Consequently, the turnover equation Eq. (4.11) pre-NiAc administration is given
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by
dF (t)
dt
= kin − kout · F0 = 0. (4.19)
A simple rearrangement gives the relation
F0 =
kin
kout
. (4.20)
Hence the system may be simplified by removing one of the parameters F0, kin, or kout in the
parameter estimation. Here, kin
3 was estimated as a secondary parameter from the product
of F0 and kout. The initial estimate of the FFA baseline level F0 was taken as the mean
response at time zero. Since the minimum FFA level is close to zero, initially for high NiAc
dosages, we conclude that NiAc has a high efficacy and that Imax is close to 1. Furthermore,
for high NiAc infusion rates, the inhibitory drug-mechanism function becomes saturated
while the moderators are initially in steady-state with the response. Using this, and the
initial estimate of Imax Eq. (4.11), can be approximated as
dF (t)
dt
≈ −kout · F (t), (4.21)
or
F (t) ∼= F0e−koutt. (4.22)
Using this relation, kout can be estimated from the initial slope of the response-time course,
taken on a semi-logarithmic scale. The initial estimate for the Hill exponent γ and the
amplification factor p were set to 1. Simulations of the system were used to find suitable
initial estimates for the remaining parameters.
4.5 Results and validation
Visual predictive check (VPC) plots for the FFA levels, constituting the observed data, the
model predicted median, and 90% Monte Carlo prediction intervals (Robert and Casella,
2004) are illustrated in Fig. 4.4 for lean and obese rats. The FFA concentrations were
suppressed in all animals receiving NiAc. Adaptation towards the FFA baseline was seen for
the individuals that received a 300 min constant rate infusion of NiAc (see Fig. 4.4f and 4.4m).
The adaptation was more pronounced the higher the infusion rate. All infusion regimens give
rise to a rebound effect, i.e., the FFA level overshoots the initial baseline after the infusions
stopped. The rebound effect was more pronounced the higher the infusion rate. Apparent
oscillations around the FFA baseline level followed after the rebound. Oscillations were
more pronounced the higher the NiAc doses and the longer the infusion regimens. The rats
that received an oral dose of NiAc experienced an FFA drop followed by an approximately
constant FFA level (Fig. 4.4i, 4.4j, and 4.4k). The higher the dose, the longer the rats stayed
3Note that since F0 and kout are assumed to be log-normally distributed, kin also becomes log-normally
distributed.
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Lean Sprague-Dawley rats Obese Zucker rats
Parameter Estimate Half-life 90% PIa Estimate Half-life 90% PIa
kout (min
−1) 0.31 2.3 [1.3, 4.0] 0.191 3.6 [1.6,6.2]
ktol (min
−1) 0.024 29 [15, 51] 0.0116 60 [29,95]
Ki (min
−1) 0.0017 400 [210, 710] 0.0000645 11000 [0.95,5 000 000]
Table 4.3: Estimated system rate constants with corresponding half-lives (in minutes) with
90% non-parametric bootstrap prediction intervals for lean Sprague-Dawley and obese Zucker
rats, respectively.
a90% non-parametric bootstrap prediction interval
at a suppressed FFA level. Rebound and oscillations followed the FFA suppression. The
suppression of FFA, the occurrence of rebound, and the extent of the oscillations were more
pronounced the higher the oral dose. Individual observed FFA response-time data, with
individually fitted FFA response levels, are illustrated in Fig. 4.5 for one individual per
administration route and rate. The individual behaviour was captured by the model for
all provocations. The estimated population biophase amount-time courses are illustrated
in Fig. 4.6. For the constant rate NiAc infusions, the biophase amount quickly reached
steady-state. The wash-out kinetics were rapid with a half-life of around 2 min. For the
highest oral doses, the biophase amount declined in a non-linear fashion post-peak due
to the absorption rate-limited elimination of NiAc. Here, both a linear and non-linear
biophase absorption model were fitted, with the latter providing the best fit. The fitted
population parameters and inter-individual variations with corresponding relative standard
errors for the full system are illustrated in Table 4.4. The biophase elimination rate constant
k and the fractional turnover rate of FFA, kout, are of the same order of magnitude (for
both lean and obese rats), indicating little to no time-delay between biophase kinetics and
FFA dynamics. Since the absorption into the biophase is non-linear, we observed typical
absorption rate-limited elimination at higher oral doses of NiAc. The estimated Km,g of
about 40 µmol kg−1 implies that the two higher oral doses (81.2 and 812 µmol kg−1) approach
and exceed saturation. The efficacy parameter Imax was estimated as 0.893 and 0.694 < 1
for lean and obese rats, respectively; therefore, NiAc cannot completely suppress FFA levels.
The estimated biophase potency ID50 shows that the drug-mechanism function (Eq. 4.5) will
be saturated at the highest infusions and for all of the oral doses (Fig. 4.6). The estimated
Hill exponent γ indicates a steep NiAc biophase amount—FFA response relationship at
equilibrium (for both lean and obese rats). The estimated FFA baseline was higher for the
obese rats, and the turnover of FFA slower. The rate constants kout, ktol, and Ki all have
different orders of magnitude, and thus act over different time-scales. Half-lives for these
three rate constants with 90% non-parametric bootstrap prediction intervals (Davison and
Hinkley, 1997) are given in Table 4.3. All processes acted slower in the obese rather than
the lean rats. However, the parameter Ki for the obese rats is practically non-identfiable
given the current data (indicated by the extreme uncertainty in the point estimate).
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Figure 4.4: Visual predictive checks (VPC) of the FFA levels (in mM) for all experiments. The
first row represents 30 min infusions of NiAc (rates of 0.033, 0.17, and 0.67 µmol min−1 kg−1,
respectively), the second 300 min infusions (rates of 0.017, 0.033, and 0.017 µmol min−1 kg−1,
respectively), the third step-down protocol (from 0.17 to 0 µmol min−1 kg−1a with an addi-
tional 30 min infusion of 0.17 µmol min−1 kg−1 in (h)), the fourth oral dosing (doses of 24.4,
81.2, and 812 µmol kg−1, respectively), and the fifth 30 repectively 300 min infusions (rates
of 0.17 µmol min−1 kg−1) for obese rats (experiments are detailed in Sec. 3.3). The dots
represent the data, with colours indicating separate individuals, the black line the estimated
median individual, and the grey area the 90% population prediction interval.
aThe details of the protocols are given in Sec. 3.3
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FFA (mM) - obese rats
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Figure 4.5: Individually fitted FFA response-time courses. The first row represents 30 min
infusions of NiAc (rates of 0.033, 0.17, and 0.67 µmol min−1 kg−1, respectively), the second
300 min infusions (rates of 0.017, 0.033, and 0.017 µmol min−1 kg−1, respectively), the third
step-down protocol (from 0.17 to 0 µmol min−1 kg−1a with an additional 30 min infusion of
0.17 µmol min−1 kg−1 in (h)), the fourth oral dosing (doses of 24.4, 81.2, and 812 µmol kg−1,
respectively), and the fifth 30 repectively 300 min infusions (rates of 0.17 µmol min−1 kg−1)
for obese rats (experiments are detailed in Sec. 3.3). The dots represent the data and the
black lines the estimated individual behaviour.
aThe details of the protocols are given in Sec. 3.3
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Figure 4.6: Population model predicted biophase drug amounts. The first row represents
30 min infusions of NiAc (rates of 0.033, 0.17, and 0.67 µmol min−1 kg−1, respectively), the
second 300 min infusions (rates of 0.017, 0.033, and 0.017 µmol min−1 kg−1, respectively), the
third step-down protocol (from 0.17 to 0 µmol min−1 kg−1a with an additional 30 min infusion
of 0.17 µmol min−1 kg−1 in (h)), the fourth oral dosing (doses of 24.4, 81.2, and 812 µmol kg−1,
respectively), and the fifth 30 repectively 300 min infusions (rates of 0.17 µmol min−1 kg−1)
for obese rats (experiments are detailed in Sec. 3.3). The black line represent the predicted
biophase amount and the dashed blue line the predicted drug potency.
aThe details of the protocols are given in Sec. 3.3
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4.5.1 Model predictions
By using the predicted population parameters, we explored the long-term effects of NiAc
provocation on FFA level for the infusion rate of 0.17 µmol kg−1 min−1(Fig. 4.7), aiming at
a therapeutic plasma concentration of NiAc of 1 µmol (Ahlstro¨m et al., 2013a). The model
predicted 90% adaptation within approximately ten days of constant NiAc exposure for lean
rats, and about 80% adaptation in obese rats during the same period. The effect of the first
moderator (M1) feedback can be seen immediately after the initial drop, where the system
rapidly returns towards the baseline. The effect of the slower moderator feedback (M8) is
seen as a slower terminal return with oscillations in the FFA level. The effect of the integral
feedback controller is seen as the slow return to baseline over time.
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Figure 4.7: The long-term FFA response under constant rate infusions in lean (left figure)
and obese rats (right figure). Here, the infusion rate is set to 0.17 µmol kg−1 min−1 (aiming
at a therapeutic NiAc concentration of 1 µmol (Ahlstro¨m et al., 2013a)) and the infusions
last for 10 days. The inserted figure shows in more detail the dynamics during the first day
of the NiAc provocation.
Some of the pivotal parameters were compared to previously published estimates based on a
meta-analysis of NiAc concentration–FFA response data (Tapani et al., 2014). These results
are given in Table 4.5.
Lean Sprague Dawley rats Obese Zucker rats
Parameter DRT study Tapani et al. DRT study Tapani et al.
kout (min
−1) 0.306(8.1) 0.316(9.8) 0.191(30) 0.343(31)
ktol (min
−1) 0.0242(5.2) 0.0239(1.9) 0.0116(30) 0.0245(2.0)
Table 4.5: Pharmacodynamic parameter comparison between this dose-response-time analysis
(DRT) and the PK-PD analysis by Tapani et al. (2014) for lean Sprague-Dawley and obese
Zucker rats, respectively. The parameter estimates are given with corresponding relative
standard errors (RSE%) in parentheses.
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4.5.2 Shrinkage analysis
Shrinkage analysis was used to quantify the parameter assumptions (log-normality) and to
assess the model fits (Savic and Karlsson, 2009). The η-shrinkage of the EBEs are given in
Table 4.7. The standard deviation of the residual additive error and the ε-shrinkage for the
infusion and oral data are presented in Table 4.6.
Lean Sprague-Dawley rats Obese Zucker rats
Data Residual add. error σ ε-shrinkage Residual add. error σ ε-shrinkage
Infusion 0.0982(14) 9.5% 0.112(5.2) 7.3%
Oral 0.149(5.0) 7.7% - -
Table 4.6: Model residual additive errors with corresponding relative standard errors (RSE%)
and ε-shrinkage for lean Sprague-Dawley rats (infusion and oral data) and obese Zucker rats
(infusion data), respectively.
Parameter Sprague-Dawley Obese Zucker
k (min−1) 21.4 24.9
F0 (mM) 4.2 1.03
kout(min
−1) 46 33.5
ktol (min
−1) 52 67.2
Ki (min
−1) 58 98.5
Table 4.7: Estimated η-shrinkage of the EBEs to the corresponding parameters k, F0, kout,
ktol, and Ki.
4.5.3 Sensitivity analysis
A local sensitivity analysis was performed to examine which of the model parameters affect
the FFA response the most. The local analysis was conducted at the maximum likelihood
estimate θˆML on a system perturbed by a 300 min constant rate infusion of NiAc with the
infusion rate of 0.17 µmol min−1 kg−1. The sensitivity of, for example, the parameter F0 is
given by
∂F (t)
∂F0
∣∣∣∣∣
θˆML
. (4.23)
The results of the analysis are seen in Fig. 4.8 at the maximum likelihood estimates obtained
from the study of the lean and the obese rats. The parameters Ki and ktol had the greatest
impact on the system output, while the parameters γ and p had the least significiant impact.
This holds around both the lean and the obese parameter estimates.
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Figure 4.8: Local sensitivity analysis. The impact of each of the model parameters on the out-
put is examined during a 300 min infusion of NiAc at an infusion rate of 0.17 µmol min−1 kg−1.
The analysis was performed at the maximum likelihood estimate, obtained from the analysis
of the lean rats (upper plots) and the obese rats (lower plots).
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4.5.4 Goodness-of-fit plots
The empirical distribution of the standardised residuals was investigated to assess the
assumption of normality. This is illustrated in the form of a histogram in Fig. 4.9a and
Fig. 4.9b for lean and obese rats, respectively. The standardised residuals were also plotted
against time, seen in Fig. 4.9d and Fig. 4.9d. The assumption of normality was further
assessed by investigating the quantile-quantile relationship of the theoretical and observed
distributions of the standardised residuals. These are illustrated in Fig. 4.9e and Fig. 4.9f
for lean and obese rats, respectively. Finally, the predicted vs. observed behaviour was
investigated to determine if the performance of the model was consistent for all FFA levels.
These dependencies are illustrated as scatter plots in Fig. 4.9g and Fig. 4.9h for lean and
obese rats, respectively.
4.6 Discussion
DRT data analysis has previously proved to be a viable alternative to exposure-driven
modelling when exposure data are sparse or absent (Bragg et al., 1994; Fisher and Wright,
1997; Fisher et al., 1997; Warwick et al., 1998; Gabrielsson et al., 2000; Gabrielsson and
Peletier, 2014; Jacqmin et al., 2007; Luu et al., 2009; Wu et al., 2011). The technique
has been successful in studies where the pharmacodynamic response behaves non-linearly,
where time-lags are present in the data, and when the system displays potential feedback
mechanisms (Gabrielsson et al., 2000). The present study has shown the utility of a non-linear
biophase model (as a linear model were not sufficient in describing the absroption kinetics),
permitting the description of more complex absorption kinetics.
Although DRT analyses cannot completely replace exposure-driven modelling, particularly
when safety is an issue, DRT modelling can be considered even in studies where exposure
assays are available (Hamberg et al., 2010). By avoiding drug plasma measurements, the
pharmacological analysis becomes more biomarker oriented, focusing on the drug effect,
provided time-series of the pharmacological response are available (Jacqmin et al., 2007).
The non-invasiveness of DRT data analysis makes it useful in cases where invasive procedures
are undesired, as in paediatric studies (Tod, 2008).
4.6.1 DRT modelling
In contrast to exposure-driven pharmacodynamic modelling, the biophase kinetics and the
pharmacodynamic properties of a DRT model must be estimated simultaneously. Conse-
quently, there may be difficulties in discriminating whether specific artefacts in the data
originate from the concentration-time course or the response-time course.
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Figure 4.9: Histogram of the standardised residuals in (a) and (b), the standardised residuals
over time in (c) and (d), Q-Q plots of the observed residuals vs. the theoretical residuals
in (e) and (f), and scatter plots showing the relationships between the observed and predicted
responses in (g) and (h). The left column represents lean Sprague-Dawley rats and the right
obese Zucker rats.
4.6.2 Strategy when selecting the biophase model
The biophase model structure is preferably derived in a series of steps where data from
different administration routes are sequentially analysed, and the biophase structure refined
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if necessary (Table 4.1). In this way, different properties, for example, elimination rate and
absorption rate, can be addressed separately.
In this study, the intravenous data were initially analysed to address the biophase disposition.
Both a linear first-order and a Michaelis-Menten elimination model were successfully fitted
to the data. The two models had approximately the same likelihood and fitted the data
equally well when the function plots were inspected graphically. However, when the AIC
was applied, the simpler model was preferred and therefore selected. The similarity between
the linear first-order and Michaelis-Menten elimination models was due to the high estimate
of the Michaelis-Menten constant (Table 4.4), in comparison to the biophase amounts (see
Figs. 4.6), rendering an approximately linear elimination rate at all dose levels.
When the disposition model was selected, oral data were included to assess the absorption
process into the biophase. Both a first-order and nonlinear Michaelis-Menten absorption
model were analysed (Table 4.1). The first-order absorption model failed to capture the full
dynamic behaviour of the data—as the model systematically overpredicted the response-time
course for the highest oral dose (812 µmol kg−1). However, the Michaelis-Menten absorption
model captured the absorption rate-limited elimination.
4.6.3 DRT model
The model captures the general trends of the populations, and the Monte Carlo prediction
intervals cover approximately 90% of the individuals (see Figs. 4.4).
The integral feedback control, moderator feedback, and the turnover of FFA are shown to act
over different time-scales (Table 4.3). Turnover of FFA occurs within minutes, the feedback
triggered by insulin and other hormones operates within 30 min and 60 min for lean and
obese rats, respectively, while the slow build-up of NiAc tolerance occurs within a couple
of hours for lean rats and within a week for obese rats. However, the integral feedback
control had extreme uncertainty for the obese rats, indicating practical non-identifiability
(Table 4.4). Furthermore, the sensitivity of the system output, with respect to Ki, was high
(Fig. 4.8e and 4.8n). Thus, the high sensitivity, yet extreme uncertainty, suggest that the
data obtained from the experiments on the obese rats did not provide enough information
about the build-up of tolerance. This adaptation, for the obese rats, is most likely occurring
over a larger time-span. In conclusion, more data, preferably from long-term experiments,
are needed to identify Ki for the obese rats.
The model predicts full system adaptation for long-term constant rate infusions with the
therapeutic infusion rate of 0.17 µmol kg−1 min−1 (Fig. 4.7). This homoeostatic behaviour
has been proven experimentally in studies of long-term NiAc provocation (Oh et al., 2011).
However, 90% of adaptation typically occurs within 24 h at therapeutic concentrations of
NiAc. As mentioned, a better estimate for the adaptation Ki is expected when longitudinal
data are generated and added to the analysis.
The standardised residuals fits the standard normal distribution well (see Fig. 4.9a and
Fig. 4.9b), yet with slightly heavier tails (see Fig. 4.9e and Fig. 4.9f). There is no apparent
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trend in the standardised residuals over time for normal rats (Fig. 4.9c). For obese rats,
the standardised residuals seem to be systematically biased, specifically around the rebound
(Fig. 4.9d). The prediction vs. observed values are consistent over the entire range of FFA
levels (see Fig. 4.9g and Fig. 4.9h).
The disease impact was manifested by higher baseline levels of FFA (Table 4.4) and system-
atically slower rate processes (biophase elimination rate as well as turnover of FFA and the
moderators) (Table 4.5) in the obese rats rather than in the lean rats.
In general, there is high consistency between our derived parameter estimates and exposure-
driven model parameter estimates (Tapani et al., 2014) for lean rats, but not for the obese
rats (see Table 4.5). For the lean study, the data consisted of 95 individuals taken from
experiments of different rates, routes, and modes of NiAc provocations. The obese study
only included 19 rats, taken from experiments of intravenous NiAc administration at only
two different rates. These results illustrate the importance of having rich data (generated
from experiments of different rate and route of drug administration) when performing DRT
modelling, to obtain reliable results.
The models used for the infusion (lean and obese) and oral (lean) data resulted in relatively
low levels of ε-shrinkages, less than 10%, indicating that the models describe the data without
being over-fitted (Table 4.6).
This study has demonstrated the utility of DRT modelling in developing biophase-driven
pharmacodynamic models. Given extensive data (with different rates, routes, and modes of
administration), the biophase structure can be assessed even though the data demonstrate
time-lags, feedback mechanisms, functional adaptation, and rebound phenomena.
We envisage that DRT data analysis will have great significance with regard to pharmacolog-
ical responses (biomarkers) used in the future assessment of dynamics. DRT analysis has
proven to be an acceptable alternative to exposure-driven PD modelling in situations where
plasma concentrations are sparse or missing, or if extreme differences are seen for the initial
and terminal disposition phases in plasma (such as with oligonucleotides, where rate and
extent of exposure vary significantly between tissues (Callies et al., 2011; Heemskerk et al.,
2010)).
4.6.4 Control theory
In this study, techniques from systems and control theory were utilised to describe feedback
mechanisms and systemic adaptation. By applying integral feedback control, the system
demonstrated full adaptation under constant long-term NiAc pressure (see Fig. 4.7). In fact,
integral feedback control is a prerequisite for perfect adaptation in systems that experience
constant disturbance (Ang et al., 2010; Sontag, 2003).
Many biological systems, experiencing adaptation when put under external disturbance, have
been successfully modelled using control theory techniques, including metabolic networks
(Bates and Cosetino, 2011; He et al., 2013), synthetic biology (Cosentino and Bates, 2011),
the osmoregulation in yeast (Gennemark et al., 2006; Muzzey et al., 2009), and bacterial
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chemotaxis (Barkai and Leibler, 1997; Yi et al., 2000). El-Samad et al. (2002) showed how
integral feedback control could, for example, be derived from enzymatic relations when the
goal is to address the control of plasma calcium levels. Control theory techniques have been
used sparsely within PK-PD modelling and mostly in dose control (Schwildren et al., 1987;
Stone and Howell, 2002; Urquhart and Li, 1969a; Vozˇch and Steimer, 1985; Veng-Pedersen
and Modi, 1993). Control theory methods have a definite potential in modelling intrinsic
control and feedback systems.
4.6.5 Inter-individual and intra-individual variability
In the initial stage, when the data were fitted on an individual level to assess parameter spread
in the population, no parametric model (e.g., normal or log-normal) was successfully matched
to the distributions of the EBEs. Nonetheless, a log-normal distribution was chosen to model
the EBEs spread due to its positive range, a feature expected in the parameters. Fitting
a log-normal distribution to the EBEs resulted in high levels of shrinkage for some of the
parameters. While F0 and k had low η-shrinkages, indicating that the log-normal assumption
on the parameter distributions might be reasonable, the remaining three parameters had high
η-shrinkages of 30− 100%, suggesting that the standard deviation of the EBEs had shrunk to
0 and that the log-normal distribution did not fit the corresponding distribution of the EBEs.
Consequently, one should be careful in interpreting the behaviour of the EBEs—like, for
example, examining EBE vs. EBE plots or EBE vs. covariate plots. These are not reliable
under high levels of shrinkage and, for that reason, omitted in this study. However, the
estimated random effects are still useful when describing the data and when extrapolating
to, for example, other dosing regimens.
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Chapter 5
DRT II - Free fatty acid and
insulin dynamics
The second study sought to extend the dose-response-time (DRT) model used in the previous
analysis to obtain a more general, NiAc-FFA interaction model—applicable to a broad
set of dosing regimens and NiAc exposure durations. The model aimed at quantitatively
determining the impact of disease on the FFA-insulin system and to provide predictions
for optimal drug delivery. A meta-analysis on an extensive pre-clinical data set of the
interaction between NiAc and FFA, as well as insulin, was conducted in a nonlinear mixed-
effects (NLME) modelling framework. Using various routes and modes of NiAc provocations,
concentration-time course data of insulin and FFA was collected. All information regarding
the exposure to NiAc was excluded to demonstrate the utility of a DRT model. Experiments
were done both in lean Sprague-Dawley and obese Zucker rats—to evaluate the impact of
the disease. Furthermore, by including insulin as a covariate of the FFA response, we could
quantitatively analyse the endogenous antilipolytic effects of insulin (Arner et al., 1981)
under NiAc provocations. Two forms of systemic adaptation were discovered—covering both
NiAc and insulin resistance. Moreover, optimal dosing regimens, consisting of constant rate
infusion periods followed by washout periods, were investigated. Finally, the results were
compared to those for an exposure-driven analysis to assess the performance of the DRT
model.
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5.1 Model development
The dynamics of the two biomarkers, insulin and FFA, were described by separate DRT
models. We assumed that NiAc inhibits the release of both insulin and FFA and that insulin
inhibits the release of FFA (due to its antilipolytic effects). This assumption allows for a
sequential approach to the model development; starting by fitting the insulin DRT model
to the data, the resulting parameters estimated could then act as covariates in the ensuing
FFA DRT model. This approach was adopted in the current study—including both the fixed
effects (population parameters) and the Empirical Bayes Estimates (individual parameters)
from the insulin model as covariates in the subsequent FFA model. Fig. 5.1b illustrates the
interactions between the two DRT models (insulin and FFA) and Fig. 5.1a illustrates model
interactions of previously published NiAc-FFA DRT models (Andersson et al., 2015).
(a) Previous model
4 6
7
(b) Current model
1 2
3
4
65
Figure 5.1: Schematic illustration of how the dependency between NiAc and FFA was
modelled in previous studies (a) and how the dependencies between NiAc, insulin, and FFA
were modelled in this study (b). Solid lines represent fluxes while dashed lines represent
control. NiAc inhibits the turnover of insulin (1). Insulin, in turn, has feedback mechanisms
that inhibit its turnover (2) and stimulates its fractional turnover (3). Both NiAc (4) and
insulin (5) inhibit the turnover of FFA. In this study, FFA has a single feedback mechanism
which inhibits its turnover (6), while in previous studies, FFA was modelled using an
additional feedback mechanism which stimulates its fractional turnover (7).
5.1.1 Disease modelling and inter-study variability
The pharmacodynamics (PD) were significantly different between lean (normal) and obese
(diseased) rats. Consequently, the parameter estimation for lean and obese rats was performed
separately. Moreover, varying experimental conditions (separate time periods, anaesthetized
vs. conscious animals) may have provoked different dynamic behaviours. Therefore, inter-
study variability was included the models in the form of fixed-study effects (Laporte-Simitidis
et al., 2000).
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5.1.2 Notation conventions
To simplify for the reader, and differentiate between separate sub-model parameters, the
model parameters are labelled with a subscript, indicating to which model they belong. For
example, the turnover rate of FFA will be referred to as kinF while the turnover rate of
insulin is kinI (i.e., F for FFA and I for insulin). Parameters that link the biophase NiAc
amount, insulin, and FFA will be labelled with both sub-model subscripts (e.g., the potency
of NiAc as an FFA inhibitor will be called ID50NF—N for NiAc and F for FFA).
5.2 The biophase function
Suitable biophase functions for NiAc have been developed previously for intravenous and
oral administration (Andersson et al., 2015). The proven biophase function for intravenous
administration was adopted in this study, while a new biophase function was developed for
subcutaneous drug administration. The biophase dynamics are given by
dAb(t)
dt
= Input(t)− k ·Ab(t) with Ab(0) = 0, (5.1)
where Ab(t) represents the biophase drug amount (expressed in µmol kg
−1), k (min−1) the
biophase elimination rate, and Input(t) a time-dependent function determined by the route
administration according to
Input(t) =
Inf. rate Intravenous administrationka ·Asc(t) Subcutaneous administration, (5.2)
where Inf. rate (µmol kg−1 min−1) is the infusion rate, Asc (µmol kg−1) is the drug amount in
the subcutaneous compartment, and ka (min
−1) the absorption rate from the subcutaneous
compartment to the biophase. The infusion rate is modelled as either a constant, or stepwise
decreasing Heaviside function to mimic the infusion regimens used in the experiments. The
rate of change of Asc(t) is given by
dAsc(t)
dt
= Inf. rate− ksc ·Asc(t) with Asc(0) = 0. (5.3)
The biophase functions are illustrated in Fig. 5.2.
5.3 The pharmacodynamics of insulin
The primary aim of the insulin model was to establish smooth trajectories that would
accurately describe the insulin-time courses under various provocations of NiAc, rather than
explain all of the mechanistic aspects of insulin dynamics. To this end, the model structure
chosen was as simple as possible. The insulin model could subsequently be used to provide
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a) b)
Figure 5.2: Illustration of the biophase models used in this case study. Fig. (a) represents a
zero-order input into, and first-order elimination from, the biophase—used for modelling
intravenous drug administration. Fig. (b) represents a first-order absorption into, and a
first-order elimination from, the biophase—used for modelling subcutaneous administration.
input to the FFA model, enabling a quantitative analysis of the antilipolytic effects of insulin.
Given this premise, we applied a phenomenologically based modelling approach. Under the
assumption that NiAc perturbs insulin, the characteristics seen in the data were used to
establish an insulin model with NiAc as input. The characteristic behaviour of the data
for acute and long-term NiAc provocations in lean and obese rats is illustrated in Fig. 5.3.
Attributes seen include indirect action, tolerance, rebound, and complete adaptation. Data
with similar properties to those observed in the acute experiments (Figs. 5.3a and 5.3c) have
been modelled using turnover equations with moderator feedback control (Ahlstro¨m et al.,
2013a; Gabrielsson and Peletier, 2007). Furthermore, to capture the different long-term
adaptive behaviours with (Fig. 5.3b), and without (Fig. 5.3d) rebound, a ’NiAc action
compartment’ was included, as well as an integral feedback control (a schematic illustation
of the model is shown in Fig. 5.4).
The insulin dynamics are given by
dI(t)
dt
= kinI ·RI(t) ·HNI(Ab(t)) · M0I
M1I(t)
− koutI · M2I(t)
M0I
· I(t), (5.4)
dM1I(t)
dt
= ktolI ·
(
I(t)−M1I(t)
)
, (5.5)
dM2I(t)
dt
= ktolI ·
(
M1I(t)−M2I(t)
)
, (5.6)
with initial conditions
I(0) = I0, (5.7)
and
M1I(0) = M2I(0) = M0I = I0, (5.8)
where I(t) denotes the observed insulin level (expressed in nM), Ab(t) the biophase amount,
and M1I(t) and M2I(t) the first and second moderator compartments, respectively (both
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Figure 5.3: Example of insulin-time course data during acute NiAc dosing (a) and (c), and
chronic NiAc dosing (continuous infusion) (b) and (d) for lean and obese rats, respectively.
The blue lines represent the NiAc treated animals and the red lines the vehicle control group.
expressed in nM). The parameters kinI (nM min
−1) and koutI (min−1) are the turnover
rate and fractional turnover rate of insulin, respectively, and ktolI (min
−1) is the fractional
turnover rate of the moderators. The regulator RI(t) compartment is given by
dRI(t)
dt
= kinRI − kRI · I(t) with RI(0) = 1, (5.9)
where kinRI (min
−1) is the turnover rate, koutRI (min−1 nM−1) the fractional turnover rate,
and I(t) the insulin concentration. The regulator is initially at steady-state with
dRI(0)
dt
= kinRI − koutRI · I0 = 0 (5.10)
or
I0 =
kinRI
koutRI
. (5.11)
By integrating Eq. (5.9), the dynamics of RI(t) can be expressed as
RI(t) = 1 +
∫ t
0
kinRI − koutRI · I(τ) dτ. (5.12)
Hence, by construction, RI(t) represents the output of an insulin-driven integral feedback
controller (Glad and Ljung, 2000) with I0 as the set-point and koutRI as the integral gain
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parameter (koutRI will from hereon be referred to as the integral gain parameter). The
integral feedback controller ensures that insulin levels return to the baseline I0, despite
persistent external effects on insulin turnover and fractional turnover. The inhibitory NiAc
function for insulin is given by
HNI(Ab(t)) = 1− ENI(NI(t)) · A
n
b(t)
IDn50NI +A
n
b(t)
, (5.13)
where ID50NI (µmol kg
−1) is the potency of NiAc on insulin and n the Hill coefficient of the
inhibitory function. The term ENI(NI(t)) represents the drug efficacy, which is fixed for lean
rats and dependent on the concentration in a hypothetical NiAc action compartment, NI(t)
(µmol kg−1), for obese rats, according to
ENI(NI(t)) =
ImaxNI leanImaxNI (1− SNI·NγI (t)Nγ50I+NγI (t)) obese, (5.14)
where ImaxNI is the initial efficacy of NiAc for insulin, N50I (µmol kg
−1) the potency of the
NiAc action compartment, SNI the long-term NiAc efficacy loss, and γ the corresponding
Hill coefficient of the efficacy relation. The dynamics of NI are in turn given by
dNI(t)
dt
= kNI · (Ab(t)−NI(t)), (5.15)
with NI(0) = Ab(0). Here kNI (min
−1) is the turnover rate of the NiAc action concentration.
The NiAc action compartment is initially at steady-state with the biophase NiAc amount
Ab. As infusions are initiated, and the biophase amount increases, NI(t) increases until it
reaches the steady-state biophase NiAc amount Nss(t) = Abss. With increasing levels in the
NiAc action compartment, E(NI(t)) decreases to a minimum of 1− SNI and, consequently,
the efficacy of NiAc as an insulin inhibitor is down-regulated. In other words, the system
has developed tolerance to the drug. The turnover rate kNI determines the rate at which
tolerance develops.
Assuming that the system in Eq. (5.4) is at an initial steady-state with dIdt = 0 and knowing
that the initial biophase drug amount is zero, i.e., Ab(0) = 0, the inhibitory NiAc function
for insulin is HNI(Ab(0)) = 1 and we obtain
dI
dt
∣∣∣∣
t=0
= kinI − koutI · I0 = 0, (5.16)
or
kinI = koutI · I0. (5.17)
Thus, we can eliminate kinI from the estimation procedure and obtain an estimate for this
parameter from Eq. 5.17.
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Figure 5.4: Mechanisms of insulin dynamics. The parameters kinI and koutI represent the
turnover rate and fractional turnover rate, respectively. The turnover of insulin is inhibited
by the NiAc action function HNI(Ab). Tolerance and rebound are captured by the moderator
compartments M1I and M2I, which act on the turnover rate and fractional turnover rate of
insulin, respectively. The integral feedback controller acts on the turnover rate of insulin, in
that it strives to maintain the insulin baseline, I0, despite persistent external effects on the
turnover.
5.3.0.1 Between-subject, inter-study, and residual variability
The insulin data illustrate individual variations (as can be seen in Fig. 5.3), which were
described by incorporating random effects in the model and allow the parameters I0, ktolI,
and ID50NI to vary in the population. These parameters were assumed to be log-normally
distributed. Thus, for example, the insulin baseline level I0i of subject i is given by
I0i = I0 · exp ηi, (5.18)
where I0 is the median population insulin baseline level and ηi is the corresponding random
effect of subject i. The covariance matrix of the random effects was assumed to be diagonal
in order to simplify the estimations. Hence, the vector of random effects ηi of subject i is
normally distributed ηi ∼ N (0,Ω) where
Ω =
ω11 0 00 ω22 0
0 0 ω33
 . (5.19)
Here, ω11, ω22, and ω33 are the standard deviations of the random effects. The choice of
these parameters was guided by an a priori sensitivity analysis (see Sec. 2.4 or Saltelli et al.
(2008); Saltelli (2002) for more details). Moreover, the parameters I0 and ktolI varied over
study groups according to fixed-study effects on both the mean and individual parameter
distributions (Laporte-Simitidis et al., 2000). In other words, for S the number of groups,
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the parameter I0 for an individual j was modelled as
I0j = (I01 · Study1 + . . .+ I0S · StudyS)· (5.20)
exp(η1 · Study1 + . . .+ ηS · StudyS), (5.21)
where Studyk = 1 if individual j is in group k and 0 otherwise. The residual variability was
modelled using an additive model (with normally distributed errors).
5.4 The pharmacodynamics of FFA
The model suggested in this study is founded on preceding approaches (Ahlstro¨m et al.,
2013a,b; Andersson et al., 2015; Tapani et al., 2014); however here, insulin has been included
as the primary endogenous regulator of FFA as it provides a homoeostatic force on the
system—thereby keeping FFA levels in the vicinity of its baseline concentration. Further,
the NiAc efficacy is dynamic in that it is decreasing during long-term infusions, which
allows for full systemic adaptation—a feature apparent in the data (Fabbrini et al., 2010;
Poynten et al., 2003). The characteristic behaviour of the data, for acute and chronic NiAc
provocations in lean and obese rats, is illustrated in Fig. 5.5. Attributes observed include
indirect response, tolerance, rebound, and full adaptation. The behaviour observed in the
acute experiment (Fig. 5.5a and Fig. 5.5c) has been described by turnover equations with
moderator feedback (as described for the insulin system). The long-term behaviour, and in
particular the adaptations with, and without, rebound, is captured by dynamic NiAc efficacy
and an insulin integral controller (a schematic illustation of the model is shown in Fig. 5.6).
The FFA model is given by
dF (t)
dt
= kinF ·RF(t) ·HNF(Ab(t)) · M0F
MF(t)
− koutF · F (t), (5.22)
with initial condition
F (0) = F0. (5.23)
Here, F (t) denotes the observed FFA level (expressed in mM), Ab(t) the biophase amount,
kinF (mM min
−1) the turnover rate, and koutF (min−1) the fractional turnover rate. The
moderator compartment MF (mM) is given by
dMF(t)
dt
= ktolF ·
(
F (t)−MF(t)
)
, (5.24)
with initial condition
MF(0) = M0F = F0, (5.25)
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Figure 5.5: Example of FFA-time course data under acute NiAc dosing (a) and (c), and
chronic NiAc dosing (continuous infusion) (b) and (d) for lean and obese rats, respectively.
The blue lines represent the NiAc treated animals and the red lines the vehicle control group.
where the parameter ktolF (min
−1) represents the turnover rate of the moderator compartment.
The moderator compartment provides a feedback mechanism for the turnover of FFA, that
strives to dampen deviations from the baseline response. The regulator compartment RF(t),
that links the insulin dynamics to FFA release, is similar to that for the insulin model in
Eq. (5.26) and is given by
dRF(t)
dt
= kinRF − koutRF · I(t), RF(0) = 1, (5.26)
where kinRF (min
−1) is the turnover rate, koutRF (nM min−1) the fractional turnover rate,
and I(t) (nM) the insulin concentration. As for the insulin regulator, RF(t) represents the
output of an insulin-driven integral controller with I0 (nM) as the set-point and koutRF as
the integral gain parameter. The contribution of this integral controller during acute and
chronic NiAc treatments in lean and obese rats is illustrated in Fig. 5.13b. The inhibitory
NiAc function on FFA (similar to that for the insulin model in Eq. (5.13)), is given by
HNF(Ab(t)) = 1− ENF(NF(t)) · A
m
b (t)
IDm50NF +A
m
b (t)
, (5.27)
where ID50NF (µmol kg
−1) is the potency of NiAc as an inhibitor of FFA release and m
is the Hill coefficient. The drug efficacy is dynamic and changes (down-regulates) during
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long-term infusions of NiAc. The efficacy is given by
ENF(NF(t)) = ImaxNF ·
(
1− SNF ·N
φ
F (t)
N φ50F +N
φ
F (t)
)
, (5.28)
where ImaxNF is the initial efficacy of NiAc on FFA, N50F the potency of the NiAc action
compartment, SNF the long-term NiAc efficacy loss, φ the Hill coefficient, and NF(t) the con-
centration in the NiAc action compartment. The dynamics of the NiAc action compartment
are in turn described by
dNF(t)
dt
= kNF · (Ab(t)−NF(t)), (5.29)
with initial condition NF(0) = Ab(0). Here, the parameter kNF is the turnover rate of the
NiAc action state.
Figure 5.6: Mechanisms of FFA dynamics. The parameters kinF and koutF represent the
turnover rate and fractional turnover rate, respectively. The turnover of FFA is inhibited by
the NiAc action function HNF(Ab). Tolerance and rebound are captured by the moderator
compartment MF, which acts on the turnover rate of FFA. The upper control arrow represents
the insulin-driven integral controller with set-point I0.
Assuming that the system in Eq. (5.22) is at an initial steady-state with dFdt = 0 and that
the initial biophase drug amount is zero, then the inhibitory NiAc function for insulin is
HNF(Ab(0)) = 1 and we obtain
dF
dt
∣∣∣∣
t=0
= kinF − koutF · F0 = 0, (5.30)
or
kinF = koutF · F0. (5.31)
Thus, we can eliminate kinF from the estimation procedure and obtain an estimate for this
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parameter from Eq. (5.31).
5.4.0.1 Between-subject, inter-study, and residual variability
Random effects were again selected using an a priori sensitivity analysis (see Sec. 2.4) (Saltelli
et al., 2008; Saltelli, 2002). The analysis was performed around a local point in the parameter
space around which the optimal solution was assumed to be found. Here, the parameters that
affected the system output the most, and thus having the highest sensitivity, were assumed
to vary in the population. The parameters that varied in the population were F0, ktolF,
and ID50NF (according to a log-normal distribution). The covariance matrix of the random
effects was chosen to be diagonal in order to simplify the estimations. Moreover, inter-study
variability was incorporated in the model according to a fixed-study effect (as described for
the insulin model). The parameters that varied between experimental groups were F0 and
ktolF (only for the obese rats). The residual variability was modelled using an additive model
(with normally distributed errors), which is often sufficient in pharmacodynamic modelling
(rather than using, for example, a proportional residual error model or a combination of
additive and proportional residual error (Mould and Upton, 2013)).
5.4.1 Structural identifiability
All population model structures analysed in this study were proven to be structurally
locally identifiable in a fixed effects setting (identifiability of the population model (fixed
effects) implies identifiability of the statistical model (random effects) (Janze´n, 2016)) (a
summary of the models—including fixed and random effects, input, and output—can be
found in Table 5.1). The identifiability analysis was performed using the Exact Arithmetic
Rank (EAR) approach (Anguelova et al., 2012; Karlsson et al., 2012; Raue et al., 2014)—
implemented in the IdentifiabilityAnalysis Wolfram Mathematica package, developed
by the Fraunhofer-Chalmers Centre (see Sec. 2.2.1.3 and Appendix C for an example code
for the Mathematica package). The EAR algorithm requires that all states and system
parameters are rational functions of their arguments. This requirement is not fulfilled in the
insulin and FFA systems (for example, the state space variable Ab is raised to the power of
n in Eq. (5.13)). We will now provide an illustrative example of how this requirement can
be achieved by rewriting the system in a rational form.
5.4.1.1 System on rational form
The insulin system, given by Eqs. (5.4) to (5.15), with the NiAc biophase amount Ab as
input and the insulin level I as output, does not fulfill the requirement that all states and
system parameters must be rational functions of their arguments (for example, the state
space variable Ab(t) is raised to the power of n in Eq. (5.13)). This issue is overcome by
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introducing the auxiliary state variable B(t) = Anb(t) (Lindskog, 1996) with
dB(t)
dt
= n ·An−1b (t) ·
dAb(t)
dt
= n · B(t)
Ab(t)
· dAb(t)
dt
, (5.32)
and the parameter B0 as the initial condition
B(0) = B0 (= A
n
b(0)). (5.33)
Furthermore, we introduce IB50 as IB50 = ID
n
50NI. Given these transformations, the drug
mechanism function in Eq. (5.13) becomes
HNI(B(t)) = 1− ENI(N(t)) B(t)
IB50 +B(t)
, (5.34)
and the augmented insulin system, with Eq. (5.32) to (5.34) with parameters B0 and IB50
included, will fulfil the requirements of the EAR algorithm (this augmented system is
equivalent to the original one). Now, explicit relations such as B0 = A
n
b(0)) cannot be
included in the algorithm. This leaves B0 structurally locally unidentifiable and, consequently,
IB50 structurally locally unidentifiable. However, all other parameters are structurally locally
identifiable and the number of degrees of freedom of the system, given by the algorithm, is 1.
Given that we can identify n and that we know the initial input Ab(0), we can identify B0
from B0 = A
n
b(0)). Hence, we can also identify IB50 (since the degree of freedom was 1),
and the system is structurally locally identifiable.
5.5 Parameter estimation
The parameter estimation of the DRT model in this study was performed using a mixed effects
modelling framework implemented in Mathematica, developed at the Fraunhofer-Chalmers
Research Centre for Industrial Mathematics (Gothenburg, Sweden) (Almquist et al., 2015).
This framework is described in Sec. 2.3.5. Diagonal covariance matrices were chosen to
simplify the parameter estimation. From the steady-state relations in the insulin and FFA
models, dependencies were derived which enabled the parameters kinI, kinF, kinRI, and kinRF
to be expressed in terms of other model parameters. Consequently, these parameters were
redundant and could be replaced in the parameter estimation. Furthermore, some parameters
were initially estimated to be very close to their physiological limit (e.g. ImaxNI = 0.9999 ≈ 1
for obese rats) and were consequently fixed for numerical stability. Finally, to simplify
the parameter estimation, some parameters were fixed (e.g., SNI = 1 for obese rats—this
is motivated by the full systemic adaptation apparent in the long-term insulin-time data,
implying that SNI must be 1). A full summary of the models can be found in Table 5.1.
The Mathematica code used for the parameter estimation of the FFA model in DRT study
I can be found in the Appendix B. The code used for this model is omitted as the codes are
practically the same.
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5.6 Results and validation
The parameter estimation for the two DRT models (insulin and FFA) was performed
sequentially, as described in the Model development section 5.1. The estimates and between-
subject variabilities (expressed in CV%), both with corresponding relative standard errors
(RSE%), for normal Sprague-Dawley rats and obese Zucker rats are given in Table 5.3.
Weighted summaries (Laporte-Simitidis et al., 2000) are presented for the parameters that
varied between studies. The resulting models were qualitatively evaluated using visual
predictive check (VPC) plots (Bergstrand et al., 2011); illustrating the data, the model
predicted median individual, and 90% Monte Carlo prediction intervals generated from the
models (Bergstrand et al., 2011; Post et al., 2008). The VPC’s are shown in Fig. 5.7 for lean
Sprague-Dawley rats and in Fig. 5.10 for obese Zucker rats. The VPCs were generated from
the insulin and FFA models for all provocations of NiAc. Individually fitted insulin-time
courses and FFA-time courses are illustrated in Fig. 5.8 for lean rats and in Fig. 5.11 for
obese rats. Predicted biophase amounts from the insulin and FFA DRT models for lean and
obese rats are illustrated in Fig. 5.9 and Fig. 5.12, respectively.
5.6.1 Biophase dynamics
The driving biophase functions were estimated for each submodel, both insulin and FFA, and
for lean and obese rats. The biophase elimination and absorption rates are given in Table 5.3.
The biophase amount reached steady-state quickly for all infusions, seen in Fig. 5.9 and
Fig. 5.12. The wash-out kinetics were predicted to have a half-life of between 4 and 12 min
for lean rats and between 2.5 and 3.2 min for obese rats (the ranges are derived from the
estimates obtained from the insulin and FFA DRT models).
5.6.2 Insulin model
The insulin concentration was suppressed below its baseline value for all provocations of
NiAc. The suppression was more pronounced at an early stage of the infusions; at later
stages, the insulin concentrations drifted back towards their baselines. After the infusions
were terminated, the insulin concentrations rebounded before reaching their baseline values.
The individuals receiving the 12 h Off protocols (Fig. 5.7d and Fig. 5.10d) had the highest
rebound, while individuals receiving step-down protocols had less pronounced rebound
(Figs. 5.7e, 5.7g, 5.10e, and 5.10g). The insulin concentrations returned to their baselines
after long-term infusions of NiAc in the obese rats (Fig. 5.10c). No rebound was observed
after the extended infusions were terminated (Fig. 5.10c).
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VPC FFA
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Figure 5.7: Visual predictive checks for lean Sprague-Dawley rats. The upper seven
illustrations show the insulin fits, the lower seven the FFA fits. The dots represent the data,
with colours indicating separate individuals, the black lines the estimated median individual,
and the grey area the 90% population prediction interval.
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Individual Insulin
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Individual FFA
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Figure 5.8: Individual fits for lean Sprague-Dawley rats. The upper seven illustrations
show the insulin fits, the lower seven the FFA fits. The dots represent the data and the black
lines the estimated individual behaviour.
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Insulin model
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FFA model
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Figure 5.9: Fitted biophase amounts for the insulin and FFA DRT models for lean Sprague-
Dawley rats. The upper seven illustrations show the fitted biophase amounts for the insulin
model, the lower seven for the FFA model. The dashed lines represent the potency of NiAc
to inhibit insulin (upper) and FFA (lower), respectively.
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VPC FFA
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Figure 5.10: Visual predictive checks for obese Zucker rats. The upper seven illustrations
show the insulin fits, the lower seven the FFA fits. The dots represent the data, with colours
indicating separate individuals, the black lines the estimated median individual, and the
grey area the 90% population prediction interval.
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Individual Insulin
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Individual FFA
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Figure 5.11: Individual fits for obese Zucker rats. The upper seven illustrations show the
insulin fits, the lower seven the FFA fits. The dots represent the data and the black lines the
estimated individual behaviour.
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Insulin model
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FFA model
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Figure 5.12: Fitted biophase amounts for the insulin and FFA DRT models for obese
Zucker rats. The upper seven illustrations show the fitted biophase amounts for the insulin
model, the lower seven for the FFA model. The dashed lines represent the potency of NiAc
to inhibit insulin (upper) and FFA (lower), respectively.
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The median baseline concentrations of insulin across groups were 0.206 nM and 3.74 nM for
lean and obese rats, respectively. The estimates for the individual groups ranged between
0.152-0.346 nM for the lean rats and 2.91-4.85 nM for the obese rats. The median turnover
half-lives of insulin, for the moderator, the integral controller, and the NiAc action level for
lean and obese rats are given in Table 5.2. For lean rats, the efficacy of NiAc on insulin
inhibition, ImaxNI, was estimated to be 0.805; consequently, NiAc cannot completely inhibit
insulin release. The established NiAc biophase amount was approximately 1 µmol kg−1 for
both the insulin and FFA DRT models, which is approximately three times the NiAc potency
related to inhibition of insulin (ID50NI =1.02 µmol kg
−1). This implies that the inhibitory
function was saturated at steady-state. The estimated Hill coefficient n indicates a steep
NiAc concentration-insulin response relationship at steady-state. Furthermore, for obese
rats, the efficacy was fixed to 1 (motivated in the Parameter estimation section 5.5), and
the corresponding potency was high with low ID50NI in comparison to the NiAc steady-state
biophase amount. However, since the estimated Hill coefficient was 0.817 < 1, indicating a
gentle NiAc biophase amount-insulin response relationship at steady state, the NiAc biophase
amount never reached high enough levels to saturate the inhibitory function. The estimated
N50I of the NiAc action compartment was lower than the steady-state NiAc biophase amount
(0.607 < Abss(≈ 1)) and the Hill coefficient for the dynamic efficacy γ was estimated to
be 55.6 (suggesting an all or non-response). This implies that the efficacy was completely
down-regulated at the end of the long-term experiments in obese rats, implying no NiAc
inhibition on insulin release. However, the estimates for N50I and γ were highly uncertain,
with RSE% values of 170 and 180, respectively, suggesting practical non-identifiability.
Half-lives (min)
Lean rats Obese rats
Turnover Insulin FFA Insulin FFA
Biomarker 1.81 0.0716 2.61 0.149
Moderator 7.24 21.8 262 73.0
Controller 10.1 4.85 1660 4620
NiAc action - 8570 231 1160
Table 5.2: Turnover half-lives (expressed in min) in the insulin and FFA model for lean
and obese rats of the biomarkers (insulin or FFA—corresponding rate constant kout), the
moderator (rate constant ktol), the integral controller (rate constant koutR), and the NiAc
action (rate constant kN).
5.6.3 FFA model
The FFA concentration was suppressed below its baseline value for all provocations of
NiAc. The suppression of the FFA was more pronounced initially during NiAc infusions.
FFA concentrations then drifted back towards their baselines (cf. Fig. 5.7h to Fig. 5.7j
or Fig. 5.10h to Fig. 5.10j). After the infusions were terminated, the FFA concentrations
rebounded before reaching their baselines. The step-down protocols resulted in less rebound.
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The FFA concentrations returned to their baselines during extended exposure of NiAc in
both the lean and the obese rats (Fig. 5.7j and Fig. 5.10j, respectively). However, as the
long-term exposure was terminated, rebound was seen in the lean rats, but not in the obese
rats (Fig. 5.7j and Fig. 5.10j).
The median FFA baseline concentrations across groups were 0.734 mM and 1.01 mM for the
lean rats and the obese rats, respectively, with corresponding ranges between studies of
0.834-1.16 mM for the obese rats. The median turnover half-lives of the FFA, the moderator,
the integral controller, and the NiAc action level are given in Table 5.2. The estimated
turnovers for the moderator, the integral controller, and the NiAc action level were extremly
uncertain for the FFA model for lean rats, suggesting practical non-identifiability.
Model simulations of the acute and chronic action of NiAc (HNF(Ab(t))), the insulin-driven
integral controller (RF(t)—also referred to as the insulin-controlled regulator), and the
moderator feedback (M0F/MF(t)) on the FFA turnover are illustrated in Fig. 5.13 with the
corresponding acute and chronic FFA responses. The turnover rate of FFA was initially
inhibited about 80 % (lean) and 70 % (obese) by the NiAc infusion (Fig. 5.13a). Upon the
extended exposure to NiAc (120 h) the inhibitory action for the turnover rate was decreased
by approximately 13 % due to intrinsic tolerance mechanisms (Eq. D.5). In the obese
rats the NiAc action totally vanished (Fig. 5.13a). The insulin-driven controller Eq. (5.26)
provides a stimulatory action on the FFA turnover rate as insulin concentrations fall below
the baseline (Fig. 5.13b). The positive (stimulatory) action increases from 100 % (at baseline)
to approximately 200 % after extended (120 h) exposure to NiAc in the lean rats. The insulin
action is totally abolished at equilibrium (120 h) in the obese rats (Fig. 5.13b). The positive
impact of the moderator is seen acutely in both the lean rats and the obese rats, whereas
the moderator action has receded in the obese rats at equilibrium (Fig. 5.13c). In the lean
rats the combined inhibitory (NiAc) and stimulatory (insulin, moderator) action for the
FFA turnover rate causes a rebound in FFA response upon cessation of the NiAc infusion
(Fig. 5.13d). This is not seen in the obese rats since all of the NiAc, insulin, and moderator
actions return to baseline levels at equilibrium (120 h). The potency of the NiAc action
compartment was low (N50F > N(t) ) for the lean rats and high (N50F < N(t)) for the obese
rats at equilibrium (120 h). Consequently, the loss of efficacy was low, respectively high, in
the lean rats and the obese rats at equilibrium. Furthermore, the estimated of Hill coefficient,
φ = 10.9, for the obese rats suggests an all or none-efficacy loss in the obese rats.
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a) b)
c) d)
Figure 5.13: Model simulations of acute and chronic action of NiAc exposure HNF (a),
insulin-driven integral control (b), and moderator feedback (c) on the FFA turnover. Acute
and chronic FFA response (d). Red lines show lean rats and black lines obese rats. The
dashed lines show the baseline FFA response.
5.6.4 Shrinkage analysis
Shrinkage analysis was used to assess the distributions of the residuals and the EBEs. The
standard deviations of the residual additive errors and the ε-shrinkages for the different DRT
models are presented in Table 5.4.
Lean Sprague-Dawley rats Obese Zucker rats
Data Residual add. error σ ε-shrinkage Residual add. error σ ε-shrinkage
Insulin 0.0677(14) 6.3% 0.763(3.2) 6.3%
FFA 0.116(4.7) 6.3% 0.131(3.0) -0.14%
Table 5.4: Insulin and FFA model residual additive errors with corresponding relative
standard errors (RSE%) and ε-shrinkage for lean Sprague-Dawley rats and obese Zucker
rats, respectively.
The η-shrinkages of the EBEs are given in Table 5.5.
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Parameter Sprague-Dawley Obese Zucker
I0 (nM) 5.98 1.46
ktolI (min
−1) -3.33 20.4
ID50NI (µM) 6.95 8.06
F0 (mM) -8.91 -8.53
ktolF (min
−1) 22.9 33.1
ID50NF (µM) 9.01 44.9
Table 5.5: Estimated η-shrinkage of the EBEs to the corresponding parameters I0, ktolI,
ID50NI, F0, ktolF, and ID50NF.
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Figure 5.14: Model predicted reduction in FFA exposure in a median obese rat at steady-
state (i.e., after multiple dosing), illustrated as the percentage reduction relative to the FFA
baseline. (a) represents the predicted reduction in this DRT study, and (b) the predicted
reduction in an exposure-driven analysis by Andersson et al. (2017). The predictions are
made for a range of infusion protocols with 0.25-12 h of NiAc exposure followed by 0-12 h
washout period. The x-axis represents the infusion time and the y-axis represents the washout
time. The model predicts an optimal infusion regimen of ∼2 h longer washout period than
the infusion.
5.6.5 Predicted FFA lowering
The resulting model was used to predict 24 h FFA lowering (AUC24) for a range of protocols
at steady-state (i.e., after multiple dosing). Here, the lowering over a period T is given by
AUCT = F0 · T −
∫ T
0
F (τ) dτ. (5.35)
The protocol design consisted of a 1-12 h NiAc exposure period followed by a 0.25-12 h
washout period. The FFA lowering is illustrated as a reduction in percentage, relative
baseline levels, for a median obese ratin Fig. 5.14. Here, Fig. 5.14a represents the predicted
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reduction of the DRT model and Fig. 5.14b the predicted reduction of the exposure-driven
model by Andersson et al. (2017). The DRT model predicted an optimal dosing strategy of
∼2 h longer washout period than the exposure period (Fig. 5.14a). The maximal reduction
in percentage of the baseline was about 10%. The results were consistent when thes FFA
reductions were predicted for outliers with high/low potencies (ID50NF), baseline responses
(F0), and/or moderator turnover rates (ktolF). The exposure-drivne model predicted an
optimal strategy of ∼1.25 h longer washout period than the exposure period (Fig. 5.14b).
The maximal reduction in percentage of the baseline was about 18%.
5.6.6 Comparison to exposure-driven analysis
The estimates of the system parameters were compared to that of an exposure-driven analysis
by Andersson et al. (2017) (the results of the study are presented in Appendix D). The
comparison is given in Table 5.6.
Lean Sprague Dawley rats Obese Zucker rats
Parameter DRT study Andersson et al. (2017) DRT study Andersson et al. (2017)
koutI (min
−1) 0.382(16) 0.110(14) 0.266(45) 0.180(17)
ktolI (min
−1) 0.0149(30) 0.0108(28) 0.00265(6.0) 0.00208(48)
koutRI (min
−1) 0.684(16) 1.08(17) 0.000417(54) 0.00102(27)
kNI (min
−1) - - 0.00229(170) 0.000403(35)
koutF (min
−1) 9.68(0.82) 7.13(140) 4.64(150) 2.88(120)
ktolF (min
−1) 0.0318(1000) 0.0202(67) 0.00950(4.3) 0.0118(24)
koutRF (min
−1) 0.143(300) 0.0161(29) 0.000150(58) 0.000275(38)
kNF (min
−1) 0.0000809(330) 0.000109(65) 0.000600(24) 0.000628(14)
Table 5.6: Pharmacodynamic parameter comparison between this dose-response-time analysis
(DRT) and the exposure-driven pharmacodynamic analysis by Andersson et al. (2017) (results
from this study are presented in Appendix D) for lean Sprague-Dawley and obese Zucker
rats, respectively. The parameter estimates are given with corresponding relative standard
errors (RSE%).
5.6.7 Goodness-of-fit plots
Goodness-of-fit plots were investigated to assess the distribution of the resiudals and any
eventual systematic misspecifications. The plots showing these are given in Fig. 5.15 and 5.16
for lean and obese rats, respectively.
5.6.8 Sensitivity analysis
A local sensitivity analysis was performed to examine which of the model parameters affect
the FFA response the most. The local analysis was conducted at the maximum likelihood
estimate θˆML on systems perturbed by 300 min (acute) and 7200 min (chronic) constant
rate infusions of NiAc with the infusion rate of 0.17 µmol min−1 kg−1. The sensitivity of, for
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Figure 5.15: Goodness-of-fit plots for the insulin and FFA model for lean Sprague-Dawley
rats. Histogram of the standardised residuals in (a) and (b), the standardised residuals over
time in ?? and ??, Q-Q plots of the observed residuals vs. the theoretical residuals in (e)
and (f), scatter plots showing the relationships between the observed and predicted responses
in (g) and (h). The left column represent the insulin model and the right the FFA model.
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Figure 5.16: Goodness-of-fit plots for the insulin and FFA model for obese Zucker rats.
Histogram of the standardised residuals in (a) and (b), the standardised residuals over time
in (c) and (d), Q-Q plots of the observed residuals vs. the theoretical residuals in (e) and (f),
scatter plots showing the relationships between the observed and predicted responses in (g)
and (h). The left column represent the insulin model and the right the FFA model.
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Figure 5.17: Local sensitivity analysis. The impact of each of the model parameters on the
output is examined during 300 min (acute—upper plots) and 7200 min (chronic—lower plots)
constant rate NiAc infusions at rates of 0.17 µmol min−1 kg−1. The analysis was performed
at the maximum likelihood estimate, obtained from the analysis of the obese rats.
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example, the parameter F0 is given by
∂F (t)
∂F0
∣∣∣∣∣
θˆML
. (5.36)
The results of the analysis are seen in Fig. 5.17. The model output is more sensitive to
changes in the parameters k, ksc, F0, koutF, ID50NF, m, ktolF, and koutRF during acute
treatments, while being more sensitive to changes in the parameters kNF, N50F, and φ during
the chronic treatments. In general, ktolF and koutRF have high sensitivity, while N50F and φ
have low sensitivity.
5.7 Discussion
In the present study, we applied a population modelling approach to a unique pre-clinical
pharmacodynamic data set containing insulin and FFA-time courses obtained from acute
and chronic provocations of NiAc in lean and obese rats. All information regarding the
drug exposure was neglected to examine the utility of a dose-response-time (DRT) analysis.
The aim was to identify a general model to be used in future predictions of optimal NiAc
exposure profiles, to generate durable chronic dosing regimens.
5.7.1 Model evolution
Recent experimental data of long-term NiAc protocols have illustrated full systemic adap-
tation, with FFA concentration returning to its baseline value (Kroon et al., 2015). These
findings challenge previous models (Ahlstro¨m et al., 2011b; Tapani et al., 2014) for long-term
dosing predictions. Hence, new models are needed.
The PK/PD model applied in this study was derived based on previous models (Ahlstro¨m
et al., 2011b; Andersson et al., 2015; Tapani et al., 2014). However, crucial mechanistic
components were added to describe two different kinds of adaptation, one seen in lean rats
and one in obese. In particular, insulin was included as an endogenous regulator of the
turnover of FFA (Oh et al., 2011). To this end, a separate insulin model was developed to
describe the insulin dynamics for all provocations of NiAc.
5.7.2 Model characteristics
A fundamental observation from the FFA-time course data is that both the lean and the
obese rats acquire complete adaptation, with FFA levels returning towards baseline at
equilibrium (Fig. 5.5). The post-infusion FFA rebound in lean rats implies a NiAc-sensitive
system (Fig. 5.5b). However, the rebound was less pronounced than that for the 1-12 h
experiments (cf. Fig. 5.5a). Consequently, the inhibiting effect of NiAc has been down-
regulated during the long-term infusions. For obese rats, the rebound has completely
vanished, which implies a NiAc-insensitive system (Fig. 5.5d). The observations above
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suggest two separate feedback mechanisms that result in complete adaptation. An insulin-
driven integral feedback control (Nocedal and Wright, 2006) was incorporated in the model
to describe adaptation with drug effect (seen in lean rats). Control system techniques have
previously been applied in glucose-insulin models in the form of PID (proportional-integral-
derivative) controllers (Watson et al., 2011). The set-point of the insulin-driven integral
controller is the insulin baseline and, hence, its action reflects the deviations from baseline
insulin concentrations. The traditional Imax-equation was modified with a dynamic efficacy
function to capture the phenomenon of NiAc resistance. The insulin-driven integral controller
represents the antilipolytic effect of insulin (Arner et al., 1981) about the insulin baseline;
as the insulin level increases, the antilipolysis will be more pronounced and, consequently,
the release of FFA will be lowered (and vice versa). Hence, the antilipolytic effects of
insulin at baseline concentrations are included in the turnover rate of FFA, kin, and the
integral controller will provide any increase/decrease in antilipolysis in the form of an
inhibitory/stimulatory effect. The dynamic efficacy could represent the down-regulation of
the PDE3B gene expression (Heemskerk et al., 2014).
The impacts of the dynamic efficacy and the integral controller (Fig. 5.13) demonstrate
that both adaptive actions push FFA concentrations back towards baseline (at equilibrium)
despite ongoing NiAc exposure. The impact of the insulin-driven controller is lower for
the obese rather than the lean rats in spite of 10-fold higher insulin concentrations in the
obese rats (Fig. 5.13). This lack of impact of the insulin-driven controller reflects the insulin
resistance of the obese rats (Heemskerk et al., 2014).
5.7.3 Model evaluation
Some estimated median responses for the insulin and FFA models were under- or over-
predicted (cf. Fig. 5.7k or Fig. 5.7d). This is most likely due to the low number of individuals
per trial (5-10), implying that every 4-9th population median will be estimated below or
above the trends seen in the individual data (Grimmett and Stirzaker, 2002). Furthermore,
some predicted 90 % population spans also under- or over-predicted the response for the
insulin and FFA model (cf. Fig. 5.7k or Fig. 5.7d). This is most likely due to correlations
of the between-subject parameter variabilities—which were not captured since diagonal
covariance matrices were used in the FFA model (Bonate, 2011). When sampling from the
resulting distributions to generate the VPCs, non-feasible parameter combinations may occur
which render a skewed population (Bonate, 2011).
5.7.3.1 Lean rats
The VPCs in Fig. 5.7 and the individual fits in Fig. 5.8 demonstrate the flexibility of the
insulin and FFA models in that response-time courses were captured in both acute and
chronic settings. However, while the parameter estimates for the insulin model were precise
in general, many of the estimates for the FFA model had extreme variability—indicating
practical non-identifiability (Table 5.3). Consequently, the validity of the results of the FFA
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model should be seriously questioned. As is Andersson et al. (2017) demonstrated that
an exposure-driven FFA model could be identified for the same data set (see Table D.2 in
Appendix D), the results of this study indicate that lack of exposure data have rendered
parts of the PD model practically non-identifiable.
5.7.3.2 Obese rats
The VPCs in Fig. 5.10 and the individual fits in Fig. 5.11 demonstrate the flexibility of
the insulin and FFA models in that response-time courses were captured in both acute
and chronic settings. In contrast to the model for the lean rats, the parameters of the
obese FFA model were generally practically identifiable (Table 5.3). However, the fractional
turnover rate of FFA is functions on a significantly narrower time-scale than the feedback
and adaptive mechanisms (Table 5.2). This resulted in a low precision of koutF (RSE%
of 150). To achieve higher precision a denser sampling of the FFA time-course is needed.
Moreover, the parameter related to efficacy loss of NiAc on insulin, kNI, N50I and γ, had
generally low precision (RSE% of 170, 27, 180, respectively). Precision in these estimates
would probably increase if intermediate data, covering the time-span between the acute and
chronic experiments, are added—thereby covering more of the time-course where efficacy is
lost.
The insulin and FFA models have relatively low ε-shrinkages, indicating that the models were
not overfitted (Table 5.5). Moreover, the standardised residuals appeared to be normally
distributed, albeit with slightly heavier tails and slightly skewed distributions in comparison
to the standard normal distribution for the insulin and FFA models, respectively (Fig.5.16a
and Fig. 5.16b). Looking at the standardised residuals over time, there is no apparent bias
in the insulin model (Fig. 5.16c). For the FFA model, the standardised residuals tend to
have a slight positive trend between 750-1000 min (Fig. 5.16d). However, the bias is not
overwhelmingly large.
The turnover processes in the insulin and FFA models operate over entirely different time
scales (Table 5.2). In the FFA model, turnover of FFA is more than 100 times faster than
for the moderator feedback and integral controller. Since the turnover of FFA acted on
a very narrow time-scale, the precision of the estimate was low. Denser sampling of the
FFA response-time course would have been decrease the uncertainty of koutF. Furthermore,
turnover of the NiAc action compartment had a half-life of more than 100 h for the lean rats,
thus spanning the entire duration of the experiment. The corresponding half-life in the obese
rats was 18 h.
The uncertainty in the estimate of the turnover of the integral gain parameter was high, even
though the model output is sensitive to perturbations in koutRF (Fig. 5.17). This suggests
that the data are insufficient to identify the insulin-driven integral controller in the obese
rats. A possible reason for this is that the obese rats experience severe insulin resistance.
The insulin and FFA models predicted similar biophase kinetics with elimination half-lives
of 3.2 and 2.5 min−1 and absorption half-lives of 4.5 and 5.3 min−1 for the insulin and FFA
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model, respectively.
Due to the nature of the FFA dynamics, with tolerance development and rebound post-
infusions, constructing an optimal dosing protocol is complicated. By selecting an inap-
propriate dosing regimen, the NiAc provocation can yield an increased FFA exposure in
comparison to controls (Fig. 5.14). There is an optimal strategy of having 2 h longer washout
periods than infusion periods in rats; this is illustrated in Fig. 5.14 with the purple optimal
lowering area. These strategies were consistent in that they were tested on both the median
individual and on 90% quantiles (i.e., individuals that had the 5% and 95% quantiles of the
parameters that varied in the population, IC50NF, F0, and ktolF). The predicted optimal
designs were compared to those of the exposure-driven analysis by Andersson et al. (2017)
(seen in Fig. 5.14b. The two model predictions are similar, but the DRT analysis predicts a
somewhat narrower window of optimal designs as well as a slightly lower maxinal reduction.
In general, there is high consistency between the parameter estimates derived from this
DRT study and the exposure-driven PD study by Andersson et al. (2017) (see Table 5.6 and
Appendix D for the results of the exposure-driven analysis), with differences mostly within
one standard deviation.
We believe that the performance of the DRT models for the obese rats are better than those
for the lean rats due to slightly more data (61 obese rats vs. 54 lean rats) being available in
the obese case, and that the obese rats have developed more drug and insulin resistances
during the experiments, thereby providing a wider range of response behaviours and richer
data.
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Chapter 6
Conclusions
This thesis has served as an introduction to dose-response-time (DRT) data analysis and as a
demonstration of the utility of DRT modelling. The primary aim, stated in the Introduction,
was to answer the following questions:
• When and how do we use DRT data analysis?
• What are the limitations of DRT data analysis?
This aim was obtained by conducting an extensive review of the published research, by
providing a detailed tutorial on how to develop a DRT model, and by introducing two
comprehensive DRT modelling case studies where the technique was applied. The following
paragraphs will summarise the essence of this thesis and provide concluding remarks on the
studies conducted. The first paragraph will examine the first of the main questions, while
the last paragraph will summarise the limitations of the technique. In the intermediate
paragraphs, the two case studies are discussed and conclusions are drawn from their respective
results.
Dose-response-time (DRT) data analysis is a quantitative pharmacological modelling tech-
nique applied in pharmacodynamic studies where no exposure data are available. This
includes situations when the drug exposure precedes the effect (for example pulmonary
drug administration), when the drug is locally administered (for example ophthalmics), in
clinical trials where invasiveness is undesired (for example in paediatrics or oncology), when
measuring the exposure is complicated (for example small molecules or quick turnover), when
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there are extreme differences between the initial and terminal disposition phases (such as
with oligonucleotides), and so forth. In DRT modelling, we assume that the response data
contain information about the drug kinetics, whereby a biophase model can be identified
and act as the driver of the pharmacological response. The biophase function generally has
a simple structure with few parameters. The choice of biophase depends on the route of
administration, and its performance is assessed by evaluating the fit of the DRT model to
response data. Given that the drug is administered directly into the biophase, the biophase
function is typically described with a single-compartment model with first-order elimination.
On the other hand, given indirect administration (such as oral administration when the
biophase represent the plasma), the biophase is typically described with a single-compartment
model with first-order absorption and first-order elimination.
This work has demonstrated that nonlinear biophase absorption or elimination can be identi-
fied, and utilised given that simpler first-order processes are insufficient in describing the
biophase dynamics. Nonetheless, the lacking information about the drug kinetics heavily
constrains the complexity of the biophase function, as involved biophase functions will
suffer from structural or practical non-identifiability. Beyond the biophase dynamics, the
pharmacodynamics of a DRT model are addressed in a similar fashion as in the standard
pharmacokinetic-pharmacodynamic modelling framework; that is, by examine the char-
acteristic behaviours observed in the response-time data. Examples include time-delays,
saturations, nonlinear dose-response relations, feedback mechanisms, tolerance, and so forth.
The first DRT case study was a meta-analysis conducted on an extensive pre-clinical
biomarker data set of the nicotinic acid-induced (NiAc) reduction of free fatty acids (FFA).
The study was performed using the nonlinear mixed-effects modelling framework (NLME).
The main objective was to demonstrate the utility of DRT data analysis on complex phar-
macodynamic systems. To this end, FFA response-time course data were collected from
experiments conducted on lean (normal) Sprague-Dawley and obese (diseased) Zucker rats.
The experiments on the lean rats were comprehensive, covering various routes, rates, and
modes of NiAc administration, while the experiments on the obese rats were limited in that
only a single route and mode of NiAc administration was applied. In total, 95 lean rats were
analysed and 19 obese rats. The FFA response-time data displayed indirect dose-response
behaviour, rebound post infusion, and a gradual build-up of tolerance—all of which were
captured by a turnover model with a moderator, and integral, feedback control. The corre-
sponding biophase functions were developed sequentially; starting with data obtained from
experiments with intravenous (IV) drug administration, the biophase elimination rate was
assessed. Here, two candidate models were suggested; one single-compartment biophase with
first-order elimination, and one single-compartment model with nonlinear Michaelis-Menten
(MM) elimination. By applying the Akaike Information Criterion (AIC), the first-order
elimination model was considered to be the best fit. Following the assessment of the biophase
elimination, data obtained from experiments with oral drug administration were analysed
to determine the biophase absorption rate. Again, two candidate models were suggested,
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one with first-order absorption and one with MM absorption. The AIC suggested that the
MM absorption model was the best fit. All model structures were proven to be structurally
locally identifiable using the Exact Arithmetic Rank (EAR) approach, implemented in
Mathematica.
The DRT model was successfully fitted to all FFA-time courses in the lean rats, with high
precision in the parameter estimates (all with relative standard errors (RSE) ≤ 25%), low
ε-shrinkage (9.5% and 7.7% when fitting to the infusion and oral data, respectively, suggesting
that the model was neither under- nor overfitted), and visual predictive checks that captured
the median population behaviour, as well as the between-subject variations. Furthermore,
the model was successfully fitted to all FFA-time courses in obese rats, yet with substantially
lower precision in the estimates (when compared to those of the lean rats) with some of
the parameters having RSE between 30-50%. Moreover, the adaptation rate had an RSE
of 250%, indicating practical non-identifiability. These findings suggest the importance of
having a rich pharmacological data set when conducting DRT modelling.
The results were compared to those of an exposure-driven analysis. In general, the precision
of the parameter estimates of the DRT model was lower than that of the exposure-driven
analysis. This is expected as less data generally imply lower precision. Finally, while the
results of the study demonstrate the utility of DRT modelling in cases where exposure data
are sparse or lacking, the technique is not meant to replace the traditional pharmacokinetic-
pharmacodynamic framework when knowledge of the exposure is attainable.
The second study extended the DRT model applied in the previous analysis to develop a
more general NiAc-FFA model, able to describe both acute and chronic response behaviours.
The model aimed at quantitatively determine the impact of disease on the system, and to
be applied in future predictions of optimal dosing design. To this end, a comprehensive
meta-analysis on a pre-clinical biomarker data set of FFA and insulin response-time courses
was conducted. The study was performed using the NLME framework. The data were
obtained from experiments on lean (normal) Sprague-Dawley (a total of 54 individuals)
and obese (diseased) Zucker rats (a total of 61 individuals) treated with intravenous or
subcutaneous NiAc infusions during 5, 12, and 120 h, using different modes of administration
(step-down protocols, intermittent drug flush-outs). The insulin and FFA data were analysed
sequentially; starting with the development of an insulin turnover model, followed by the
FFA turnover model. In this way, the insulin could be fixed, and act as an input signal into
the FFA model. Both the insulin and FFA response-time data displayed indirect response
behaviour, rebound post infusion, and two completely separate adaptive mechanisms present
during chronic treatments; one observed in the lean rats and one in the obese rats. For the
lean rats, the insulin and FFA level returned to their baselines during chronic treatments,
with rebounds occurring when the infusions were terminated. The adaptations seen in the
FFA is believed to be governed by insulin control. A similar mechanism was assumed for the
insulin (i.e., a feedback insulin controller). The rebounds indicate that the lean rats were not
resistant to the drug. For the obese rats, the insulin and FFA level returned to their baselines
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during chronic treatment, but no rebounds occurred when the infusions were terminated.
This is an indication of drug tolerance. These two different adaptive mechanisms of tolerance
with, and without, resistance to NiAc were captured using an insulin-driven regulator and a
dynamic efficacy. The insulin-driven regulator was designed to down-regulate the release of
insulin and FFA if the insulin drops below its baseline levels, and increase the release of insulin
and FFA if the insulin level reaches above its baseline. For the FFA dynamics, this model
component serves to capture the physiological duality of insulin—where insulin has both an
antilipolytic effect, which inhibits the release of FFA, and a slower re-esterification of FFA
to triglycerides. The dynamic efficacy was governed by the amount in a hypothetical NiAc
action compartment. During NiAc infusions, the amount in the action compartment increases
until it reaches the steady-state biophase amount. As the amount of the action compartment
increases, the effect of the drug gets down-regulated according to a nonlinear Hill relation.
The insulin-driven regulator and the dynamic efficacy were incorporated into biophase-driven
turnover models. The biophase was modelled either as a single-compartment model with
zero-order input and first-order output (for IV administration—this model was adapted
from DRT study I) or with a first-order input and first-order output (for subcutaneous
administration). The full DRT models were proven to be locally structurally identifiable
using the EAR approach, again implemented in Mathematica. The VPCs generated from
the insulin and FFA models followed the general trends seen in all populations. However,
the parameter estimates of the insulin and FFA models for the lean rats displayed issues
associated with practical non-identifiability as many of the parameters had extreme variability
(for example, the integral gain parameter koutRF and the turnover rate of the NiAc action
compartment kNF had RSE of ∼ 300%). Since the exposure-driven analysis generated a
practically identifiable model, we conclude that the lack of exposure data have rendered parts
of the DRT model practically non-identifiable. In contrast to the model for the lean rats,
the parameters of the insulin and FFA models for the obese rats were generally practically
identifiable. However, the part of the insulin model that describes the dynamic efficacy had
low precision (RSE% of 170, 28, and 180 for the turnover of the NiAc action compartment
kNI, the potency of the NiAc action compartment N50F, and the Hill coefficient γ). This is
believed to be a consequence of the lack of data describing the dynamics between the 12 and
120 h treatments, where the tolerance for the drug is developed. Furthermore, the turnover of
FFA acted on more narrow time-scale than the other turnover processes. As a consequence,
the estimate for koutF had low precision (150%). Denser sampling at certain stages of the ex-
periments (for example, at the initial FFA drop) would increase the precision of the turnover
rate. The ε-shrinkage for the insulin and FFA models for obese rats were relatively low,
indicating that the models were not overfitted. Finally, there was generally high consistency
between the parameter estimates of the DRT study and those of an exposure-driven analysis
for the obese rats—indicating that the lack of exposure data did not radically alter the results.
DRT modelling poses structural and practical identifiability challenges. Since less data
are available than in the standard pharmacokinetic-pharmacodynamic modelling framework,
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the bias and variability of the model is expected to increase. This was shown when comparing
the results of the two DRT meta analyses with those of exposure-driven analyses, and by
the fact that one of the DRT submodels were practically non-identifiable (the FFA model
for lean rats in DRT study II). Given these limitations of the technique, it is important to
have rich pharmacodynamic data available, preferably with drug administered via different
routes and using various rates and modes.
6.1 Future work
Dose-response-time (DRT) data analysis is a relatively unknown modelling technique (Ta-
ble 1.1 comprises the majority of the published studies). We believe that the field has great
potential in future pharmacological studies where drug exposure data are sparse or lacking.
However, more extensive studies are needed to comprehend the full utility of the technique.
The following discussion will encompass three aspects of possible extensions to this work;
covering limitations in, and alternative approaches to, the studies conducted in this thesis,
development of the DRT modelling methodology, and an exploration of the different areas
where the framework could be applied.
Extensions of the presented studies
In neither of the presented case studies did we utilise the potential impact of the known
covariates of the data sets; for example, the individual weights of the rats were known—a
covariate that potentially could affect the individual pharmacology. It would be interesting
to examine the relationships between the empirical Bayes estimates (EBEs) and the weight
of the rats. Another possible alteration of the models would be to make obesity a covariate
and estimate lean and obese rats simultaneously.
Moreover, plasma glucose concentration-time data were collected from the experiments in
the second case study. Glucose is known to be a significant player in the analysed metabolic
network—having a close connection to both insulin and FFA. However, these data were
omitted in the current studies to reduce the complexity of the models. Furthermore, the
primary aim of the PD modelling in the second study was to focus on how insulin affects
FFA and not vice versa. To this end, the insulin was assumed to be unaffected by the FFA
levels (for simplicity), while FFA was affected by insulin. A logical continuation of this
project would be to integrate FFA dynamics in the insulin model, and thereby to approach
a more mechanistic insulin model. However, this would require the insulin and FFA models
to be fitted simultaneously, which is bound to be computationally heavy.
A potential model extension would be to include the effect of fasting and feeding on the FFA
dynamics. A study by Kroon et al. (2016) suggests that NiAc administration timed with
feeding profoundly improves the lipolytic effect of the drug.
The covariance matrices were assumed to be diagonal, to simplify the estimations (i.e., by
reducing the number of parameters). From the estimated EBEs, one could investigate if
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there are any potentially relevant correlations between the random effects. These could then
be added to the covariance matrices in a subsequent estimation, where the initial guesses
of the off-diagonal elements are estimated from the empirical distributions of the EBEs.
By using non-diagonal covariance matrices, we could obtain a better understanding of the
population variations, which may be of use when, for example, designing future experimental
trials.
Finally, when optimising the NiAc protocol to predict the maximal AUC24 reduction (in
DRT study II), a range of protocols was explored, rather than stating a proper optimisation
problem with an objective function and certain constraints on the infusion protocol. A
nonlinear programming approach could be applied in future studies.
Developing the DRT framework
In a study by Janze´n et al. (2016), the parameter identifiability of fundamental pharma-
codynamic models was investigated. A similar study for DRT models, incorporating both
practical and structural identifiability on a variety of paired biophase functions and pharma-
codynamic models, would be valuable. In such study, one could investigate how the practical
identifiability of the DRT models changes about the extension of the pharmacodynamic data
analysed. Furthermore, it would be of importance to examine if the design of experimental
trials should change when conducting DRT modelling, rather than with traditional PK-PD
modelling.
Examine DRT modelling in new areas
Over the recent years, a variety of clinical oncology studies has utilised the DRT modelling
framework (Buil-Bruna et al., 2014; Frances et al., 2011; Parra-Guillen et al., 2013; Paule
et al., 2012; Ramon-Lopez et al., 2009; Wilbaux and He, 2014). We envisage that the
modelling framework will continue to play a fundamental role in future clinical oncology
studies, as well as other clinical areas where it is desirable to avoid any unnecessary invasive
procedure. One such area is paediatrics, where Tod (2008) has stressed the potential of the
technique in a study from 2008.
Biologics have during the recent years rose up as one of the most significant advancements
in modern medicine, due to their promise and potential (Zhao et al., 2012). Some biologics
are administered during in small doses, with extended periods between each dose. Here,
DRT modelling can play a paramount role in early development, such that a suitable dosing
strategy can be decided without developing complex physiologically-based PK models (Lange
and Schmidli, 2015).
To promote the technique and to provide these suggestive areas of future application to a
wider audience, an extensive review of the field (which is currently lacking) would be of
highly valuable. We aim to use this thesis as a blueprint of a future DRT modelling review
article.
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Chapter A
Mathematica code -
Identifiability analysis of DRT I
model
The following Mathematica code was used for the EAR identifiability analysis of the DRT
model used in the first study.
Load the IdentifiabilityAnalysis package.
In[7]:= Get["IdentifiabilityAnalysis‘"];
Simplify the system by replacing kin with kout ·R0.
In[8]:= fixedParamRules={kin->kout*R0};
Define the system.
In[9]:= system = {Ab’[t] == u[t] - kb*Ab[t],
B’[t] == n*B[t]*(u[t] - kb*Ab[t])/Ab[t],
R’[t] == kin*(1+Ki*y[t])*(1 - Imax*B[t] /(ID50 + B[t]))*(z0/z[t]) -
(M8[t]/R0)*kout*R[t],
M1’[t] == ktol (R[t] - M1[t]),
M2’[t] == ktol (M1[t] - M2[t]),
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M3’[t] == ktol (M2[t] - M3[t]),
M4’[t] == ktol (M3[t] - M4[t]),
M5’[t] == ktol (M4[t] - M5[t]),
M6’[t] == ktol (M5[t] - M6[t]),
M7’[t] == ktol (M6[t] - M7[t]),
M8’[t] == ktol (M7[t] - M8[t]),
z’[t] == -p*ktol*(z[t]*R[t]/M1[t]-z[t]),
y’[t] == R0 - R[t],
Ab[0] == A0, B[0] == B0, R[0] == R0, M1[0] == R0, M2[0] == R0,
M3[0] == R0, M4[0] == R0, M5[0] == R0, M6[0] == R0, M7[0] == R0,
M8[0] == R0, z[0] == z0, y[0]==0};
Define the output.
In[10]:= output = {R[t]};
List of parameters, replace kin in the system, and define list of state variables.
In[11]:= parameters = {kb, kout, R0, Imax, ID50, n, ktol, p, z0, A0, B0};
system = system/.fixedParamRules;
stateVariables = {Ab, B, R, M1, M2, M3, M4, M5, M6, M7, M8, z, y};
Run the identifiability analysis.
In[12]:= iad = IdentifiabilityAnalysis[{system, output}, states,
parameters, t, input]
Out[12]= "IdentifiabilityAnalysisData[False, <>]"
In[13]:= iad["NonIdentifiableParameters"]
Out[13]= {B0, ID50}
In[14]:= iad["DegreesOfFreedom"]
Out[14]= 1
Since B0 = A
γ
0 = 0, where A0 and γ are identifiable, B0 is identifiable. Thus, ID50 is also
identifiable due to the degrees of freedom.
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Chapter B
Mathematica code - Parameter
estimation of DRT I model
The following Mathematica code was used for the parameter estimation of the DRT model
used in the first study.
Define the system
Specify fixed parameter rules and random effects.
In[15]:= fixedParamRules = {kin -> R0*kout, Imax -> 1/(1 + Exp[-\[Theta]1])};
randomEffects = {kb -> (kb*Exp[\[Eta]1]), Ki -> (Ki*Exp[\[Eta]2]),
R0 -> (R0*Exp[\[Eta]3]), kout -> (kout*Exp[\[Eta]4]),
ktol -> (ktol*Exp[\[Eta]5])};
Define system, initial conditions and measured variables.
In[16]:= system = {Ab’[t], R’[t], M1’[t], M2’[t], M3’[t], M4’[t], M5’[t],
M6’[t], M7’[t], M8’[t], y’[t]} ==
{bioInput - kb*Ab[t], (1 + Ki*y[t])*
kin*(1 - Imax*Ab[t]^\[Gamma] /(ID50^\[Gamma] + Ab[t]^\[Gamma]))*
(R0/M1[t])^p - kout*R[t]*(M8[t]/R0), ktol (R[t] - M1[t]),
ktol (M1[t] - M2[t]), ktol (M2[t] - M3[t]),
ktol (M3[t] - M4[t]), ktol (M4[t] - M5[t]),
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ktol (M5[t] - M6[t]),
ktol (M6[t] - M7[t]),
ktol (M7[t] - M8[t]),
1 - R[t]/R0};
inititalConditions = {Ab[0], R[0], M1[0], M2[0], M3[0], M4[0], M5[0],
M6[0], M7[0], M8[0],
y[0]} == {0, R0, R0, R0, R0, R0, R0, R0, R0, R0, 0};
output = {R[t]};
In[17]:= oralSys = {Aa’[t], Ab’[t], R’[t], M1’[t], M2’[t], M3’[t], M4’[t],
M5’[t], M6’[t], M7’[t], M8’[t], y’[t]} ==
{-aVmax*Aa[t]/(aKm + Aa[t]), bioInput - kb*Ab[t],
(1 + Ki*y[t])*kin*
(1 - Imax*Ab[t]^\[Gamma] /(ID50^\[Gamma] + Ab[t]^\[Gamma]))*
(R0/M1[t])^p - kout*R[t]*(M8[t]/R0),
ktol (R[t] - M1[t]), ktol (M1[t] - M2[t]), ktol (M2[t] - M3[t]),
ktol (M3[t] - M4[t]), ktol (M4[t] - M5[t]), ktol (M5[t] - M6[t]),
ktol (M6[t] - M7[t]), ktol (M7[t] - M8[t]),
1 - R[t]/R0};
oralInitialConditions = {Aa[0], Ab[0], R[0], M1[0], M2[0], M3[0],
M4[0], M5[0], M6[0], M7[0], M8[0], y[0]} == {absInput, 0, R0,
R0, R0, R0, R0, R0, R0, R0, R0, 0};
Specify input.
In[18]:= bioInputFunctions = {RATE*UnitStep[DOSE/RATE - t],
RATE*UnitStep[30 - t] +
Piecewise[{{RATE - Ceiling[(t - 30)/10]*RATE/19, t > 30 && t < 210}}] +
Piecewise[{{RATE*UnitStep[210 + (DOSE - 20)/RATE - t], t > 210}}],
Aa[t]*aVmax/(aKm + Aa[t])};
absInputFunctions = {RATE*DOSE};
Specify systems with correct inputs.
In[19]:= infusionSystem = system /. Thread[bioInput -> bioInputFunctions[[1]]]
/. fixedParamRules;
stepSystem = system /. Thread[bioInput -> bioInputFunctions[[2]]]
/. fixedParamRules;
oralSystem = oralSys /. Thread[bioInput -> bioInputFunctions[[3]]]
/.
fixedParamRules;
Define states.
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In[20]:= stateVariables = {Aa[t], Ab[t], R[t], M1[t], M2[t], M3[t], M4[t],
M5[t], M6[t], M7[t], M8[t], y[t]};
Define random variables.
In[21]:= randomParams = {\[Eta]1, \[Eta]2, \[Eta]3, \[Eta]4, \[Eta]5};
Set up models consisting of {sys}, {ic}, out.
In[22]:= modelInfusion = {{infusionSystem}, {initialCondition}, output}
/. randomEffects;
modelStep = {{stepSystem}, {initialConditions}, output}
/. randomEffects;
modelOral = {{oralSystem}, {oralInitialCondtions}
/. Thread[absInput -> absInputFunctions], output} /. randomEffects;
models = {modelInfusion, modelStep, modelOral};
Estimation of parameters
The following is the Mathematica code used for the parameter estimation of the DRT of
the first study.
Define Omega matrix (interindividual variation).
In[23]:= L = {{\[Omega]11, 0, 0, 0, 0}, {0, \[Omega]22, 0, 0, 0},
{0, 0, \[Omega]33, 0, 0}, {0, 0, 0, \[Omega]44, 0},
{0, 0, 0, 0, \[Omega]55}};
\[CapitalOmega] = L.Transpose[L];
Define the S matrix for all models (measurment noise).
In[24]:= S1 = {{s1}};
S2 = {{s2}};
S3 = {{s3}};
SList = {S1, S2, S3};
Construct a data list of data from all models.
In[25]:= infusionData = {Join[prepDataDose0Time0, prepDataDose1Time30,
prepDataDose5Time30, prepDataDose20Time30, prepDataDose5Time300,
prepDataDose10Time300, prepDataDose51Time300]};
stepData = {Join[prepDataDose20, prepDataDose25]};
oralData = {Join[prepDataOralDose24, prepDataOralDose81,
prepDataOralDose812]};
data = Join[infusionData, stepData, oralData];
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Define covariates.
In[26]:= listOfInputs = {DOSE, RATE};
Construct a parameter list with all the initial values - for the fixed effects, the random effects,
and the measurement noises - and a list of all parameters.
In[27]:= parameterStartValue = {{aVmax, 5}, {aKm, 30}, {\[Theta]1, 2},
{kb, 0.3}, {Ki, 0.001}, {ID50, 0.05}, {kout, 0.30}, {R0, 0.70},
{\[Gamma], 1}, {ktol, 0.03}, {p, 1}};
\[Omega]StartValue = {{\[Omega]11, 0.1}, {\[Omega]22, 0.1},
{\[Omega]33, 0.1}, {\[Omega]44, 0.1}, {\[Omega]55, 0.1}};
sStartValue = {{s1, 0.1}, {s2, 0.1}, {s3, 0.1}};
fullParameterList = Join[params, {s1, s2, s3}];
Call parameter estimation.
In[28]:= {pExpValues, pValues, history} =
FitPopulationModel[data, models, listOfInputs,
parameterStartValue, {SList,
sStartValue}, {randomParams, \[CapitalOmega], \[Omega]StartValue}, t,
fullParameterList];
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Chapter C
Mathematica code -
Identifiability analysis of DRT
II insulin model
The following Mathematica code was used for the EAR identifiability analysis of the DRT
insulin model used in the second study.
Load the IdentifiabilityAnalysis package.
In[29]:= Get["IdentifiabilityAnalysis‘"];
Simplify the system by replacing kin with kout · I0 and kinRI with koutNI · I0.
In[30]:= fixedParamRules={kin->kout*INS0,kinRI->koutRI*INS0};
Define the system.
In[31]:= system = {Ab’[t] == u[t] - kb*Ab[t],
INS’[t] == kin*RI[t]*(1 -(1-X[t]/(X[t]+X50)) Imax*
Y[t] /(Y50 + Y[t]))*(INS0/M1[t]) -
(M2[t]/INS0)*kout*INS[t],
M1’[t] == ktol (INS[t] - M1[t]),
M2’[t] == ktol (M1[t] - M2[t]),
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RI’[t] == kinRI-koutRI*INS[t],
NI’[t] == kNI*(Ab[t]-NI[t]),
X’[t] == m*X[t]*kNI*(Ab[t]-NI[t]),
Y’[t] == n*Y[t]*(u[t] - kb*Ab[t])/Ab[t],
Ab[0] == A0, INS[0] == INS0, M1[0] == INS0, M2[0] == INS0,
RI[0] == 1, NI[0] == A0, X[0]==X0,Y[0]==0};
Here, X(t) = NmI (t)
1 and Y (t) = Anb(t). These auxiliary state variables are introduced to
transform the system to rational form. Define the output.
In[32]:= output = {INS[t]};
List of parameters, replace kin and kinRI in the system, and define list of state variables.
In[33]:= parameters = {kb, A0, X50, Imax, Y50, INS0, kout, ktol, koutRI,
kNI, m, X0, n, Y0};
system = system/.fixedParamRules;
stateVariables = {Ab, INS, M1, M2, RI, NI, X, Y};
Run the identifiability analysis.
In[34]:= iad = IdentifiabilityAnalysis[{system, output}, states,
parameters, t, input]
Out[34]= "IdentifiabilityAnalysisData[False, <>]"
In[35]:= iad["NonIdentifiableParameters"]
Out[35]= {X0, X50, Y0, Y50}
In[36]:= iad["DegreesOfFreedom"]
Out[36]= 2
But n and m are identifiable, and X50 = ID
n
50NI and Y50 = N
m
50I . Thus, X50 and Y50 can be
found from the identities. Since the degress of freedom is 2, we conclude that the system is
structurally locally identifiable.
1In the study, m was denoted γ.
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Chapter D
Exposure-driven
pharmacodynamic modelling -
DRT II study
Using the pharmacokinetic model presented in Sec. 3.2 and the pharmacodynamic insulin
model in Sec. 5.3 and FFA model in Sec. 5.4, a full, exposure-driven analysis was performed
on the insulin- and FFA-response data used in DRT study II, as well as the corresponding
exposure-time data (presented in Figs. D.1 and D.2) that were obtained during the experi-
ments. This section will present the results from the exposure-driven study as a comparison
to the DRT study conducted in this thesis.
NiAc exposure model
The base structure of the NiAc exposure model is presented in Sec. 3.2.
Between-subject and residual variability
The parameters that varied within the population were ka, Vmax1, and Synt, though Synt
varied only in lean rats. These were assumed to be log-normally distributed in order to keep
the parameter values positive. The five-day continuous infusion group of obese rats did not
have exposure data. Consequently, these rats were assumed to behave like the estimated
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median individual. The residual variability was assumed to be normally distributed, and
modelled using a proportional error model.
Estimated parameters
Because of sparse sampling, all parameter values could not be estimated from the data. By
applying an a priori sensitivity analysis Saltelli et al. (2008); Saltelli (2002), we identified
the parameters that had the greatest influence on the output. These were then estimated
from the data, while the remaining parameters were obtained from the literature Tapani
et al. (2014). The population parameters estimated from the data were ka, δ, and Vmax1.
Insulin model
The insulin model used in the exposure-driven analysis was the same as the one presented
in Sec. 5.3, with the exception that the drug-mechanism function was driven by the NiAc
concentration in the plasma, rather than the biophase drug amount. Thus, the drug-
mechanism function is given by
HNI(Cp(t)) = 1− ENI(NI(t)) ·
Cnp (t)
ICn50NI + C
n
p (t)
, (D.1)
where IC 50NI is the potency of NiAc on insulin and n the Hill coefficient of the inhibitory
function. Moreover, the term ENI(NI(t)) represents the drug efficacy, which is fixed for lean
rats and dependent on the concentration in a hypothetical NiAc action compartment, NI(t),
for obese rats, according to
ENI(NI(t)) =
ImaxNI leanImaxNI (1− SNI·NγI (t)Nγ50I+NγI (t)) obese, (D.2)
where ImaxNI is the initial efficacy of NiAc on insulin, N50I the potency of the NiAc action
compartment, SNI the long-term NiAc efficacy loss, and γ the corresponding Hill coefficient
of the efficacy relation. The dynamics of NI are in turn given by
dNI(t)
dt
= kNI · (Cp(t)−NI(t)), (D.3)
with NI(0) = Cp(0). Here kNI is the turnover rate of the NiAc action concentration. Hence,
the NiAc action compartment is driven by the NiAc concentration, rather than the biophase
drug amount (which is the case in DRT study II).
Mechanistic FFA model
The FFA model used in the exposure-driven analysis was the same as the one presented
in Sec. 5.4, with the exception that the drug-mechanism function was driven by the NiAc
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plasma concentration, rather than the biophase drug amount. Thus, the drug-mechanism
function is given by
HNF(Cp(t)) = 1− ENF(NF(t)) ·
Cmp (t)
ICm50NF + C
m
p (t)
, (D.4)
where IC 50NF is the potency of NiAc as an inhibitor of FFA release and m is the Hill
coefficient. As in DRT study II, the drug efficacy is dynamic and changes (down-regulates)
during long-term infusions of NiAc. The efficacy is given by
ENF(NF(t)) = ImaxNF ·
(
1− SNF ·N
φ
F (t)
N φ50F +N
φ
F (t)
)
, (D.5)
where ImaxNF is the initial efficacy of NiAc on FFA, N50F the potency of the NiAc action
compartment, SNF the long-term NiAc efficacy loss, φ the Hill coefficient, and NF(t) the con-
centration in the NiAc action compartment. The dynamics of the NiAc action compartment
are in turn described by
dNF(t)
dt
= kNF · (Cp(t)−NF(t)), (D.6)
with initial condition NF(0) = Cp(0). Here, the parameter kNF is the turnover rate of
the NiAc action state. Hence, as for the exposure-driven insulin model, the NiAc action
compartment of the FFA model is driven by the NiAc concentration.
Results
The parameter estimation for the three sub-models (NiAc, insulin, and FFA) was performed
sequentially. In this way, the PK were fixed in the insulin estimation and the PK and
insulin were fixed in the FFA estimation. The estimates and between-subject variabilities
(expressed in CV%), both with corresponding relative standard errors (RSE%), for normal
Sprague-Dawley rats and obese Zucker rats are given in Table D.2. Weighted summaries
Laporte-Simitidis et al. (2000) are presented for the parameters that varied between studies.
The resulting models were qualitatively evaluated using visual predictive check (VPC) plots
Bergstrand et al. (2011); illustrating the data, the model predicted median individual, and
90% Monte Carlo prediction intervals generated from the models Bergstrand et al. (2011);
Post et al. (2008). The VPCs are shown in Fig. D.1 for lean Sprague-Dawley rats and in
Fig. D.2 for obese Zucker rats. The VPCs are generated from the PK, insulin, and FFA
models for all provocations of NiAc.
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Figure D.1: Visual predictive checks for lean Sprague-Dawley rats. The first column
shows the PK fits, the second column the insulin, and the third column the FFA. The
rows represent the different protocols of NiAc (as described in the Experimental protocols
section 3.3.1). The dots represent the data, with colours indicating separate individuals,
the black lines the estimated median individual, and the grey areas the 90% population
prediction intervals.
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Figure D.2: Visual predictive checks for obese Zucker rats. The first column shows the
PK fits, the second column the insulin, and the third column the FFA. The rows represent
the different protocols of NiAc (as described in the Experimental protocols section 3.3.1).
The dots represent the data, with colours indicating separate individuals, the black lines the
estimated median individual, and the grey areas the 90% population prediction intervals.
No exposure data were available from the Cont. protocol (Fig. (g)).
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Pharmacokinetic model
The pharmacokinetic system reached a steady-state concentration of about 1 µM for all
protocols, both in the lean and the obese rats (first column in Fig. 5.7 and first column in
Fig. 5.10). The steady-state was attained faster with the intravenous rather than with the
subcutaneous administration. When the infusions were terminated, the drug was cleared
from the system within minutes and the NiAc concentration approached the endogenous
level.
The absorption from the subcutaneous compartment had half-lives of 0.16 h and 0.13 h for
the lean and the obese rats, respectively. At steady-state, the elimination of NiAc from the
plasma compartment in the lean rats was approximately 3 times faster for the high affinity
pathway than the low affinity one. Moreover, the drug elimination rate from the plasma at
steady-state was ∼20 µmol kg−1 h−1 and ∼25 µmol kg−1 h−1 for the lean and the obese rats,
respectively. The lumped diffusion coefficient was estimated to be 77 h−1/2 and 62 h−1/2 for
the lean and the obese rats, respectively, implying that the NiAc dosing solution was diluted
during the first ∼1.5 h.
Insulin model
Half-lives (h)
Lean rats Obese rats
Turnover Insulin FFA Insulin FFA
Biomarker 0.105 0.00162 0.0643 0.00401
Moderator 1.07 0.570 5.53 0.979
Controller 0.176 0.719 11.3 42.0
NiAc action - 106 28.7 18.4
Table D.1: Turnover half-lives (expressed in hours) in the insulin and FFA model for the
lean and the obese rats of the biomarkers (insulin or FFA - corresponding rate constant
kout), the moderator (rate constant ktol), the integral controller (rate constants kinRl), and
the NiAc action (rate constant kN).
The median insulin baseline concentrations across groups were 0.233 nM and 3.51 nM for the
lean and the obese rats, respectively. The estimates of the individual groups ranged between
0.151-0.264 nM for the lean rats and 2.69-4.82 nM for the obese rats. The median turnover
half-lives of insulin, for the moderator, the integral controller, and the NiAc action level for
the lean and the obese rats are given in Table D.1. For the lean rats, the efficacy of NiAc
on insulin inhibition, ImaxNI, was estimated to be 0.793. The established NiAc exposure
was about 1 µM which is approximately three times the NiAc potency related to inhibition
of insulin (IC 50NI =0.338 µM). This implies that the inhibitory function was saturated at
steady-state. The estimated Hill coefficient n indicates a steep NiAc concentration-insulin
response relationship at steady-state. Furthermore, for the obese rats, the efficacy was fixed
to 1 and the corresponding potency was high since the IC 50NI was low in comparison to
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the NiAc steady-state exposure. However, since the estimated Hill coefficient was 0.84 < 1,
indicating a gentle NiAc-concentration insulin-response relationship at steady state, the
NiAc concentrations never reached levels high enough to saturate the inhibitory function.
The estimated N50I of the NiAc action compartment was lower than the steady-state NiAc
concentration (0.897¡1) and the Hill coefficient of the dynamic efficacy was estimated to
be 18.9 (suggesting an all or non-response). This implies that the efficacy was completely
down-regulated at the end of the long-term experiments in the obese rats, implying no NiAc
inhibition on insulin release.
FFA model
The median FFA baseline concentrations across groups were 0.707 mM and 1.14 mM with
corresponding ranges of 0.652-0.801 mM in the lean and 0.789-1.22 mM the obese rats,
respectively. The median turnover half-lives of the FFA, the moderator, the integral controller,
and the NiAc action level are given in Table D.1.
The potency of the NiAc action compartment was low for the lean rats, since N50F >> N(t)
at equilibrium (120 h), and high for the obese rats, since N50F < N(t) at equilibrium
(120 h). Consequently, the loss of efficacy was low in the lean rats and high in the obese
ones. Furthermore, the estimate of Hill coefficient φ = 8.37 for the obese rats suggests an
all-or-none efficacy loss in the obese rats.
Model predictions
The resulting model was used to predict 24 h FFA lowering (AUC24) for a range of protocols
at steady-state (i.e., after multiple dosing). The protocol design consisted of a 0.25-12 h NiAc
exposure period followed by a 0-12 h washout period. The NiAc infusions were designed to
generate concentrations around the therapeutically relevant level (∼1 µM) that was used
in the experiments Ahlstro¨m (2011). The predicted AUC24 and proportional reduction,
in comparison to baseline levels, on a median obese rat are given in Fig. D.3. The model
predicted an optimal dosing strategy of ∼2 h longer washout period than the exposure period
and the maximal AUC reduction is 5.60 mM h. These results were consistent when AUC24
was predicted for outliers with high/low potencies (IC 50NF), baseline responses (F0), and/or
moderator turnover rates (ktolF).
Furthermore, the NiAc-concentration FFA-response relationship at steady-state, for the obese
rats, is illustrated in Fig. D.4, with the corresponding NiAc-, insulin-, and moderator actions.
The largest reductions in FFA exposure occurs within a ‘window of opportunity’, with NiAc
concentrations between the IC50NF and the N50F. The predicted AUC24 at steady-state, for
the optimal NiAc exposure of 0.500 µM, was 7.40 mM h.
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Figure D.3: Model predicted reduction in FFA exposure in a median obese rat at steady-state
(i.e., after multiple dosing). (a) illustrates the predicted average reduction in 24 h FFA area
under the curve and (b) illustrates the proportional reduction, in comparison to the baseline
level. The predictions are made for a range of infusion protocols with 0.25-12 h of NiAc
exposure followed by 0-12 h washout period. The x-axis represents the infusion time and the
y-axis represents the washout time. The model predicts an optimal infusion regimen of ∼2 h
longer washout period than the infusion. The maximal AUC reduction is 5.60 mM h.
Figure D.4: Predicted steady-state concentration-response (left-hand y-axis) and
concentration-action (right-hand y-axis) relationships for obese rats. The black line represents
the FFA response, the blue line the inhibitory action of NiAc on FFA turnover, the red line
the insulin action on FFA turnover, and the purple line the moderator action on the FFA
turnover. The IC50F and the N50F concentrations are given by the black vertical lines.
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